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Abbreviations 
ACC/AHA American Heart Association/American College of Cardiology 
ACS  acute coronary syndrome  
BMS  bare metal stent 
CABG coronary artery bypass grafting 
CRP   C Reactive Protein 
C-SES  Cypher sirolimus eluting stent 
DAPT  dual antiplatelet therapy 
DES  drug eluting stent 
ECM   extracellular matrix  
E-ZES Endeavor  zotarolimus eluting stent 
ESC  European Society of Cardiology  
GR  glucocorticoid receptor 
hs-CRP highly sensitive CRP 
HPA  hypothalamic pituitary adrenal 
ISR  in-stent restenosis 
IVUS  intravascular ultrasound  
MACE major adverse cardiovascular events 
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MACCE  major adverse cardiovascular and cerebrovascular events 
MI  myocardial infarction 
MLD  minimal luminal diameter  
MR  mineralocorticoid receptor 
NAD  nicotinamide adenine dinucleotide  
NADPH nicotinamide adenine dinucleotide phosphate 
NICE  National Institute of Health and Care Excellence 
PCI  percutaneous coronary intervention  
PTCA   Percutaneous transluminal coronary angioplasty  
QCA  Quantitative coronary angiography  
R-ZES Resolute zotarolimus eluting stent 
SMC  smooth muscle cell 
TLR  target lesion revascularisation 
T-PES Taxus paclitaxel eluting stent 
TVF  target vessel failure 
TVR  target vessel revascularisation  
X-EES Xience V everolimus eluting stent 
11β-HSD  11β-hydroxysteroid dehydrogenase 
 
12 
 
INTRODUCTION  
I am a specialty training registrar in the Northern Deanery training in 
interventional cardiology. There is a strong emphasis on research within the 
cardiology unit at The James Cook University Hospital and when I joined,  
initially  as a clinical registrar, I was presented with an opportunity to 
undertake clinical research. This led to my interest in this project. The 
SSTARS (STeroids and stents Against Re-Stenosis) Trial was at an early 
stage when I joined the unit in my role as research fellow.  The trial structure 
and committees are described in section 2.2. As one of the investigators I was 
involved with the design of the trial, trial protocol, recruitment, data collection, 
analysis and interpretation.  
Abstract 
Stent design and technological modifications to allow for anti-proliferative drug 
elution influence restenosis rates following percutaneous coronary 
intervention (PCI).  
The main aim of this study was to investigate whether peri-procedural 
administration of corticosteroids  or the use of thinner strut cobalt alloy stents  
would reduce rates  of binary angiographic restenosis (BAR) after PCI. In 
addition, the role of the acute phase highly sensitive C-Reactive protein (hs-
CRP) in restenosis in bare metal stents (BMS) was also investigated. This 
was a two centre, mixed single and double blinded, randomised controlled 
trial using  a factorial design.  
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The use of prednisolone  was compared against placebo, starting at least six 
hours pre-PCI and continued for 28 days post-PCI. Additionally,  cobalt 
chromium (CoCr) stents were compared to stainless steel (SS) alloy stents, in 
patients admitted for PCI. The primary end-point was BAR at six months.  
Three hundred and fifteen (359 lesions) were randomly assigned to either 
placebo (n=145) or prednisolone (n=170) and SS (n=160) or CoCr (n=160). 
The majority (58%) presented with an acute coronary syndrome (ACS), 11% 
had diabetes and 287 (91%) completed angiographic follow up. The primary 
endpoint, binary angiographic restenosis, occurred in 26 cases in the placebo 
group (19.7%) versus 31 cases in the prednisolone group (20.0%) 
respectively, p=1.00. For the comparison between SS and CoCr stents, BAR 
occurred in 32 patients (21.6%) versus 25 patients (18.0%) respectively, 
p=0.46.  
Hs-CRP was monitored at 5 points during the trial. The pre-PCI hs-CRP 
measurement was ≤5mg/l in 213 patients (71%) of whom only 28 (13%) had a 
raised CRP at day 7.  There was some evidence of prednisolone suppressing 
hs-CRP response at day 7 (-5.98 mg/L, 95%CI: -8.35 to -3.61, p<0.001). 
There was no correlation between lowering hs-CRP and stenosis diameter at 
follow-up. 
This study showed that treating patients with a moderately high dose of 
prednisolone to cover most of the period of inflammation associated with 
restenosis in BMS did not reduce the incidence of BAR. There was also no 
significant reduction in six month BMS restenosis rates with stents composed 
of CoCr alloy compared to SS alloy and no observed relationship to hs-CRP. 
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Research Questions 
a) To investigate whether the peri-procedural use of oral corticosteroids 
in elective/acute patients undergoing percutaneous coronary 
intervention would reduce the incidence of in-segment re-stenosis. 
b) To investigate whether the use of cobalt chromium stents results in 
lower restenosis rates than stainless steel stents in elective/acute 
patients undergoing percutaneous coronary intervention. 
c) To investigate whether elevated systemic levels of highly sensitive C- 
Reactive Protein resulting from coronary plaque disruption will be 
associated with degree of restenosis at follow-up and whether there is 
any relationship to oral steroid therapy. 
 
Aims 
Primary aims 
The primary aims of the SSTARS study were twofold. The first was to 
evaluate the use of peri-procedural corticosteroid administration versus 
placebo on the incidence of coronary artery in-segment restenosis rates 
following PCI. The second was to compare the incidence of coronary artery 
in-segment restenosis rates between chromium cobalt and stainless steel 
bare metal stents. 
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Secondary aims 
The secondary aims were to evaluate the use of peri-procedural corticosteroid 
administration versus placebo and to compare chromium cobalt and stainless 
steel bare metal stents with regards to the following endpoints: 
 Late loss, defined as the difference between minimum lumen diameters 
after the index PCI and at follow up. 
 Target lesion revascularisation, defined as repeat intervention of 
restenotic lesions, which include the target site of the stent implantation 
or 5mm proximal and distal in the same epicardial coronary artery. 
 Target vessel revascularisation, defined as repeat intervention within 
the same epicardial coronary artery. 
 Incidence of death. 
 Myocardial infarction (MI*) – classified as fatal or non-fatal and whether 
related to the target vessel or not 
 Unstable angina. 
 Cerebrovascular accident (CVA). 
 Repeat hospitalisation. 
 Major/minor bleeding complications. 
 Poor glycaemic control. 
 *A new MI was defined by the presence of at least two of onset of typical 
ischaemic chest pain lasting > 20 minutes, typical ECG changes i.e. ST 
elevation/ new LBBB and elevation in cardiac markers (Troponin T > 
0.1ng/ml) 
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CHAPTER 1 
Review of literature 
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1.1 The evolution of percutaneous coronary intervention 
relative to restenosis 
Percutaneous transluminal coronary angioplasty (PTCA) was first performed 
in the late 1970s by Dr. Andreas Gruentzig and colleagues (1). They were 
able to successfully dilate initially focal atherosclerotic segments of coronary 
arteries using specially modified catheters and balloons in the majority of 
patients undergoing the procedure. However, abrupt arterial closure resulting 
from coronary dissection, coronary vasospasm and thrombus formation were 
limitations of PTCA (2, 3).  Consequences included acute myocardial 
infarction and emergency coronary artery bypass grafting (CABG) (4, 5). A 
later complication of PTCA was the gradual recurrence of stenosis 
appropriately referred to as restenosis. In Gruentzig’s original series of 
patients, 31% of patients who had follow up coronary angiograms at 6 months 
had restenosis (6). Another group also noted a similar rate of restenosis (7).  
An understanding of the underlying mechanism of restenosis was necessary 
to improve the success of PTCA. One factor thought to be implicated was 
elastic recoil of the dilated vessel following balloon inflation. This began early, 
within days of the procedure (8). A second mechanism was the development 
of what would later be termed neointimal formation (see section 1.3). The 
prevailing theory was that an inflammatory cascade initiated by injury to the 
arterial vessel wall as a result of PTCA resulted in the formation of a new 
fibro-proliferative layer leading to a reduction in the lumen of the vessel (9, 
10). A third mechanism was negative arterial remodelling after PTCA, "vessel 
shrinkage", which was measured with intravascular ultrasound (11). 
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Following an understanding of the causes of restenosis, other modalities of 
vessel dilation were explored, including atherectomy, laser ablation of 
atheroma and intracoronary stenting. Stenting has clearly become the 
dominant technique.  The mostly widely used form of atherectomy involved 
the use of a windowed cylindrical housing compressed against the stenosis. 
An attached balloon was inflated against the opposite wall of the artery. 
Atherosclerotic plaque was then shaved from the vessel wall by advancing a 
rotating metal blade and debris was collected at the tip of the catheter. The 
luminal area was increased by the dilating effect of the device itself, inflation 
of the balloon, and removal of atherosclerotic material (12, 13). However there 
was little or no advantage seen over PTCA in early randomised trials and, in 
particular, restenosis rates were worse (14, 15) or similar (15).  On the 
contrary, the first human coronary stent implantation in 1986 reported by 
Sigwart et al. (16) was  a major advance in the field of interventional 
cardiology. This was achieved by the delivery of a self expanding device 
which acted as a scaffold within coronary arteries to treat acute vessel 
dissection and reduce the risk of restenosis. Their introduction helped to 
overcome the problem of abrupt closure seen with PTCA with resultant 
reduction in the need for emergency CABG (17, 18).  Relative restenosis 
rates were also reduced by up to 20-30% in pivotal early trials compared to 
PTCA (19, 20), predominantly as a result of abolishing the problems related to 
elastic recoil and negative vascular remodelling following PTCA. More 
widespread approval for their use followed these trials. With the development 
of these other techniques, the term percutaneous coronary intervention (PCI) 
was eventually introduced to encompass all forms of coronary intervention. 
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The early stents, plus future generations of different metallic stents, without 
additional coatings or other means of applying pharmaceutical agents, have 
become collectively known as “bare metal stents” (BMS). 
Despite the introduction of BMS,  the rates of repeat revascularisation at one 
year remained relatively high at 10 to 20 percent of patients (21). This was 
predominantly related to neointimal proliferation within the stented segment. 
Neointimal proliferation can occur to a greater extent with a BMS than with 
PTCA, probably as a reaction to the foreign material remaining in the vessel 
(22). But restenosis is less because the dilation result is so much better. 
Although late loss is more, the acute gain is much higher, and the net gain is 
therefore more (Figure 1 A-B). So, research was targeted at how to get the 
benefits of stenting without the downside of neointimal growth. A number of 
different strategies were employed. These included improving stent design but 
also pharmacological, mainly systemic, therapies in conjunction with BMS. 
But the most promising was the development of drug eluting stents (DES) in 
the early 2000s. Safety and feasibility of this new concept, involving the use of 
drug coated stents with local delivery of powerful anti-proliferative drugs, was 
demonstrated by Sousa et al. along with remarkably low late loss (23). Pivotal 
trials demonstrating superiority over BMS in terms of restenosis and repeat 
revascularisation (24, 25) led to approval from the United States Food and 
Drug Administration (FDA) and widespread use. With the introduction of DES, 
it seemed as though there was finally an effective strategy for preventing 
restenosis but concerns over their long term safety were raised with higher 
rates of late stent thrombosis reported once dual antiplatelet therapy (DAPT) 
was stopped (26) (see section 1.6). The use of DAPT therapy had become 
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standard practice in the stenting era but only for 1 month with BMS. Calls for 
more prolonged DAPT use in the case of DES would potentially come at a 
cost of higher bleeding rates. Further research and development was 
therefore still required (section 1.6).   
Vascular brachytherapy (VBT), introduced in the mid- late 1990s also 
deserves some mention. This involved the successful use of intracoronary 
radiation mainly to treat restenosis following PTCA or BMS implantation (27, 
28).  Preliminary animal studies showed that these benefits may have been 
mediated by apoptosis, inhibition of the first wave of cellular proliferation, and 
prevention of adventitial fibrosis (29). However, DES were subsequently found 
to be superior in treating restenosis in BMS compared to VBT and this led to a 
decline in its use (30, 31).   
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Figure 1. Diagram showing changes in luminal diameter over time after 
coronary intervention. A) Acute gain is the difference between the minimal 
luminal diameter post procedure and pre procedure. Late loss is the 
difference between the minimal luminal diameter post procedure and follow up 
and net gain is the difference between acute gain and late loss. B) Net gain is 
higher with stents compared to PTCA because acute gain is proportionally 
higher than late loss.  
PTCA = Percutaneous Transluminal Coronary Angioplasty  
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1.2 Definitions 
Restenosis has historically been defined angiographically as reduction in 
coronary artery lumen diameter following PCI, regardless of mechanism, but 
which predominantly reflects neointimal formation when stents are used. 
However, there are some agreed definitions that are commonly employed 
including: 
Binary angiographic restenosis which refers to a greater than or equal to 50% 
reduction in the minimal luminal diameter (MLD) in the stented segment at 
follow up angiography (32).  
Clinical restenosis which is either binary angiographic restenosis and 
symptoms or signs of ischaemia or, a greater than or equal to 70% reduction 
in the MLD in the stented segment (33) . 
Although different definitions have been adopted in various scientific studies, 
binary angiographic restenosis is the most widely accepted with some 
physiologic basis. An early animal study showed that constriction of coronary 
arteries beyond 50% resulted in a reduction in coronary flow reserve (34). 
Following the widespread adoption of BMS, a  group from the Mount Sinai 
Medical Center and the Cardiovascular Research Foundation further 
proposed an angiographic classification of restenosis (Table 1) (35). The 
clinical classification has been defined in the drug eluting stent (DES) era 
(Table 2) (33). 
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Angiographic restenosis and classification 
Diameter stenosis ≥50 percent 
Type I focal: ≤10 mm in length 
-IA articulation or gap 
-IB margin 
-IC focal body 
-ID multifocal 
Type 2 diffuse: >10 mm intrastent 
Type 3 proliferative: >10 mm extending beyond the stent margins 
Type 4 total occlusion: Restenotic lesions with TIMI flow grade of 0 
 
 
Table 1. Classification of restenosis. Adapted from  Mehran R, Dangas G, 
Abizaid AS, Mintz GS, Lansky AJ, Satler LF, et al. Angiographic patterns of in-
stent restenosis: classification and implications for long-term outcome. 
Circulation. 1999 Nov 2;100(18):1872-8. 
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Clinical restenosis: Assessed objectively as requirement for ischemia-driven 
repeat revascularization 
 Diameter stenosis ≥50 percent and one of the following: 
- Positive history of recurrent angina pectoris, presumably related to target vessel 
- Objective signs of ischemia at rest (ECG changes) or during exercise test (or 
equivalent), presumably related to target vessel 
- Abnormal results of any invasive functional diagnostic test (eg, coronary flow 
velocity reserve, FFR <0.80); IVUS minimum cross-sectional area <4 mm2 (and 
<6.0 mm2 for left main stem) has been found to correlate with abnormal FFR and 
need for subsequent TLR 
- TLR with diameter stenosis ≥70 percent even in absence of the above ischemic 
signs or symptoms 
 
Table 2. Clinical restenosis. Adapted from Cutlip DE, Windecker S, Mehran R, 
Boam A, Cohen DJ, van Es GA, et al. Clinical end points in coronary stent 
trials: a case for standardized definitions. Circulation. 2007 May 
1;115(17):2344-51. 
FFR = fractional flow reserve, IVUS= Intravascular ultrasound, TLR = target 
lesion revascularisation 
The clinical definition also introduces the terms target lesion revascularisation 
(TLR), target vessel revascularisation (TVR) and target vessel failure (TVF) 
(21).  
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 TLR is defined as repeat PCI of the treated coronary segment or 
bypass surgery of the target vessel.  
 TVR includes repeat PCI of the target vessel irrespective of the 
location of the stenosis.  
 TVF is defined as TVR, any death, or myocardial infarction (MI) of the 
target vessel territory after hospital discharge. 
In the earlier days of PCI, with both balloon angioplasty and stenting, there 
was a rough rule of halves that the clinical restenosis rate was roughly half the 
angiographic restenosis rate (21). So, if one group had a 30% restenosis rate 
you would expect about 15% to have represented with recurrent symptoms.   
Quantitative coronary angiography (QCA) has been used for decades as a 
validated tool to assess stenosis severity (36). It involves computer assisted 
quantification of both disease and restenosis severity. It can be performed on-
line during PCI as well as off-line with image acquisition and processing. 
Various software packages are available and offer different techniques 
including automated edge-detection and densitometry (37). The main 
advantage of QCA in clinical trials assessing restenosis is to provide an 
objective measure compared to visual assessment. This would theoretically 
mean freedom from observer bias and therefore minimise intra- and inter-
observer variability (38, 39).Visual assessment of the severity of coronary 
stenoses leads to overestimation in severe lesions and underestimation in 
mild to moderate lesions (40).  
There are many different angiographic parameters measured by QCA (Figure 
2). Amongst them are the minimum luminal diameter (MLD), lesion length and 
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percentage diameter stenosis calculated as a percentage of the reference 
diameter of the artery. This is reliant on the reference vessel diameter being 
normal which is not always the case considering the often diffuse nature of 
coronary atherosclerosis or indeed neointimal proliferation in the case of 
restenosis. Reference diameters can also vary depending on other factors 
such as vasomotor tone and pharmacological interventions such as the 
administration of intracoronary nitrates. The MLD and its derived 
measurements, acute gain (post-PCI MLD minus pre-PCI MLD), late loss 
(MLD at follow-up minus post-PCI MLD)  and net gain (acute gain minus late 
loss) are therefore important parameters in assessing restenosis and 
minimising variability (see section 1.1, Figure 1). The late loss index is the 
relation of late loss to acute gain: late loss index is late loss divided by acute 
gain. 
There are other advanced imaging techniques such as intravascular 
ultrasound (IVUS) and more recently optical coherence tomography (OCT) 
that enhance visualisation of the vessel wall and also allow quantitative 
measurements including MLD. QCA measurements, more so with 
densitometry rather than edge detection methods, have been shown to 
correlate with IVUS following PTCA (41).  
Another key concept in evaluating restenosis is the difference between in-
stent and in-segment measurements (Figure 2 B). In-segment refers to the 
stented segment plus five millimetres proximal and distal to it. This is 
important because of the issue of “geometric miss”, caused by a response to 
barotrauma outside the stent from either the end of the stent balloon or post 
dilatation balloons. It is important that the stent balloon or post-dilatation 
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balloons do not overhang the stent too much. In order to prevent or minimise 
the effects of geometric miss, balloons were redesigned and the position of 
markers were placed relative to the shoulder of the inflated balloon.  
 
Figure 2. Diagram illustrating various parameters relating to assessing 
coronary stenoses  in relation to PCI before, after and at follow up. A) 
Coronary stenosis pre-PCI, demonstrating MLD, PRD and DRD. Diameter 
stenosis is MLD as a percentage of the averaged RD. B) Post-PCI, in-
segment measurements refer to the region within the vessel including the 
stent (in-stent) and 5mm proximal and distal to it. Acute gain is the difference 
in MLD post stenting and pre stenting. C) At follow up angiography, late loss 
is the difference between MLD at follow up and post stenting. 
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PRD = proximal reference diameter, DRD = distal reference diameter, RD = 
reference diameter, MLD = minimum luminal diameter, FU= follow up 
1.3 Pathophysiology/mechanism of restenosis 
Normal coronary arteries consist of 3 distinct layers: 
1) The intima, or innermost layer, is a narrow layer which is bound on the 
luminal side by a single layer of endothelial cells and peripherally by a 
fenestrated sheet of elastic fibres, the internal elastic lamina. There is 
also a sub-endothelial layer comprising of various components of 
extracellular connective-tissue matrix including collagenous bundles 
and some elastin. 
2) The media, or middle layer of the muscular artery, consists mainly of 
diagonally oriented smooth muscle cells (SMCs), surrounded by 
variable amounts of collagenous fibrils.  
3) The adventitia, or outermost layer of the artery, consists principally of 
fibroblasts intermixed with SMCs loosely arranged between bundles of 
collagen and ground substance. It is usually divided from the media by 
an elastin layer, the external elastic lamina (very elastic and allows 
most of the stretch of an artery). 
The most reported underlying mechanism is the response to mechanical 
injury resulting in neointimal formation (Figure 3).  This hypothesised 
mechanism stemmed from earlier work looking at the inflammatory basis for 
atherosclerosis. Experimental work involving injury to endothelial cells using 
balloon catheters provided an early insight into the cellular processes 
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occurring after arterial injury including platelet aggregation and smooth 
muscle cell (SMC) proliferation (42).  
Trauma to the arterial vessel wall by intracoronary stenting within the intima 
leads to disruption of the endothelial cell layer and actual damage to vascular 
endothelial cells. This triggers a remodelling process. Local deposition of 
platelets and fibrin mark the onset of this process (43). There is an influx of 
inflammatory cells including macrophages and T cells with consequent 
release of pro-inflammatory cytokines by these cells as well as the damaged 
endothelial cells. These, in turn, stimulate migration and proliferation of medial 
SMCs across the internal elastic lamina towards the intima. Once in the sub-
endothelial space, these SMCs co-ordinate synthesis of extracellular matrix 
(composed of proteoglycans and collagens) which is the main component of 
neointima (44-49). This process is enhanced by local production of various 
growth factors such as transforming growth factor β and platelet derived 
growth factor which are thought to shift the phenotype of these smooth 
muscle cells such that they produce abundant extracellular matrix proteins 
(50). If there is excessive growth of this neointimal layer, there will be 
resultant loss of lumen diameter. 
 Another postulated mechanism for the development of neointima includes 
differentiation of circulating progenitor cells into SMCs capable of secreting 
extracellular matrix under the influence of cytokines released by endothelial 
cell injury and triggering growth factor production. This was based on 
observations from experimental studies in animals with the use of Dacron 
grafts that became covered with endothelial cells and vascular smooth muscle 
cells despite being a barrier to smooth muscle cell migration from the media 
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(51-53). More recently, studies have provided evidence that bone marrow 
derived progenitor cells can give rise to neointimal SMCs in various types of 
native and accelerated atherosclerotic lesions, including post-PCI restenosis 
(54, 55). 
Cytokine release also stimulates migration of advential fibroblast cells across 
the external elastic lamina, through the tunica media, and across the internal 
elastic lamina to the intima. These migratory fibroblasts then differentiate into 
smooth muscle cell-like cells known as myofibroblasts with subsequent 
extracellular matrix secretion under the influence of pro-inflammatory 
cytokines and growth factors (56). 
 
Figure 3. Diagram depicting the cellular mechanism of ISR. The migration and 
phenotypic modification of SMCs within the media by platelets, inflammatory 
cells and damaged ECs is the predominant process leading to synthesis of 
ECM. ECM is the predominant component of neointima responsible for ISR.  
Differentiation of BM derived PG cells and fibroblasts with subsequent 
migration into the intima are also thought to contribute to ECM. 
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EC = Endothelial cell, BMPGC = Bone marrow derived progenitor cells, SMC 
= Smooth muscle cell, ECM = Extracellular matrix, ISR = In-stent restenosis 
1.4 Time course of restenosis 
 From post mortem and post CABG analysis of stented vessels in the BMS 
era, the time course of histological vascular responses to coronary stenting 
have been documented (Figure 4). Early (≤11 days) changes included the 
presence of fibrin, platelets and acute inflammatory cells such as neutrophils 
in association with stent struts. The severity of these changes was determined 
by the arterial wall-stent interface with more inflammatory cells seen if the 
stent was adjacent to a lipid core or injured media as compared to fibrous 
plaque. 
Chronic inflammatory cells including lymphocytes and macrophages were 
present at all time points but more so late in the process (≥12 days). 
Neointima, which comprised of spindle-shaped mesenchymal cells (α-actin 
positive smooth muscle cells) within a proteoglycan matrix, was not seen in 
any of the sections ≤11days after stent implantation. They were seen in 45% 
of sections at 12-30 days and in all sections ≥30 days after stent implantation. 
As with the early inflammatory changes where a more severe response was 
seen when stent struts were adjacent to medial laceration or rupture, 
neointimal thickness was also greater when stent struts were adjacent to 
medial injury compared to fibrous plaque in those stents implanted for ≥30 
days (48). 
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Figure 4. The time course of restenosis in bare metal stents. The early phase 
predominantly occurs within 11 days of stent implantation and represents the 
initial injury and subsequent acute inflammatory process. The late phase is 
usually complete by 30 days post implantation and involves the formation of 
extracellular matrix (ECM). Neointimal hyperplasia, in turn, is responsible for 
restenosis. 
The processes described above were mainly investigated during the PTCA 
and early BMS era. Neointima was identified as a target for reducing 
restenosis and this led to the development of DES (section 1.6). In current 
practice, and with the widespread use of DES, further mechanisms can also 
be considered (57). These include: 
 Biologic factors such as drug resistance or hypersensitivity which can 
be due to the stent platform, anti-restenotic drug or polymer carrying 
the drug. 
 Mechanical factors such as stent under expansion, non-uniform stent 
strut distribution, stent fracture and non-uniform drug elution. 
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 Technical factors such as barotrauma outside the stented segment, 
stent gap or residual uncovered atherosclerotic plaques.  
1.5 Risk factors for restenosis 
A number of clinical features have been implicated in restenosis following 
BMS implantation. The presence of diabetes mellitus has been shown to be 
an important risk factor (58). Anatomic factors shown to have an increased 
likelihood of restenosis include small vessel diameter, long lesions, chronic 
total occlusions, bifurcations, ostial location, complex lesions as defined by 
the American Heart Association/American College of Cardiology (ACC/AHA) 
classification and saphenous vein graft intervention (59-62). Diabetic patients 
are more likely to have these types of lesions. These findings may be 
explained by observations from pooled analyses of BMS studies which 
showed that by obtaining a larger luminal diameter post stenting, the chances 
of developing significant restenosis are lower because this allows for more 
neointimal hyperplasia to develop before in-stent restenosis (ISR) occurs (63). 
In other words, just as with the PTCA versus stent comparison, higher acute 
gain results in greater net gain within the stented segment. The acute gain in 
lesions with the unfavourable characteristics described above is likely to be 
smaller than in focal lesions in large vessels. Also, lesion complexity often 
relates to vessel tortuosity and calcification which make it more difficult to 
deliver and dilate larger balloons and stents. 
Following on from this, procedure and stent related factors also have an 
impact on ISR (section 1.9). It is more likely to occur with thicker stent struts 
(64), in longer stented segments (65), in multiple lesion intervention (66), in 
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treatment of restenotic lesions (67) and in association with mechanical 
complications such as stent under-expansion (68). Thicker stents may cause 
more stretching of the vessel resulting in a more severe inflammatory reaction 
leading to more neointima. As for the rest, there are likely to be multiple 
factors involved but increased injury and amount of foreign body material are 
likely to have a role. 
Whilst DES have reduced restenosis, certain factors such as patients with 
diabetes mellitus, restenotic lesions, saphenous venous graft disease and 
bifurcations remain problematic (69). 
1.6 Bare metal stents versus drug eluting stents 
Drug eluting stents (DES) were developed to reduce restenosis by inhibiting 
neointimal hyperplasia (70). The first generation DES comprised of a standard 
metallic stent, a polymer coating and an anti-restenotic drug.  The most 
studied and clinically used first generation DES included sirolimus eluting 
stents (Cypher®, Cordis, Miami, FL, USA) and paclitaxel eluting 
stents  (Taxus®, Boston Scientific, Natick, MA, USA). Sirolimus was first 
developed to prevent rejection of kidney transplants in the 1970s (70) . It is a 
macrocyclic triene antibiotic and has immunosuppressive and anti-proliferative 
properties, the latter making it attractive for use in preventing restenosis. It 
works by binding to FK506-binding protein 12 (FKBP12). FKBP12 is up-
regulated in neointimal SMCs. The resultant complex inhibits the mammalian 
target of rapamycin (mTOR), which results in up-regulation of cyclin-
dependent kinase inhibitor p27Kip1. This blocks the migration and 
proliferation of SMCs by arresting the cell cycle in the gap 1 (G1) phase (70). 
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Sirolimus therefore has predominantly a cytostatic effect. Conversely, 
paclitaxel has a cytotoxic effect. Also developed in the 1970s and used as an 
anti-tumour drug, it binds to the β-tubulin subunit of microtubules, inhibiting 
the disassembly of microtubules and thereby arresting cell replication in the 
G0–G1 and mitotic phases of the cycle of SMCs (70).  
Following the successful introduction of first generation DES, there was 
widespread uptake of their use. With regards to efficacy, DES and BMS have 
been compared in multiple randomised trials mostly involving first generation 
DES. A comprehensive meta-analysis including 38 trials (18023 patients) 
showed that patients treated with first generation DES had less TLR 
compared to BMS. The reduction in TLR overall was 70% (p<0.0001) with 
sirolimus-eluting stents (SES) and 58% (p<0.001) with paclitaxel-eluting 
stents (PES) compared to BMS (71). The risks of short- and longer-term 
mortality were similar. This was, however, preceded by a period of relative 
uncertainty driven by the simultaneous presentation of two meta-analyses at 
the European Society of Cardiology (ESC) annual conference in 2006. In what 
became known as the "ESC firestorm", the main findings from these meta-
analyses were that first generation DES, in particular sirolimus eluting stents, 
were associated with higher rates of death and the combined end-point of 
death plus myocardial infarction (MI) (72, 73). Nordmann et al. demonstrated 
a statistically significant increase in non-cardiac mortality 2–3 years after SES 
implantation (72) and Camenzind et al. showed that the cumulative incidence 
of death or large MI was 6.3% for DES versus 3.9% for BMS (p=0.03) (73). 
This was later challenged by Serruys and Daemen. They analysed patient 
level data of the same cohort and widened the definition of MI to include all 
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MI. They found the actual rate of death or MI was 11.4% in the DES group 
and 10.1% in the BMS group (p=0.4) (74). 
The proposed mechanism for the difference in events found by Camenzind et 
al. was late stent thrombosis. Delayed or incomplete endothelialisation of the 
stent platform, seen with DES, is a recognised substrate for stent thrombosis 
(75-77).This is an uncommon, yet potentially, life threatening complication. 
Following the "ESC firestorm" controversy, there were two important 
consequences. Firstly, there was a non-evidence based recommendation for 
prolongation of dual antiplatelet therapy by guideline writing authorities (78, 
79) understanding concerns over an increased risk of bleeding associated 
with their prolonged use. Secondly, there was a fall in the rates of DES use.  
Although we have seen the clear benefits of DES in reducing neointimal 
hyperplasia and also clinically driven repeat revascularisation compared to 
BMS, some studies using serial IVUS measurements in patients receiving first 
generation DES have reported a small late (2-4 years after implantation) 
increase in neointimal tissue (80, 81).  Original studies with BMS showed that 
most restenosis occurred as a relatively early event, most often becoming 
clinically evident within the first 6 months, but up to 12 months after the 
procedure. Beyond this time, recurrent ischemia was more likely to be 
due to new or progressive disease at another site rather than restenosis. The 
evidence for this was illustrated in a review of 1228 patients who were 
followed for five years. After the first year, the annual hazard rate was 1.7 
percent for target lesion events compared to 6.3 percent for non-target lesion 
events (82). Drug eluting stents, on the other hand, have a lesser degree of 
in-stent lumen loss at six to nine months (0.1 to 0.4 versus 0.8 to 1.1 mm with 
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BMS) (83, 84). The precise reason for this "late catch-up" with DES is unclear, 
but it may be related to a delayed healing response, persistent biological 
reaction caused by the drug soon after implantation, or a hypersensitivity 
reaction to durable polymer. The obvious concern here would be delayed 
restenosis. Subsequent studies have shown that “late late” restenosis occurs 
with bare metal stents as well.  
The mechanism behind very late restenosis appears to be different from early 
restenosis. Investigations have led to an understanding of what has been 
termed neoatherosclerosis. This was noted in BMS by Inoue at al. who 
reported histology findings of BMS implants on post mortem studies of 
patients who had died of non-cardiac causes. They found atherosclerotic 
changes (neovascularisation, inflammatory cells and foam cell accumulation) 
as opposed to only neointimal changes within stented segments more than 
two years old (85). They suggested the possibility that these changes were 
the result of a persistent inflammatory response to the metal foreign body. 
Hasegawa et al. also showed necrotic core elements of atherosclerosis in 
directional atherectomy specimens of patients treated for restenosis of BMS 
implants more than 5 years old (86). Interestingly, four of the series of 
fourteen samples had been from patients presenting with an acute coronary 
syndrome (ACS). In the DES era, Nakazawa et al. identified 
neoatherosclerotic changes more frequently in DES (sirolimus eluting) 
compared to BMS (35% vs 10%, p<0.001, n=143) (87). They also found that 
the timing of these changes were different, the earliest changes being seen at 
four months for DES compared to 2 years with BMS. 
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To begin with, restenosis in BMS was generally considered to be a benign 
process with most patients presenting in a stable manner with symptoms of 
recurrent ischaemia but it is now known that up to a third of patients can 
present with an ACS (88, 89). With the advent of first generation DES, 
restenosis rates were reduced but, as discussed above, there were concerns 
about delayed restenosis and stent thrombosis and all of the components of 
DES had been implicated. Newer strategies were needed. 
One of the key new developments was the evolution of second generation 
DES. Their use has now superseded first generation DES use. They include 
everolimus-, zotarolimus- and biolimus-eluting stents. These drugs are all 
derivatives of sirolimus and therefore have a similar mechanism of action. 
Everolimus was first approved for use in advanced renal carcinoma (90) 
whereas zotarolimus and biolimus were specifically developed to prevent the 
proliferation of smooth muscle and other cell types seen with restenosis (91, 
92). The newer DES also benefit from improvements in stent platform, 
including different materials and thinner stent struts, and polymer design, 
including the use of more biocompatible materials. Beyond these, there have 
also been developments in biodegradable or bioresorbable stents (93). 
However, given that some of the downside of DES might be due to these 
cytostatic anti-proliferative drugs there was also revived interest in other 
biological targets. One of these was steroids, more specifically 
glucocorticoids. 
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1.7 Glucocorticoids  
Glucocorticoids, of which cortisol is the major type in humans, are a class of 
steroid hormones that have a variety of effects but are mainly involved in 
regulation of metabolic and defence responses. They are produced in the 
adrenal cortex and are regulated by a process of negative feedback within the 
hypothalamic pituitary adrenal (HPA) axis. There is a clear circadian pattern 
with peak levels in the early morning. Most of the cortisol secreted into the 
blood is bound to corticosteroid-binding globulin and albumin with only 5-10% 
of the unbound form available to interact with receptors which are the principle 
mechanism for their interaction with cells.  Metabolic inactivation of 
glucocorticoids occurs predominantly in the liver, and also in the kidney, with 
inactive metabolites excreted in the urine (94). 
1.7.1 Mechanism of anti-inflammatory action 
Activation of the HPA axis in response to stress such as sepsis, trauma or 
tissue ischaemia results in an increase in cortisol release (95). Cortisol enters 
cells passively by diffusing across the cellular membrane and binding to the 
glucocorticoid receptor (GR) resulting in a cortisol-GR complex. It can then 
mediate its effects via three mechanisms. Firstly, the cortisol-GR complex is 
translocated into the nucleus and binds to glucocorticoid response elements 
in target genes. This leads to alterations (induction or inhibition) in 
transcription. Secondly, the cortisol-GR receptor complex can interact with 
other transcription factors, such as nuclear factor κB and thus regulate other 
glucocorticoid response elements. Thirdly, via non-genomic pathways 
involving glucocorticoid signalling through membrane associated receptors 
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and second messengers. Inflammation is inhibited by all of these pathways 
(96) (Figure 5).  
 
 
Figure 5. Mechanism of anti-inflammatory action of glucocorticoids shown in 
an endothelial cell. Adapted from Rhen T, Cidlowski JA. Anti-inflammatory 
action of glucocorticoids--new mechanisms for old drugs. N Engl J Med. 2005 
Oct 20;353(16):1711-23. 
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 Cortisol can inhibit inflammatory proteins by genomic and non-genomic 
pathways. Cortisol binds to intracellular glucocorticoid receptors (GR) 
resulting in a cortisol-GR complex. The cortisol-GR complexes enter the 
nucleus and bind to glucocorticoid responsive elements or other relevant 
transcription factors such as NF-kB (activated by cytokines in response to 
stress via membrane bound proteins) leading to induction or inhibition of 
transcription (synthesis of mRNA) (genomic signalling). The cortisol-GR 
complexes mediate their ant-inflammatory effects via second messengers 
within the cytosol as opposed to translocation into the nucleus (non-genomic 
activation). 
NF kB = Nuclear Factor kB, TNF-α = Tumour Necrosis Factor α, cortisol-GR = 
cortisol - glucocorticoid receptor, mRNA = messenger RNA 
1.7.2 Regulation of glucocorticoids and their cardiovascular effects 
Glucocorticoids also interact with mineralocorticoid receptors (MR) within the 
cell. GRs are expressed in all tissues whereas MRs are expressed in selected 
tissues only. Mineralocorticoids, principally aldosterone, are another group of 
steroid hormones that are primarily involved in regulation of electrolyte and 
water balance. Cortisol is present in much higher concentrations than 
aldosterone yet there is a difference in selectivity shown by MRs between 
cortisol and aldosterone (94).  
This difference in affinity is explained by tissue specific differences in 
expression of the enzyme 11β-hydroxysteroid dehydrogenase (11β-HSD). 
Two isozymes of 11β-HSD, type 1 and type 2 have been identified, both of 
which are microsomal enzymes of the short-chain alcohol dehydrogenase 
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superfamily. 11β-HSD type 1 (11β-HSD1) is a low affinity nicotinamide 
adenine dinucleotide phosphate (NADPH)-dependent enzyme which acts 
predominantly as a reductase converting cortisone to cortisol. Dehydrogenase 
activity is not usually seen in intact cells. 11β-HSD1 is widely expressed in 
many glucocorticoid-target tissues including liver, lung, adipose tissue, brain, 
vascular smooth muscle, skeletal muscle, anterior pituitary, gonads and 
adrenal cortex where it amplifies local glucocorticoid concentrations (97, 98).  
In contrast to 11β-HSD1, 11β-HSD2 is a high affinity nicotinamide adenine 
dinucleotide (NAD) dependent dehydrogenase isoenzyme. It converts active 
glucocorticoids into inactive 11-ketosteroids such as cortisone. It is expressed 
mainly in mineralocorticoid target tissues including kidney (distal nephron), 
sweat glands, salivary glands and colon where it protects MRs from 
occupation by glucocorticoids (97).  
This understanding of where glucocorticoids exert their influence helps to 
explain the main actions of glucocorticoids mediated by GR stimulation. The 
ubiquitous expression of GR allows glucocorticoids to have different functions. 
They are important in the regulation of carbohydrate and protein metabolism. 
Glucocorticoids are also required for blood pressure maintenance although 
the mechanisms involved are complex and incompletely understood (99). 
They also have  anti-inflammatory and immunosuppressive effects and this 
has been widely exploited from a pharmacological perspective (96). Table 3 
below illustrates the heterogeneity of glucocorticoid action on the 
cardiovascular system. 
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Site of action Via glucocorticoid 
receptors 
Via mineralocorticoid 
receptors 
Vascular smooth muscle ↑contractility e.g. to 
noradrenaline 
↑perivascular inflammation 
 ↓proliferation ↕vasoconstriction 
 ↓migration  
Endothelial cell ↓endothelium-dependent 
vasodilatation 
 
 ↓angiogenesis   
 Myocardium  ↑fibrosis 
Macrophage ↕cytokines  
 ↑apoptosis  
 ↓phagocytosis of 
apoptotic neutrophils 
 
 
Table 3. Cardiovascular effects of glucocorticoids. Adapted from Walker BR. 
Glucocorticoids and cardiovascular disease. Eur J Endocrinol. 2007 
Nov;157(5):545-59. 
1.7.3 Rationale for glucocorticoid use in restenosis 
Glucocorticoids play a key role in the response to stress, including following 
sepsis, trauma, starvation and tissue injury/ischaemia (95). Inflammation as a 
result of arterial injury with resultant SMC proliferation is the most widely 
accepted mechanism for restenosis, especially with stenting. There are a 
plethora of studies implicating pro-inflammatory mediators such as cytokines 
or chemokines in the pathogenesis of neointimal formation and restenosis and 
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this further substantiates the relevance for an inflammatory component. It is 
not surprising, therefore, that glucocorticoids, one of the most well-known and 
used anti-inflammatory agents, represented an attractive option to provide a 
crucial ‘brake’ on the innate inflammatory mechanisms that are associated 
with restenosis. They also have immunosuppressive and anti-proliferative 
effects which could be utilised to inhibit smooth muscle cell proliferation (100, 
101).  
These  mechanisms of glucocorticoid action have been described and broadly 
speaking involve transcriptional regulation of the genes associated with these 
processes (102). The anti-inflammatory effects of glucocorticoids can be 
attributed to reduction of tumour necrosis factor (TNF)-α production, nuclear 
factor (NF)-kB inhibition, inhibition of certain chemokines and interactions with 
inflammatory cell recruitment (102). TNF-α  is an inflammatory cytokine 
produced by macrophages/monocytes during acute inflammation responsible 
for a diverse range of signalling events (103). Dexamethasone has been 
shown to interfere with the production of TNF-α in endotoxin-sensitive mice 
(104). NF- kB is a protein complex controlling the  transcription of DNA in 
response to inflammation amongst other actions and is chronically active in 
atherosclerosis (105). Interference of the activated glucocorticoid receptor 
with the transactivation potential of the NF-kB p65 subunit leads to the 
reduction of gene activation by dexamethasone (106). These observations 
provide an explanation of how dexamethasone inhibits the cytokine induced 
transcription and mRNA destabilisation of inflammatory genes. As a result, 
there are reduced levels of a number of gene products potentially implicated 
in restenosis such as the chemokines monocyte chemotactic-activating factor 
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(107),  IL-8 (108), endothelial ICAM-1, E-selectin, and VCAM-1 (109-111). 
Dexamethasone has also been described to inhibit cytokine-stimulated mRNA 
expression and protein release of another chemokine, RANTES, in epithelial 
cells and T lymphocytes (112, 113), and inhibition of this has been shown to 
attenuate neointimal proliferation in mice (114). 
Dexamethasone has also been found to prevent the expression and release 
of tissue factor which induces a procoagulant response in damaged 
endothelial cells and mononuclear cells either directly or to cytokines 
indicating that it may also ameliorate endothelial dysfunction in the aftermath 
of the barotrauma of balloon injury (115, 116). 
 In addition to these anti-inflammatory mechanisms, apoptosis has also been 
implicated with restenosis. Following stretch injury by angioplasty, SMCs 
closest to the region of injury have been shown to undergo apoptosis in rats 
(117). The surviving SMCs then migrate and proliferate through phenotypic 
modulation as a response to this injury leading to neointima (118). An 
inhibition of NF-kB mobilization and NF-kB-dependent expression of anti-
apoptotic proteins (inhibitor of apoptosis protein family) has been 
demonstrated to sensitise proliferating SMCs for the induction of apoptosis, 
thereby contributing to SMC stasis (119). This could serve as an alternative 
mechanism linking anti-inflammatory and pro-apoptotic and growth-limiting 
effects (120) by which an inhibition of NF-kB transactivation with 
glucocorticoids could contribute to prevention of restenosis. 
In general terms, glucocorticoids affect key processes involved in neointimal 
formation which, when excessive, leads to restenosis. Their anti-inflammatory 
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properties allow them to affect the distribution and function of all types of 
leucocytes and, in particular, to inhibit monocytes and macrophages thereby 
targeting the early phase inflammation leading to restenosis. They may also 
have an anti-proliferative role by targeting proliferating SMCs affecting the 
later stages of the restenotic process. This may, however, be dependent on 
the delivery, dose and time-course of steroid release.  
1.7.4 Local vs. systemic delivery and clinical trials 
The discussion above has focused predominantly on the systemic effect of 
glucocorticoids mainly in the context of restenosis. Table three summarised 
the diverse actions of glucocorticoids on the cardiovascular system. Whilst 
their local anti-inflammatory properties are attractive in the battle against 
restenosis, could these be offset by adverse systemic effects?  
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Figure 6. Systemic vs. local effects of glucocorticoids on the cardiovascular 
system. Systemic actions of glucocorticoids are associated with increased 
cardiovascular risk and are likely to promote cardiovascular disease 
development. Local effects on cells of the cardiovascular system may be 
mediated by glucocorticoid (GR) and/or mineralocorticoid (MR) receptors and 
could be predicted either to promote or oppose lesion development. 
Reproduced with permission from Hadoke PW, Iqbal J, Walker BR. 
Therapeutic manipulation of glucocorticoid metabolism in cardiovascular 
disease. Br J Pharmacol. 2009 Mar;156(5):689-712.  
This question is illustrated (Figure 6) and demonstrates the interplay between 
glucocorticoid effects on GRs and MRs. For glucocorticoids to be beneficial, 
the anti-proliferative, anti-migratory and anti-inflammatory effects have to be 
greater in the blood vessels and myocardium. However, their use to prevent 
restenosis in humans has received limited investigation with variable results.  
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Synthetic compounds have potentially advantageous properties compared 
with endogenous glucocorticoid (cortisol) and therefore attempts have been 
made to utilise these to tip the balance in favour of preventing restenosis. For 
example, prednisolone and methylprednisolone have higher selectivity for GR 
than cortisol (3-8 fold) and longer bioavailability (biological half-life 16-40 
hours compared with 2-8 hours for cortisol). Other compounds such as 
dexamethasone and betamethasone have even better selectivity (25–80 
times) and longer biological half-lives (36–54 h) (121).  
With regards to systemic therapy, two general approaches have been 
investigated.  Three groups have studied the administration of 
methylprednisolone.  These studies failed to identify a benefit in reducing the 
angiographic restenosis rate (Table 4) (122-124). Two of these studies, by 
Stone et al. and the M-HEART group, were conducted in patients undergoing 
balloon angioplasty alone. The process of restenosis following balloon 
angioplasty differs from that of in-stent restenosis as in addition to neointimal 
proliferation there is also elastic coil and negative remodelling and 
glucocorticoids may have little or no impact on these. The third study involving 
stent insertion was limited in several respects.  Firstly it used single pulsed 
methylprednisolone the day of the procedure and, as such, patients received 
a relatively small total dose of corticosteroid.  The study was terminated early 
as interim analysis failed to show a prominent impact of corticosteroids on in-
stent re-stenosis.  Other limitations include incomplete angiographic follow-up 
and the selective population studied. Patients with type C lesions (most 
complex lesions) were excluded from the study and only 12% of patients 
enrolled had hyperlipidaemia. These trials did not demonstrate efficacy of a 
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pulsed approach although there were also no significant adverse systemic 
effects reported. 
Trial Year Patients 
randomly 
assigned 
Repeat 
angiogram 
(%) 
Restenosis 
rates 
(study vs. 
control) 
Dosing 
Stone et 
al(122) 
PTCA only 
1989 102 53 36 % vs. 
40% 
(p=NS) 
Methylprednisolone 
125 mg IM × 2 
doses, then 
prednisone 60 mg 
PO od × 7 days 
M-
HEART(123) 
PTCA only 
1990 915 74 40% vs. 39 
% (p=0.78) 
1000 mg 
Methylprednisolone 
IV × 1 dose 
Lee et 
al(124) 
BMS 
1998 140 91 17.5% vs 
18.8% 
(p=0.85) 
1000 mg 
Methylprednisolone 
IV × 1 dose 
 
Table 4.  Early randomized trials of glucocorticoids to prevent restenosis 
involving the use of pulsed doses of methylprednisolone. 
NS, Not significant; PTCA, percutaneous transluminal coronary angioplasty; 
BMS, bare metal stent; 
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IM, Intramuscularly; PO, bymouth; od, daily; IV, intravenously; M-
HEART, Multi-Hospital Eastern Atlantic Restenosis Trial.  
The second approach has involved the post-procedural administration of oral 
prednisone.  The IMPRESS study has shown that 45-days of oral prednisone 
in patients with elevated post-procedural C reactive protein (CRP) levels 
(CRP>0.5mg/dl at 3 days post procedure) but normal pre-procedural CRP 
levels reduces the absolute in-stent re-stenosis rate from 33% to 7% at 6 
months (125). The dose of oral prednisone used was based on the 
immunosuppressive protocol utilised for heart transplantation. This study also 
has limitations. Diabetic patients were excluded, the study population was 
highly selected with only 15% of all patients referred for percutaneous 
coronary intervention included and only 15% of their patients were receiving 
lipid lowering medication. This approach is also problematic from a logistic 
point of view. At the time of PCI, an operator needs to decide which stent type 
to give to a patient. If the only choice was a BMS, then CRP could be 
measured on day 3 and glucocorticoids prescribed accordingly, knowing that 
this might reduce the restenosis rate of at least this cohort. However, the 
majority of the population treated would not be eligible for the potential 
protective effects of glucocorticoids. Given that there is now a choice between 
a BMS and a DES, mainly on grounds of either perceived low probability of 
restenosis with a BMS, or on the desire for a short course of DAPT (eg in 
cases where early surgery for a co-existing condition is needed, or in those at 
high bleeding risk), then it is impossible to pre-emptively insert a BMS in the 
hope that the CRP will be high 3 days later. 
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Approaches involving the use of local delivery of glucocorticoid therapy have 
been employed more sparingly. In a way, they represent the best way to 
overcome the limitations associated with systemic glucocorticoid therapy and 
could potentially be an ideal solution to the question posed earlier. A small 
pilot observational study included 24 patients with high risk lesions (AHA/ACC 
Type C). Twenty one patients (in three patients the catheter did not cross the 
lesion) had local delivery of methylprednisolone acetate via a catheter based 
delivery system before elective BMS implantation. They had a restenosis rate 
of 39% and did not show any reduction in restenosis compared to matched 
controls (126). Another approach was employed in a first-in-human multi-
centre pilot trial with encouraging results (n=71). In the Study of anti-
+restenosis with the Biodivsysio dexamethasone eluting stent (STRIDE), a 
dexamethasone eluting stent which consisted of a BMS (BiodivYsio Matrix Lo, 
Abbott, USA) with a phosphorylcholine coating that was firstly bathed in 
dexamethasone and then dried was investigated. The binary restenosis rate 
was 13.3% and late loss was 0.45mm in the 60 patients with angiographic 
follow up. Diabetic patients were not included and maximum stent length was 
18mm(127).  
In contrast, a further pilot study investigating the use of the same high dose 
dexamethasone-eluting stents failed to show a reduction in restenosis. In this 
observational study of 30 patients (87% had a follow up angiogram) binary 
restenosis was observed in 8 lesions (31%) and late loss was 0.96mm which 
was similar to a comparable bare metal stent platform. Based on these 
disappointing results plans for a larger, more definitive study were abandoned 
by this group (128).  
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It is likely that despite a more targeted approach of the GR with these local 
delivery systems there remains the risk that activation of the GR in the vessel 
may induce other changes within the vessel which offset any benefit of 
conventional anti-inflammatory effects. Some of these effects include 
increasing local angiotensin II (129)  and endothelin-1 generation (130) or by 
decreasing endothelial nitric oxide generation(131)  which can be detrimental 
by stimulating smooth muscle cell migration and proliferation. 
To summarise, clinical trials on the use of systemic pulse applications after 
balloon angioplasty and stent implantation have been performed and failed to 
show a benefit. Systemic pulse application followed by a short period of 
glucocorticoid administration has been performed after balloon angioplasty 
also with disappointing results. In these studies, the failure to reduce 
restenosis could in part be attributed to an insufficient local effect, as well as a 
potentially reduced effect of a pulse application. Local delivery systems have 
had mixed results in suppression of the restenotic process in pilot studies and 
potential explanations are outlined above. The only convincing positive signal 
of glucocorticoid use in this area has been with systemic treatment with 
prednisone. This has been found to be effective in reducing restenosis and 
clinical events after stent implantation albeit in selected patients with elevated 
C-reactive protein a few days after stenting who then had a prolonged course 
of steroid. It is therefore also possible that the previous approaches did not 
sufficiently cover the period of maximal inflammation following stenting. 
These findings have to be looked at in the context of the process and timing of 
restenosis in BMS (see sections 1.3 and 1.4). The relevant merits of 
glucocorticoid therapy to prevent restenosis (sections 1.7.2 and 1.7.3) have 
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unfortunately not been realised in the majority of trials discussed above. The 
methodology employed in these trials may help to explain their results. One 
important consideration is the dose of glucocorticoid required. With regards to 
anti-inflammatory activity, the relative potencies of commonly used systemic 
glucocorticoids compared to hydrocortisone are summarised (Table 5). The 
hydrocortisone dose is roughly based on a physiological dose when used in 
patients with adrenal insufficiency (132). Ideally the dose used would have to 
be at higher than physiological levels whilst trying to avoid some of the 
complications of prolonged use. In the two studies addressing glucocorticoid 
use to prevent restenosis in BMS, the doses appear to be sufficient (Lee et 
al., 1000mg methylprednisolone and IMPRESS, a reducing regimen of 
1mg/kg for the first 10 days, 0.5mg/kg from  day 11 to 30 and 0.25mg/kg from 
day 31 to 45). The timing, however, is more relevant. The pathology of 
restenosis in BMS begins early after PCI and continues for up to 30 days post 
procedure. Lee et al. utilised only a single pulsed dose of methylprednisolone. 
They did not therefore cover the entire period. In the case of IMPRESS, 
treatment designed to cover the entire period only commenced three days 
after the procedure in a select group of patients. There was, therefore, a need 
for a more inclusive trial of glucocorticoids starting pre-PCI but extending to 
cover the majority of the period of inflammation.  
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Equivalent doses* 
(mg) 
Relative anti-
inflammatory 
activity 
Duration of action 
(hours) 
Hydrocortisone 
(cortisol) 
20 1 8 -12 
Prednisone 5 4 12-36 
Prednisolone 5 4 12-36 
Methylprednisolone 4 5 12-36 
Dexamethasone 0.75 30 36-72 
 
Table 5. Relative potencies of some commonly used glucocorticoids. 
* Equivalent anti-inflammatory dose shown is for oral or intravenous (IV) 
administration.  
Data from :  
Schimmer BP, Parker KL. Adrenocorticotropic hormone; adrenocortical 
steroids and their synthetic analogs; inhibitors of the synthesis and actions of 
adrenocortical hormones. In: The Pharmacological Basis of Therapeutics, 
11th ed, Brunton LL, Lazo JS, Parker KL (Eds), McGraw Hill, NY. p.1587. 
Copyright © 2006. 
Donohoue PA. The adrenal gland and its disorders. Kappy MS, Allen DB, 
Geffner ME (Eds), Charles C Thomas, Springfield, IL. p.403. Copyright © 
2005 Charles C Thomas, Publisher, Ltd. 
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1.8 Role of CRP 
As described earlier, inflammation is one of the predominant processes in 
restenosis following stent implantation. Cytokines such as interleukin (IL)-1 
and IL-6, secreted by activated macrophages, for example in response to 
arterial injury, are powerful stimuli for smooth muscle cell proliferation and 
hepatocyte production of a series of acute-phase proteins including C-reactive 
protein (CRP) (133, 134). CRP secretion starts four to six hours after the 
stimulus, duplicates every eight hours, and peaks within 36 to 50 hours. CRP 
has a plasma half-life of 19 hours (135). These properties led to studies on 
the role of plasma levels of CRP after PCI as a marker of the intensity of the 
inflammatory reaction responsible for neointimal proliferation and subsequent 
restenosis. There was also interest in using CRP to assess cardiovascular 
risk in the context of atherosclerosis (136) which, at least in part, shares a 
common inflammatory basis. 
In one of the early studies investigating this issue in coronary stenting, of 81 
consecutive patients with stable angina, 71% had elevated CRP levels 72 
hours following the procedure. Only these patients had adverse 
cardiovascular events during 12 month follow up, one death due to 
cardiovascular causes and 12 patients (17%) had recurrent symptoms 
requiring repeat revascularisation for ISR. The remaining 29% whose CRP 
levels had normalised had no events. The investigators excluded five patients 
with elevated cardiac biomarkers (creatine kinase (CK), CK-MB or troponin I) 
post procedure. Based on this, they concluded  that persistently elevated CRP 
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levels were not related to peri-procedural myocardial ischaemia and that this 
must be a consequence of a more intense inflammatory reaction (137).  
Two further studies also investigated the impact of elevated CRP levels on 
restenosis. However, they were interested in the effect of elevated pre-
procedural levels. Firstly, in patients treated with PTCA, Buffon et al. showed 
that after multivariate analysis in their study of 121 patients including patients 
with stable and unstable angina, elevated pre-procedural CRP levels were an 
independent predictor of clinical restenosis at 1 year (relative risk (RR) 6.2, 
95% confidence intervals (CI) 2.0-18.7, p=0.001 for comparison between the 
group in the highest and the lowest tertile of CRP levels and RR 4.5, 95% CI 
1.5-13.4, p=0.005 for comparison between the group in the middle and the 
lowest tertile of CRP levels) (138). Similarly, Walter et al. showed that there 
was a higher rate of angiographic binary restenosis after stent implantation at 
6 months for 229 of 276 patients who had repeat angiography after 
multivariate logistic regression analysis (RR 3.6, 95% CI 1.7-7.7, p<0.001)  for 
patients with pre-procedural CRP levels in the highest tertile compared to the 
lowest (139). This led the authors to conclude that patients with baseline low 
grade inflammation is an independent predictor of restenosis and therefore 
anti-inflammatory therapies could be of potential benefit in improving 
outcomes. 
Further evidence for the association of CRP with ISR comes from a small 
study using immuno-histochemical staining for CRP. Twelve consecutive 
patients undergoing angiography three to 10 months after their initial 
procedure and found to have restenosis were included. Atherectomy samples 
were obtained from them. Half of the patients had atherectomy performed and 
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half had BMS implantation as their first procedure. Exclusion criteria included 
acute or recent myocardial infarction, unstable angina pectoris, uncontrolled 
hypertension, peripheral vascular disease, heart failure, or co-existent 
conditions likely to be associated with an acute-phase inflammatory response.  
The only differences between the two groups was that the atherectomy group 
did not get the antiplatelet agent ticlopidine and the reference vessel diameter 
was larger in the atherectomy group. The patients who had stenting as their 
initial procedure demonstrated more staining for CRP and macrophages than 
those who had atherectomy performed (140).  
The studies described above have largely shown a positive association  for 
CRP with restenosis. However two studies found that raised CRP did not 
predict restenosis. In one study with 75 patients who underwent directional 
atherectomy, 58 (77%) had elevated serum levels of CRP (>0.5 mg/dl). Of 
these, 16 (27.5%) developed binary angiographic restenosis whilst 7 (41%) of 
the 17 patients with normal serum CRP levels developed restenosis. The 
difference was not statistically significant leading the authors to conclude that 
there was no correlation between elevated serum CRP levels and restenosis 
(141). Another larger study of 415 patients, also observational in design, 
included patients who underwent PTCA alone and stenting. The reported 
endpoint was clinical restenosis defined as repeat revascularisation rather 
than binary angiographic restenosis. The participants were grouped into three 
tertiles of CRP values and the ranges of CRP concentrations corresponding to 
these tertiles were: 1.06 mg/dL, 1.07 to 1.78 mg/dL, and 1.79 mg/dL for the 
first, second, and third tertiles respectively with similar numbers in each 
group. Restenosis rates were lower with increasing tertiles 18%,13% and 10% 
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respectively (OR 0.7, 95%CI 0.5-0.96,p=0.03). After adjustment for other 
confounding factors this trend was not significant (p=0.1) (142). 
As PCI with BMS became the dominant strategy, more studies assessing the 
role of CRP in predicting restenosis emerged. A meta-analysis including nine 
trials enrolling 2747 patients from 2000-2006 showed that higher pre-
procedural CRP levels were a significant predictor of angiographic restenosis 
(OR 1.59, 95% confidence interval 1.21-2.07, p=0.001). There was 
heterogeneity (χ2 14.47, p=0.07;I2=44.7%)  and publication bias was also 
detected (p=0.01, Egger's test). In particular,  a mixture of different CRP 
assays were used and three did not use highly sensitive CRP as opposed to 
the others that did. CRP threshold values were also defined differently. CRP 
was around 3 mg/l in three studies, 5 mg/l in four studies, and 6.98 and 10 
mg/l in one study. The study populations in the different studies were also 
diverse in terms of clinical syndrome. In the largest study with 834 patients, 
only patients with stable angina were recruited whilst in the other eight, the 
majority of patients had acute coronary syndromes. 
So far the role of CRP in the context of restenosis has been that of a 
biomarker. Whilst it is true that CRP is a consequence of an inflammatory 
stimulus, there is also evidence to suggest that CRP has pro-inflammatory 
effects of its own. In vitro experiments with monocytes have shown that CRP 
induces the production of inflammatory cytokines IL-1, IL-6, IL-8 and TNF-α 
(143, 144). In endothelial cells, this is less certain. CRP has been shown to 
promote endothelin-1, IL-6 (145) and activate NF-kB signalling (146) in vitro. 
But these findings have been questioned because the CRP assays used in 
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these studies were contaminated with sodium azide which was found to 
activate endothelial cells (147).  
Glucocorticoids have anti-inflammatory effects targeting some of the cytokines 
and signalling pathways described above (see sections 1.7.2 and 1.7.3). In 
addition to directly altering the response to inflammation following stenting, 
they may also therefore be able to affect the pro-inflammatory effects of CRP 
when used at pharmacological doses. Unfortunately, the studies assessing 
the role of CRP in restenosis were not randomised trials. Furthermore, they 
did not demonstrate a fall in CRP associated with glucocorticoid use.  
Glucocorticoids have been shown to decrease CRP levels in other 
cardiovascular contexts. An inflammatory basis for atrial fibrillation (AF) has 
been suggested and therefore patients with a first detected episode of 
symptomatic persistent AF were randomised to 16mg methylprednisolone for 
4 weeks followed by a tapering dose to stop at 4 months or placebo (148). 
Patients with AF secondary to a precipitating condition such as acute 
myocardial infarction or unstable angina, cardiac surgery, acute pericarditis or 
myocarditis, thyrotoxicosis, or acute pulmonary disease and patients with 
inflammatory or neoplastic conditions were excluded. CRP levels were similar 
at baseline in both groups. At one month follow up, CRP levels were on 
average 80% lower in the methylprednisolone group. They also had less 
recurrence of AF. In another study, 80 patients undergoing elective CABG 
were randomised to either glucocorticoid therapy (single dose of intravenous 
methylprednisolone) or placebo to see if the latter would attenuate the 
inflammatory consequences of cardiopulmonary bypass. IL-6, IL-8 and TNF-α 
levels were all significantly lower in the methylprednisolone group. CRP levels 
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were also significantly less at 24 and 72 hours but similar at seven days (149). 
In healthy volunteers, with no concurrent inflammatory conditions and in the 
context of normal baseline values, dexamethasone has also been shown to 
lower CRP (150). 
The evidence presented here does not provide definitive evidence for an 
association between raised CRP levels and restenosis. There is however 
potential, perhaps by association rather than causation, that it can help to 
determine which patients are most likely to benefit from aggressive anti-
inflammatory strategies such as the use of glucocorticoids. The evidence for 
benefit for such a strategy has already been described above with the results 
of the IMPRESS study.  
1.9 The influence of bare metal stents on restenosis 
Intracoronary stents were first implanted in humans  by Puel and  Sigwart in 
March 1986 (16). The original stent they employed was a stainless-steel 
multifilament, self-expanding stent and had what they described as "an 
innovative instrument for placing it" (Medinvent SA, Lausanne, Switzerland). 
In 12 of the 19 patients, in whom coronary stents were implanted with three to 
six month angiographic follow up, there was no significant luminal narrowing 
within the stents. This pioneering study represented a significant advance in 
the battle against restenosis as compared to PTCA. With greater uptake of 
this technology it became apparent that although better than PTCA, 
restenosis rates remained at an unsatisfactory level. Therefore, in addition to 
pharmacological strategies, another area of focus was stent design and 
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material. An early experimental study in rabbits showed that changing stent 
strut configurations reduced vascular injury by 42% (151). 
The ideal stents should be flexible, trackable, visible and biocompatible. The 
first two properties are dependent on stent design whilst the latter two rely on 
stent material. It follows therefore that BMSs can be classified in different 
ways: 
 By mechanism of action (section 1.9.2). 
To begin with, BMS were available as either self-expanding or balloon 
expandable (152-154). 
 By design (section 1.9.3).  
Coil stents characterised by metallic wires or strips formed into a circular coil 
shape. 
Mesh stents consisting of wires wound together in a meshwork, forming a 
tube. 
Slotted tube stents made from tubes of metal from which a stent design was 
laser cut (155). 
 By materials  (section 1.9.3) 
Stainless steel, platinum–iridium alloy, tantalum, nitinol, cobalt–chromium 
alloy, titanium, pure iron and magnesium alloys were all employed (152, 156). 
From the PTCA era, restenosis was seen only as a consequence of balloon 
injury. With the introduction of stents in their various forms, a further 
dimension had been added. Was it possible that one design was better than 
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another? Did stent material make a difference? These questions were 
especially important as numerous stent designs could be created within a coil, 
tubular mesh, or slotted tube framework. In particular, especially with slotted 
tube stents, further distinction could be made between open cell and closed 
cell types (the latter do not change form even when the stents are flexed) 
(157). There were also differences in strut pattern or thickness. These 
parameters can affect properties such as elastic recoil or rigidity of the stent 
(158, 159). With regards to materials, alloys such as stainless steel known to 
contain nickel can cause allergic reactions and so could be relevant if this led 
to excessive inflammation in susceptible patients. There were therefore early 
calls for thorough evaluation of emerging stent technologies (155). 
1.9.1 Mechanism of action 
1.9.2.1 Self expanding versus balloon expandable 
Early commercially available versions were the Wallstent™ (initially 
Schneider, then Boston Scientific, USA), a self-expanding tubular mesh stent 
with a platinum core and cobalt based alloy layer and the Palmaz-Schatz™ 
(Johnson and Johnson, USA), a balloon expandable, slotted tube stent made 
from 316L stainless steel (160). The rationale for using self-expanding versus 
balloon expandable was that they had more gentle mechanics of stent 
expansion aimed at reducing plaque fracture, edge dissections and distal 
embolisation of plaque debris. The two were compared in an observational 
study (161). Fifty patients (25 in each group), had follow up angiography 
including IVUS at a mean of six and a half months. There were differences in 
clinical and procedural factors. In the Wallstent group, more patients had a 
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history of MI (24% vs. 12%), more right coronary artery lesions were treated 
(52% vs. 13%) and coronary dissection was the indication for stenting in more 
patients (32% vs. 8%). Based on QCA and IVUS data, there was greater 
neointimal proliferation in the Wallstent group possibly due to chronic radial 
pressure exerted on the vessel wall. However, this also meant that there was 
considerable late vessel expansion (approximately 25% in terms of cross-
sectional area) in this group and therefore overall, late loss was similar 
between the two. This tendency had also been observed in nitinol based self-
expanding coronary stents  in animal studies where stent struts had migrated 
into the adventitia (162). Other limitations including the profile of the delivery 
sheath making it more difficult to cross severe lesions, mesh design making 
side branch access difficult, stent deformation (160)  and concerns about high 
rates of thrombotic occlusion (163) were among the reasons that led to the 
decline in self-expanding stent use.  
In conclusion, although self expanding stents were the first to be implanted in 
coronary arteries, they had significant limitations and this led to greater focus 
on balloon expandable stents and their design.  
1.9.2 Stent design  
1.9.2.1 Coil versus tube stents 
This discussion relates to balloon expandable BMSs. The Gianturco-Roubin™ 
(Cook,USA) was the first coronary stent approved by the FDA in 1993 (160). It 
was superseded by the GR-II™ (Cook,USA) made from 316L stainless steel 
with a coil design and was composed of a flat wire coil attached to a single 
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longitudinal strut (160). The previously mentioned Palmaz-Schatz stent, a 
modification of a peripheral artery prototype, demonstrated proof of concept 
for use in coronary arteries in an animal study (164).  It was one of the first 
BMSs with a slotted tube design made from 316L stainless steel (160) and 
was used in the defining randomised trials versus PTCA that showed 
superiority of BMS in terms of restenosis (19, 20). Consequently it became 
one of the first commercially successful stents (165). As has already been 
highlighted, the differences between these stent designs can have an impact 
on properties such as elastic recoil and rigidity. Struts are generally wider 
apart in coil stents with fewer connections between them. Tubular stents were 
found to have less recoil compared to coil stents (158, 166). Coil stents were 
more flexible (159). 
In a 'coil versus slotted tube' randomised, multicentre study of 755 patients 
between the GR-II and  Palmaz-Schatz  stents, there were better outcomes 
for the slotted tube design of the Palmaz-Schatz  stents (nine month follow-up 
angiographic binary restenosis rates at of 47.3% for GR-II vs. 20.6% for 
Palmaz-Schatz, p<0.001) (167). This was attributed to greater stent recoil with 
the GR-II (acute gain 1.57±0.52mm vs. 1.76±0.54mm for Palmaz-Schatz, 
p<0.001) and increased tissue prolapse because of more open spaces 
between struts. A design independent difference had been that operators had 
undersized the GR-II stents by approximately 20% compared to the Palmaz-
Schatz stents.  
In another such randomised study the coil design  Crossflex™ (Cordis, USA) 
stent and slotted tube NIR™ (Boston Scientific, USA) were compared in 223 
patients (168). There was a significant difference in the six month 
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angiographic primary endpoint: MLD in the Crossflex group (1.94 +/- 0.79 
mm) was less than in the NIR group (2.37 +/- 0.84 mm; P < 0.001). In contrast 
to the previous study, acute gain had been similar between the two groups. 
Consequently, late loss was also therefore higher in the Crossflex group. The 
binary restenosis rates were 26% and 17% in the Crossflex and the NIR 
groups, respectively (P = NS).   
1.9.2.2 Open versus closed cell slotted tube stents 
There was a signal that the coil design was less favourable than the slotted 
tube design and so the next generation of stents were predominantly based 
on the latter. But there was a need to incorporate some of the desirable 
properties from the coil design. Wider spaces between struts allowed more 
flexibility and also good side branch access. More contemporary BMS designs 
could therefore be further subdivided into 'open cell' and 'closed cell' tubular 
stents (Figure 7). The difference here was that closed cell stent designs do 
not change form even when flexed while open cell stents change 
conformation especially when cells grow (157). This would translate, in theory, 
to open cell designs having less radial strength (the external pressure that a 
stent is able to withstand without buckling or collapsing) and increased 
propensity to plaque prolapse but would be more conformable and have 
better side branch access compared to closed cell designs.  
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Figure 7. A) Closed cell versus B) Open cell design. Reproduced with 
permission from Cook JR, Haery C, Montoya A. M J Invasive  Cardiol 
2011;23:E183–E187 
Feasibility of this concept was demonstrated with one of the first of these 
newer generation stents, the ACS Multi-Link™ (Guidant Corporation, now 
Abbott Vascular, USA) stent (169). This was a slotted tube stent made from 
316L stainless steel with a pattern of repeating, non-overlapping loops 
connected by interposed bridges. In the Advanced Cardiovascular Systems 
MULTI-LINK Stent Clinical Equivalence in de Novo lesions Trial (ASCENT) 
trial, clinical and angiographic outcomes associated with this new stent design 
were compared to the Palmaz-Schatz stent in a randomised equivalency (or 
non-inferiority) trial design (170). At this time, the Palmaz-Schatz stent was 
the “gold standard” for regulatory-based stent comparisons. There were 1040 
patients included in the study. Angiographic inclusion criteria were single, 
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focal, de novo lesions up to 20 millimetres in length, in vessels with an 
estimated reference diameter greater than three millimetres. The primary 
outcome of TVF (death, MI or TLR) within nine months of follow up was 
similar between the groups (15.7% for Multilink vs. 16.7% for Palmaz-Schatz, 
p = 0.42). A subset of patients was chosen for routine angiographic follow up 
and this occurred in 73% of the 521 patients eligible. Binary angiographic 
restenosis was 16.0% with Multilink compared to 22.1% for the Palmaz-
Schatz group (p = 0.31). Although not a pre-specified endpoint, an interesting 
observation was that the Multilink had better deliverability with 30% fewer 
delivery failures but in addition to differences in stent design, there were also 
differences in the delivery sheath system between the stents. 
Other studies, in contrast, have shown that differences in slotted tube stent 
design can result in different outcomes. In a randomised study of 1147 
patients, patients received one of five different slotted tube stents all made 
from stainless steel: In Flow™(In Flow Dynamics, Germany), Multilink, NIR, 
Palmaz-Schatz and Pura-A (Devon Medical, Germany) (171). There was a 
statistically significant difference in the primary composite endpoint of death, 
MI and TLR at 1 year (ranging from 17.6% for the Multilink to 30.6% for the 
NIR, p = 0.004). Late loss ranged from 1.01 ± 0.70mm in the Multilink to 1.20 
± 0.84mm in the NIR (p = 0.09). After multivariate regression analysis, stent 
design remained a significant predictor of event free survival. In another 
study, the Multilink platform showed less tissue response when measured by 
IVUS compared with Palmaz-Schatz and In Flow stents (172). Mean intimal 
hyperplasia thickness (mm) was 0·16 ± 0·08, 0·26 ± 0·19, 0·39 ± 0·14 (p < 
0·001) for the Multilink, Palmaz-Schatz and In Flow respectively. 
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1.9.2.3 Modular versus slotted tube stents 
Another distinction that can be made between tubular stents is whether they 
are modular or the previously discussed slotted tube design. The modular 
cells are composed of rings welded together. This distinction has become less 
clear because of the open cell design of slotted tube stents which make them 
more like modular stents (153). The Microstent II™ (Arterial Vascular 
Engineering, USA), a type of modular stent made from stainless steel in a 
helical pattern laser fused from sinusoidal elements, was compared to the 
Palmaz-Schatz in the randomised SMART (The Microstent's ability to limit 
restenosis trial) trial (n=661). There was no difference in the primary endpoint 
of TLR (8.9% for Microstent II vs. 9.2% for Palmaz-Schatz, p = 0.83). Binary 
restenosis rates were also similar (25.2% for Microstent II vs. 22.1% for 
Palmaz-Schatz, p = 0.64). 
1.9.2.4 Strut Thickness 
Another important factor is the thickness of the stent struts. Thicker struts 
offer the theoretical advantage of better radial support but they may cause 
more injury to the vessel wall by stretching. On the other hand, whilst thinner 
struts may cause less angulation and stretching, they may slice into tissue 
more easily and therefore result in deeper injury.  
In the Intracoronary Stenting and Angiographic Results Strut Thickness Effect 
on Restenosis Outcome (ISAR- STEREO) trial, Multilink stents with different 
strut sizes were compared (173). The original thinner strut size Multilink (50 
μm) was compared to the newer but thicker strut Multilink Duet (140 μm). 
They were both made from stainless steel and were otherwise similar in 
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design apart from slightly more articulations between the struts in the thinner 
strut stent. There was significantly less late lumen loss with the thinner strut 
stent compared to the thicker strut size (0.94±0.74 versus 1.17±0.78 mm, p = 
0.001). Also, the primary end point of the trial, one year angiographic 
restenosis, was reached in 15.0% of the thin-strut stent patients and 25.8% of 
the thick-strut stent patients (p=0.003). Of note in the thin strut group, stented 
segment length was longer and final diameter stenosis post stenting was 
lower. Both of these parameters would be expected to have a negative impact 
on restenosis. Multivariate analysis confirmed this. Both of these factors were 
independent predictors of increased risk of restenosis. In addition, after 
adjusting for these variables the risk of restenosis was still significantly lower 
in the thin strut group. The investigators subsequently showed that this 
difference occurred in the most complex lesions only (174). In ACC/AHA type 
B2 or type C lesions there was a significant reduction in restenosis in the thin-
strut stent group (restenosis rate: 14.5% vs. 29.0%; P <.01 for thin-strut vs. 
thick-strut stents). The restenosis rate did not differ between stent designs in 
patients with noncomplex lesions (ACC/AHA type A or B1; restenosis rate: 
16.7% vs. 16.7%, P = 1.0 for thin-strut vs. thick-strut stents).  
In the ISAR-STEREO 2 trial, the thin strut 50 μm Multilink stent was compared 
to the BX Velocity stent (Cordis, USA), strut thickness 140 μm (64). The 
rationale for this study was to assess whether strut size made a difference in 
terms of restenosis in stents with different designs. The BX Velocity stent was 
a stainless steel, slotted tube stent with a closed cell design. Procedural data 
were also similar on this occasion and as with the previous study there was 
less restenosis in the thin strut group (17.9% vs. 31.4%, p < 0.001).   
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In another study with an observational design, stents from the Multilink 
platform were once again pitted against each other (175).  The original 
Multilink with a strut thickness of 50 μm was compared with the next 
generation Multilink Duet (140 μm), Tristar (140 μm), Tetra (mean 96 μm, 
variable strut thickness system), Penta (mean 96 μm, variable strut thickness 
system), Ultra (100 μm), and Pixel (90 μm) stents and were used when they 
became available (see section 1.10). Stents with a strut thickness of greater 
than or equal to 90 μm were considered thick-strut stents (thin strut n = 287, 
thick strut n = 376). There were significant differences in clinical and 
procedural characteristics. Patients treated with a thick-strut stent less often 
had a history of myocardial infarction or PTCA, and were receiving statin 
therapy more often at the time of inclusion, representing a change in clinical 
practice over time. The thin stent group included more patients with a 
restenotic lesion and chronic total occlusion. Stent length and reference 
diameter before the procedure were higher in the thin strut group and lesion 
length was shorter in the thin strut group. At six to ten months follow up, 
binary angiographic restenosis was 17% in both groups (p = 0.85). Late loss 
was lower in the thin strut group (0.92 ± 0.59 vs. 1.06 ± 0.71, p = 0.011).  After 
multivariate logistic regression with other factors identified from univariate 
analysis (history of PTCA, current smoking, reference diameter, stent length, 
restenotic lesions, and unstable angina pectoris) strut thickness showed an 
independent contribution to late loss. 
In all of the strut thickness comparison studies mentioned above, there were 
no differences between the groups in terms of the clinical end points of death 
and myocardial infarction. 
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With regards to the evidence presented in this discussion, a number of 
conclusions can be drawn. Of the balloon expandable stents, the tubular 
designs performed better as compared to the coil design with regards to 
restenosis, but there was little or no difference between the different types of 
slotted tube designs. Based on superior procedure success results, open 
designs such as the open cell slotted tubes or modular stents were probably 
better with regards to deliverability. One caveat that should be mentioned is 
that the results of these studies are not necessarily applicable in all lesions. 
Many of the studies did not include complex lesions such as tortuous, calcified 
or excessively long lesions. This was noted in the strut thickness studies 
where the benefits of the thinner strut stents were seen in the more complex 
lesions. The strut thickness studies, in particular the ISAR-STEREO series of 
trials, showed that within the stainless steel stents employed in those trials, 
there was a clear pattern of less restenosis with thinner strut stents. These 
findings had a profound impact on evolving stents as the message from this to 
industry was that ‘thinner is better’. There was therefore a drive towards the 
use of higher radial strength materials that would allow reductions in stent 
strut thickness such as cobalt alloys. 
1.9.3 Stent material  
Materials tested and employed for manufacturing metallic stents were 316L 
stainless steel, platinum–iridium alloy, tantalum, nitinol, cobalt–chromium 
alloy, titanium and the biodegradable pure iron and magnesium alloys (Table 
6) (156, 157). Of these, most of the early stents and indeed most of the 
evidence for intracoronary stent use were based on 316L stainless steel 
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stents (section 1.9.2). Regulatory approval for these stents led to the majority 
of commercially available stents being composed of 316L stainless steel. With 
the development of newer stents, there was a shift towards employing cobalt-
chromium alloys although it is worth noting that one of the first stents, the 
Wallstent (section 1.9.1), used cobalt chromium alloys. This shift was mainly 
because the superior radial strength of cobalt chromium would allow 
production of lower profile, thin strut stents. They were also more visible 
fluoroscopically.  
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Material Corrosion 
resistance 
Radial 
strength 
MRI 
compatibilty 
Radiopacity Bio-compatibility Commercially available 
stents (2005) 
316L SS ++ + ± + + ++ 
Pt–Ir ++ - ++ ++ ++ - 
Ta ++ - ++ ++ + + 
Ni–Ti + + ++ ± + + 
Co–Cr ++ ++ ++ ++ ++ + 
Ti ++ - ++ ± ++ - 
Fe ++ + + + ++ - 
Mg alloys + - ++ - + - 
 
Table 6. Properties and of materials used in intracoronary stent and commercial availability. 316L SS = stainless steel, Pt–Ir 
= platinum–iridium alloy, Ta = tantalum, Ni–Ti = nitinol, Co–Cr = cobalt–chromium alloy, Ti = titanium, Fe = pure iron, Mg = 
magnesium alloys
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The mechanical properties of the metals were also particularly 
important in stent development. The preferable mechanical properties 
include good elastic modulus, useful for preventing elastic recoil; high 
yield strength, the point at which the metal deforms permanently; and 
high tensile strength, the maximum stress that a material can withstand 
while being stretched or pulled before failing or breaking. For example, 
the relatively low tensile strengths of tantalum, pure iron and 
magnesium alloys theoretically make them more likely to fracture. 
Cobalt chromium and 316L stainless steel alloys appear to have the 
right balance of these mechanical properties with cobalt chromium 
having somewhat better parameters (Table 7) (156). 
Metal Elastic 
modulus(GPa) 
Yield strength 
(MPa) 
Tensile strength 
(MPa) 
316L stainless steel 190 331 586 
Cobalt chromium 210 448-648 951-1220 
Tantalum 185 138 207 
Titanium 110 485 760 
Nitinol 83 195-690* 
70-140† 
895 
Pure iron 211 120-150 180-210 
Magnesium alloy 44 162 250 
 
Table 7. Mechanical properties of metals used for making stents  
*Austenite phase, † Martensite phase 
75 
 
 
Figure 8. Chemical requirements for cobalt-chromium based on 
American Society for Testing and Materials, F90-97.Chemical 
requirements for 316L stainless steel based on American Society for 
Testing and Materials, F139-86. 
Biocompatibility is another important issue. The weight percentage of 
nickel is slightly higher in 316L stainless steel (Figure 8) (156, 176). 
Allergic reactions to the release of nickel ions can occur among 
stainless steel implants. In particular, the release of nickel ions from 
316L stainless steel stents may trigger local immune responses and 
inflammatory reactions, which in turn may induce intimal hyperplasia 
and in-stent restenosis (177). Metal ion release is not necessarily only 
related to the elemental proportions in an alloy but can be more 
influenced by stability and regeneration potential of the surface oxide 
formed when interacting with electrolytes. Nickel is disproportionately 
released from stainless steel whereas cobalt–chromium reforms the 
surface oxide faster than stainless steel leading to less nickel ion 
release (178). These may be important factors when considering the 
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disruption experienced by oxide films during stent deployment and 
therefore the likelihood of ion release from the respective materials. 
Attempts to try and circumvent this limitation by coating stainless steel 
stents (In Flow and NIR) with more biocompatible materials have been 
attempted including the use of gold coated stents but this resulted in a 
higher restenosis rate amongst the group treated with these types of 
stents (179, 180).  
Stent coatings have also been used as a means of preventing both 
thrombogenicity and restenosis. Surface characteristics of a stent 
material can influence thrombosis and neointimal hyperplasia by 
affecting how the cells involved in thrombosis and neointimal 
hyperplasia adhere and proliferate (156). In addition to gold, a variety 
of inorganic coatings have been trialled including carbon (181), silicon 
carbide (182), iridium oxide (183) and titanium-nitride-oxide (184). Of 
these, only the titanium-nitride-oxide coated stents were shown to have 
less restenosis when compared with non-coated stents. Other types of 
coatings included the use of pharmacological agents such as heparin 
and components of cell membranes such as phosphorylcholine. 
However, randomised trials failed to show a benefit in terms of both 
restenosis and stent thrombosis in heparin-coated versus non-coated 
stents (185, 186) and phosphorylcholine coated stents also did not 
confer any benefit over non-coated stents (187). Although the reasons 
why each of these coatings was chosen have not been explored in 
detail, they were selected because, in most cases, encouraging 
preclinical work had suggested they would reduce the rates of BMS 
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stent thrombosis or restenosis (156, 157). In practice, however, the 
results have mostly been disappointing. However, the advent of DES, 
also a form of ‘coated stent’, has led to renewed interest in this field 
including more biocompatible polymers for drug elution (188). 
The role of stent materials and coatings in preventing restenosis has 
been widely investigated. Early comparisons of stents were between 
stents made of the same material (primarily 316L stainless steel) and 
were primarily focused on stent design. The ‘game changer’ was the 
finding that thinner stent struts were associated with less restenosis 
compared to thicker strut stents. Despite no randomised trial data with 
regards the change in material, this led to a newer generation of stents 
made from cobalt-chromium alloys. Their superior radial strength and 
higher density allowed the production of thinner stent struts whilst 
maintaining deliverability and visibility. Stent coatings were an example 
of how early encouraging concepts may not translate into clinical 
benefit. Although this is a complex multi-factorial field, there was a 
need for a randomised trial to compare stainless steel stents with 
cobalt chromium stents. Whilst this cannot be taken as definitive 
evidence of alloy versus alloy because of differences in strut thickness 
and design, if one showed better restenosis characteristics than the 
other, it would give some strength to the arguments. If no difference, it 
may be that the expected reduction of restenosis due to reduced strut 
thickness with cobalt-chromium might be countered by some other 
factor. Ideally this comparison would be between stents of similar 
design. The Multilink platform offered the potential for this. 
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1.10 Multilink Zeta (316L stainless steel) vs. Multilink 
Vision (cobalt chromium) stents 
In 2003, the seventh generation Multilink Vision™ (Guidant, now 
Abbott Vascular, USA) was one of the earliest cobalt chromium stents 
to get FDA approval (189). The Multilink stent system had evolved from 
316L stainless steel stents beginning with the original ACS Multilink 
through to the sixth generation Multilink Zeta™. The original Multilink 
had a strut thickness of 50 μm compared with the next generation 
Multilink Duet (140 μm), Tristar (140 μm), Tetra (90-125 μm, variable 
strut thickness system), Penta (90-125 μm, variable strut thickness 
system). The original ACS Multilink was designed in the 'pre ISAR-
STEREO era' and so the impact of thinner struts in practice had not yet 
been realised. Because of its low visibility thicker strut designs were 
favoured with newer generations. There were also other subtle 
redesigns in terms of links between cells as the series progressed in 
keeping with studies of that time (section 1.9.2). For example, 
compared with the Multilink Tetra stent, the Multilink Penta stent had a 
modified link pattern, which improved flexibility and scaffolding and 
allowed better expansion of cells to help maintain side-branch access 
when treating bifurcation lesions( Figure 9). 
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Figure 9. Evolution of the MULTI-LINK ™ stent system. Reproduced 
with permission from Abbott Vascular company documents. 
The manufacturer’s product information describes the Multilink Zeta as 
being identical to the Penta (190). They were slotted tube stents with 
an open cell design. The variable strut thickness was an innovative way 
to improve visibility whilst maintaining flexibility by using thinner curved 
struts and thicker straight struts for better visibility (Figure 10). 
 
Figure 10. Variable thickness strut technology of the Multilink Zeta. 
Reproduced with permission from Abbott Vascular company 
documents. 
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Figure 11. Design of the Multilink Zeta and Vision. A) Footprint of the 
Zeta stent. B) Close up of Zeta stent. C) Footprint of the Vision stent. 
D) Close up of the Vision stent. They are both open cell stents with only 
subtle differences in the articulations between the struts. Reproduced 
with permission from Abbott Vascular company documents. 
The Multilink Vision is a chromium cobalt, balloon expandable, open 
cell slotted tube stent and is 81 μm thick (176) and has a similar design 
to the stainless steel Zeta stent (Figure 11). FDA approval was largely 
based on a prospective, multicenter registry (n=268) that demonstrated 
the efficacy of the Multilink Vision stent (176). In this study 23% of the 
patients were diabetic, 40% had complex lesions (ACC/AHA type B2 
(33%) / C (7%), mean reference diameter was 2.94 mm and mean 
lesion length was 10.6 mm. The average stent length deployed per 
patient was 17.2 mm. The primary endpoint of target vessel failure 
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defined as a composite occurrence of death, myocardial infarction, and 
target vessel or target site revascularization was 6.7% at 180 days. Six 
month QCA parameters included mean reference diameter of 2.92 mm, 
late loss of 0.83 mm and a binary restenosis rate of 15.7%. The 
authors of this registry went on to compare late loss between the 
cobalt-chromium stent with historical data from earlier registries with 
other 316L stainless steel Multilink stents (191) without any statistical 
analysis. In these registries (n=575 with angiographic follow up), the 
number of diabetics (21%) were similar but more complex lesions were 
treated (AHA/ACC Type B2, 54-56%; Type C 6-10%). Mean reference 
diameter (3.0mm), lesion length (11.65 mm) and stent length (18.8 
mm) were comparable. They showed that mean late loss was 0.83 mm 
in the 81μm Multilink Vision compared to mean late loss of 0.78 mm in 
the original ACS Multilink, 1.0 mm in the Duet and 1.05 mm in the 
Tetra. In comparison, the average binary restenosis rate for all the 
stents in the stainless steel registry was 19.6% (191).  
The data for the Multilink Vision therefore appeared favourable. 
However, more firm conclusions could be drawn by performing a 
randomised comparison with a similar contemporary stainless steel 
design, the Multilink Zeta. 
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CHAPTER 2 
Methodology 
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2.1Trial design 
The SSTARS trial was a multicentre randomised controlled trial with a 
factorial design. Double randomisation occurred, prednisolone 
compared to placebo and cobalt chromium stent compared to stainless 
steel stent. This design allowed for evaluation of the two interventions 
simultaneously. In total, there were four possible treatment 
combinations, prednisolone and stainless steel stents, placebo and 
stainless steel stents, prednisolone and cobalt chromium stents and 
placebo and cobalt chromium stents.  
2.2 Setting and Structure 
The study was performed in the cardiothoracic units of The James 
Cook University Hospital, Middlesbrough, and  the Royal Edinburgh 
Infirmary between January 2006 and October 2012. 
The trial structure and committees were as follows: 
Investigators 
Dr. Andrew Turley - Chief Investigator, Consultant Cardiologist, The 
James Cook University Hospital, Middlesbrough  
Dr. Zulfiquar Adam - Principal Investigator, Specialty training registrar 
and Research fellow, The James Cook University Hospital, 
Middlesbrough  
Dr. Steven Jones -  Co-investigator, Senior lecture/Consultant 
Endocrinologist, The James Cook University Hospital, Middlesbrough 
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Professor Rudy Bilous- Co-investigator, Senior lecture/Consultant 
Endocrinologist, The James Cook University Hospital, Middlesbrough 
Independent data and safety monitoring committee 
Dr V Connolly -  Senior lecture/Consultant Endocrinologist, The 
James Cook University Hospital, Middlesbrough    
Dr S Nag -  Consultant Endocrinologist, The James Cook 
University Hospital, Middlesbrough  
Dr R Bellamy - Senior Lecturer/Consultant Physician Infectious 
Diseases, The James Cook University Hospital, Middlesbrough 
Clinical events committee 
Dr Richard Graham -Consultant Cardiologist, The James Cook 
University Hospital, Middlesbrough      
Sr Jackie Tough - Cardiology Nurse Consultant, The James Cook 
University Hospital, Middlesbrough   
Steering committee 
Dr. Mark de Belder -Consultant Cardiologist, The James Cook 
University Hospital, Middlesbrough  
Dr Andrew Sutton - Consultant Cardiologist, The James Cook 
University Hospital, Middlesbrough   
Dr. Neil Swanson -  Consultant Cardiologist, The James Cook 
University Hospital, Middlesbrough   
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2.3 Study population and recruitment 
Patients admitted for percutaneous coronary intervention for 
obstructive coronary artery disease were considered for the study. 
They were identified from the elective waiting list or were awaiting 
angiography after an acute coronary syndrome, whether presenting 
locally or from the inter-hospital transfer list.  
For acute transfer patients, they were seen on the day of their transfer.  
Local patients were approached once a decision to perform 
angiography had been made.  For elective patients, they were seen in 
a pre-admission clinic within 7-days of their planned procedure. 
2.3.1 Inclusion criteria 
Patients were included if they met the following criteria: 
 Any patient awaiting percutaneous coronary intervention for 
symptomatic coronary artery disease (elective or acute). 
 Documented myocardial ischaemia. 
 Coronary angiography demonstrating at least a 50% reduction of 
the luminal diameter in at least one native coronary artery (as 
measured by quantitative computerised angiography). 
 Any lesion for which the operator (interventional consultant 
cardiologist) felt a non-drug eluting stent was appropriate. 
2.3.2 Exclusion criteria 
Patients were excluded if they met any of the following criteria: 
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 Proposed use of a drug eluting stent (in the study lesion(s)). 
 Left main stem stenosis 
 Primary PCI for ST elevation myocardial infarction 
 Steroid therapy within 30-days of study enrolment. 
 Contraindication to corticosteroid use. 
 Previous inclusion in this study. 
 Non-cardiac disease likely to cause death within 6-months. 
 Inter-hospital transfers from Cumbria (out of region). 
2.3.2 General assessment 
Following written informed consent, all patients had cardiovascular risk 
factors, past cardiac history, drug history, body mass index (BMI) and 
blood pressure recorded. Stable angina symptoms were defined 
according to the Canadian Cardiovascular Society (CCS) classification.  
The New York Heart Association (NYHA) classification was used to 
classify breathlessness. 
2.3.3 Medical management 
The administration of pharmacological agents including aspirin, 
clopidogrel, beta-blockers, angiotensin-converting enzyme (ACE) 
inhibitors, statins, nitrates and calcium channel blockers was at the 
discretion of the attending physician.  Clopidogrel 75mg daily (for four 
days pre-PCI) or if  less than four days pre-PCI two loading doses of 
300mg followed by 75mg daily was commenced. 
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2.4 Randomisation  
The trial featured a mixed single and double blinded randomised 
controlled design where both the patients and the physicians 
performing PCI were blind to the prednisolone/placebo allocation but 
only the patients were blinded to the stent allocation. Patients were 
block randomised to prednisolone or placebo prior to angiography and 
subsequently to cobalt chromium or stainless steel stent once eligibility 
was confirmed angiographically.  
2.4.5 Steroid randomisation procedure 
For the first randomisation, participants were randomly allocated in a 
1:1 ratio to receive prednisolone or matched placebo according to a 
randomisation sequence generated in advance by software called 
Prisym 2000. The tablets were manufactured and provided by Sharp 
Clinical Services (Powys, Wales, UK). The first randomisation was 
produced in 2005 and was generated for 500 patients as a balanced 
block of four and subsequently further consignments for 250 patients at 
a time were produced as the trial progressed. Individual sealed 
envelopes containing treatment allocations were given to trial 
pharmacists in both centres. Treatment allocation was masked from all 
trial personnel and participants.   
Elective patients were randomised at the time of their pre-admission 
clinic attendance (one week prior to the procedure) and assigned to the 
respective study arms. 
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Urgent patients were randomised before their procedure and assigned 
to the respective study arms. 
2.4.6 Stent randomisation procedure 
For the second randomisation between stainless steel and cobalt 
chromium stents, participants were also randomised in a 1:1 ratio in 
blocks of 10 using the open source statistical programme R by a 
hospital audit officer who was not part of the trial team. R is a free 
software environment for statistical computing and graphics. It compiles 
and runs on a wide variety of UNIX platforms, Windows and Mac OS 
and is available for free download from http://www.r-project.org. To use 
the package commands are typed in to the R console window, the 
command used to generate binomial random variables is the rbinom 
function (192). The command takes the following arguments rbinom (n, 
size, probability) (Figure 12). Again, individual sealed envelopes were 
used and given to the research nurses once the participant's coronary 
anatomy was deemed suitable for the trial.  
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Figure 12. An example of the generation of 10 random variables 
between 0 and 1. The numbers 0 and 1 were used to randomly assign 
the letters A and B for the second randomisation arm in the SSTARS 
study. 
2.5 Registry 
Patients found to be ineligible were withdrawn from the main study and 
instead entered into a registry. The trial initially recruited mainly elective 
patients in whom angiographic status was known prior to recruitment 
but over the course of the trial most patients progressively underwent 
PCI immediately following angiography. This was mainly because there 
was a shift towards performing more urgent coronary angiography for 
ACS patients. 
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2.6 Medication and procedures 
2.6.1 Medication protocol 
Patients were randomised to oral prednisolone or placebo. The first 
dose had to be administered at least six hours pre-procedure and this 
was to continue for a total of 28-days. The dosing regimen for 
prednisolone is shown (Table 8). 
Days Dose 
1-14 40mg 
15-19 20mg 
20-24 10mg 
25-28 5mg 
 
Table 8. Prednisolone dosing regimen. 
Study drug was handled in accordance with the protocol and the 
container label. The study medication was stored in a locked, 
designated, study drug cabinet. Study drug was dispensed by a 
suitably qualified and designated member of staff under the guidance 
of a hospital pharmacist. 
Due to dual oral antiplatelet therapy plus oral corticosteroid use, all 
patients received empirical proton pump inhibitor cover (Lansoprazole 
30mg/day for 28-days) for the duration of the glucocorticoid/placebo 
course. 
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2.6.2 Coronary angiography and PCI 
Coronary angiography was performed in the standard manner (Judkin 
technique) via femoral or radial artery puncture.  The angiographic 
information recorded was the extent of coronary artery disease (1 
vessel disease (VD), 2 VD with proximal left anterior descending artery, 
2 VD + other, 3 VD, 4 VD [i.e. including a large intermediate vessel as 
a fourth vessel], left main stem (LMS), normal coronaries or minor 
disease), modified “Duke” score and AHA/ACC lesion class. A 50% 
reduction in luminal diameter was classed as significant for left main 
stem lesions. 
As described earlier, all patients were pre-treated with clopidogrel as 
per unit protocol.  After sheath insertion, a bolus of heparin was 
administered (dose: weight related with a minimum of 70u/kg).  
Lesion predilation was recommended using standard balloons and 
guidewires, with the operator choosing the balloon size and stent size.  
Inflation pressures, duration of inflations and stent length and diameter 
were recorded.  Glycoprotein IIb/IIIa receptor blocker treatment was 
given at the discretion of the interventional cardiologist once the patient 
was in the coronary angiography lab. 
Lesions in large vessels were treated according to randomisation 
between stainless steel Multi-link Zeta™ (Guidant/Abbott vascular, 
USA) and cobalt chromium Multi-Link Vision™ (Guidant/Abbott 
vascular, USA) stents.  These stents were commercially available 
stents. Lesions in small vessels were treated with sirolimus-eluting 
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Cypher Select® stents (Cordis, USA).  After the procedure, arterial 
sheath removal occurred once the activated clotting time (ACT) fell 
below 150 seconds in the case of femoral sheath insertion. For 
procedures performed via the radial artery, the sheath was removed 
immediately post procedure with the application of a TR band® 
(Terumo) for haemostasis as per standard practice in the unit. 
Patients continued to receive aspirin 75mg od (at least) indefinitely and 
Clopidogrel 75mg once daily for a minimum of 4 weeks. 
2.7 Quantitative coronary angiography 
Quantitative angiography analysis was done by use of the automated 
edge-detection system (Philips Inturis) a research fellow. Thirty 
randomly selected measurements were reanalyzed by the same 
research fellow. Results were reproducible. The mean of the difference 
between measurements was 0.09 ± 0.3 mm (p = 0.55) for MLD and 
0.10 ± 0.25 mm (p = 0.31) for diameter stenosis. 
Measurements were made in diastole and performed in two orthogonal 
views after administration of 200μg of intracoronary nitrate.  The 
contrast filled guiding or diagnostic catheter was used for magnification 
calibration. Quantitative coronary angiography measures included: 
minimal luminal diameter (MLD); reference diameter, derived as either 
an average of the proximal and distal  reference diameters  or the 
interpolated diameter derived by the software for the selected segment; 
percent diameter stenosis; in-stent restenosis, defined as ≥50% 
diameter stenosis within the stent at follow up; in-segment restenosis, 
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defined as ≥50% stenosis within the stented segment or within 5mm 
proximal or distal to the stent edges; acute gain, defined as the 
difference between MLD after stent implantation and the MLD before 
PCI; late loss, defined as the difference between the MLD after stent 
insertion and the MLD at follow up; net gain,  defined as the difference 
between acute gain and late loss. 
2.8 Follow up 
Patients were seen by a research nurse at three intervals. They were 
seen seven days after taking the first dose of study medication, 
subsequently at 30 days and finally when they attended for their follow 
up angiogram at six months. For registry patients there was only 
telephonic follow up at six months. 
2.8.1 Clinical assessment 
Mortality, non-fatal ischaemic event rate (re-admission rates for an 
ACS), additional revascularisation rate, NYHA and CCS classification 
data, and repeat hospitalisation rates were collected at each follow up 
visit for all patients recruited into the study. 
2.8.2 Blood tests 
Blood samples were taken from all patients as part of the standard pre-
assessment work-up for percutaneous coronary intervention (full blood 
count, coagulation, urea and electrolytes, serum glucose/HBA1c and 
lipid profile).  These samples were fasting samples. Once the patient 
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was entered into the study, further samples were taken for the 
measurement of highly sensitive CRP (hs-CRP) at different intervals 
prior to and after PCI. 
Serum hs-CRP was stored for subsequent analysis in a –80oC freezer.  
The samples were measured in batches after the patient had 
undergone coronary revascularisation. Biochemistry scientists were 
blinded to the clinical condition and angiographic findings of the study 
cohort. 
All patients also had fasting serum glucose and glycated haemoglobin 
(HbA1c) checked seven days post PCI, on completion of the oral 
prednisolone course and at the time of angiographic follow up. 
Due to the potential problem of hyperglycaemia in patients randomised 
to corticosteroid treatment, all patients were given home monitoring BM 
sticks. Prior to hospital discharge they were instructed on the correct 
use of home monitoring by a qualified cardiology or research nurse. 
They were also educated on normal values and provided with contact 
details of the research team, in hours, or cardiology on call team, out of 
hours, for support and advice if their BM recordings were high. 
2.8.3 Angiographic assessment 
A follow up coronary angiogram was performed six months after the 
initial procedure or earlier if clinically indicated. The follow up 
angiogram was also performed using standard techniques and 200g 
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of intracoronary nitrate was administered using the same projections as 
the baseline angiogram.  
Follow up was terminated after an end-point had been attained or the 
follow up angiogram had been performed. The time window for 
performing diagnostic angiography was 6 ± 2months. A time window 
was included for the six month angiogram because it would not always 
be possible to perform an angiogram exactly at six months. There are 
various reasons for this including clinical priority overriding research 
interests during busy periods, patient preference for angiogram to be 
delayed due to personal circumstances or clinical need to delay 
angiography. 
2.9 Outcome measures 
The primary endpoint was in-stent restenosis determined 
angiographically as restenosis of at least 50% diameter within the stent 
segment at 6 months follow-up, or determined earlier for clinical 
reasons. 
Angiographic measures included minimal luminal diameter (MLD) and 
reference diameter determined proximally, distally, averaged and 
interpolated; as well as derived measures percent diameter stenosis, 
late loss, acute gain and net gain.  Anticipated major complications 
death, myocardial infarction, cerebrovascular accident and repeat 
hospitalisation were recorded together with revascularisation, ECG and 
cardiac markers changes.  
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2.10 Withdrawal and safety 
Patients could withdraw from the trial at any point without alteration in 
standard care. The patient could be withdrawn if their attending 
clinician judged that circumstances arose as a consequence of being in 
the trial that were detrimental to the individual. All patients were 
monitored for bleeding or hyperglycaemia due to steroid administration. 
Adverse events were recorded according to expectedness and 
relatedness. 
2.11 Ethics and governance 
Conduct of the trial was subject to local site and London Multicentre 
Research Ethics Committee (MREC) approvals (ref: 04/MREC2/061) 
and registered with UK Trials (ISRCTN 05886349). 
 
 
 
 
 
 
 
 
 
97 
 
CHAPTER 3 
Statistical Analysis 
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The primary research question was whether treatment with steroids 
was associated with a reduction in the proportion of patients 
experiencing in-segment restenosis. The study also investigated 
whether any such benefit was available with both stainless steel and 
cobalt chromium stents. The in-segment restenosis rate of the cobalt 
alloy stent was estimated to be 15% based on registry data available at 
the time (176, 193), compared to 30% for the stainless steel. This effect 
size between stents was likely to be smaller than the difference for the 
estimated effect of prednisolone. The IMPRESS study using 
prednisolone and stainless steel stents demonstrated a reduction in the 
in-segment re-stenosis rate from 33% to 7% (125). 
Participants were randomised in a balanced 2 x 2 factorial design. 
Using the smaller effect size of 15% (for the stent comparison), and 
assuming loss to follow-up of 15%, a value for  of 0.05 and a power 
(1-) of 80%, 137 patients per group (548 in total) would be needed, 
provided there was no interaction between the two comparisons. The 
sample size would thus be sufficiently large to detect both the effect of 
administration of prednisolone and of cobalt chromium stents assuming 
no interaction. 
In factorial designs, if interaction is an important factor a Variance 
Inflation Factor (VIP) is needed to ensure sufficient power to detect the 
two effects and their interaction (only a factorial design is capable of 
investigating interactions). The maximum theoretical inflation requires a 
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doubling of the sample sizes for each effect (making the sample 4 
times larger overall) (194). 
In this case, the sample size would be approximately two fifths larger 
than needed (in the absence of interaction) to detect the predicted 
effect size for the use of steroid because the sample size had been 
calculated using the smaller effect size for the difference between 
stents (i.e. 15% rather than 26%). This conservative sample size 
calculation therefore allowed some room for interaction whilst achieving 
a statistically significant result for use of steroids. If an important 
interaction did exist, the benefit of one of the stents may not achieve 
statistical significance and further research would be needed to 
investigate this unexpected phenomena. The loss to follow-up estimate 
was also conservative at 15%. 
As outlined in Chapter 4, the planned sample size was not achieved 
and 315 patients were recruited within the constraints of unplanned 
complexities for patient identification and recruitment. The power 
calculation for the study was revisited prospectively before analysis of 
trial data and informed by recent evidence. Assuming restenosis 
occurred in 30% of patients, and that both cobalt chromium stenting 
and prednisolone might halve the risk of restenosis, the average 
‘intervention rate’ would be 11.25% and the average ‘control’ would be 
22.5% within each comparison group. Assuming alpha=5%, the trial 
now had 72% power to detect an absolute difference of 11.25% 
between groups, assuming a two-sided test (nQuery+nTerim 2.0). 
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Analysis was performed by the principle of intention to treat (ITT), with 
analyses conducted according to assignment at randomisation (195, 
196).  Primary inference was based on the primary endpoint analysis 
as a difference in proportions, using Fisher’s exact test (197) with 
statistical significance at the 5% level (2-sided), for combined stent 
groups and drug groups. Analyses of all secondary endpoints and 
adjusted analyses were considered supportive to the primary analysis 
so no adjustments for multiple comparisons were made. 
Sensitivity analysis of the primary endpoint was analysed at the level of 
the patient and lesion using generalized linear models (GLMs) with 
separate indicator variables for steroid and stent groups as well as their 
interactions. Secondary analyses explored changes in angiographic 
measures using GLMs (198, 199), and the role of covariates such as 
CRP level . Major adverse cardiac events (MACE) such as death were 
analysed as time-to-event by survival analysis to compare hazard of 
death in the comparison groups. 
Patient demographics and other study endpoints involving categorical 
variables were estimated using Fisher’s exact test; continuous 
measures were evaluated using Students t-test where appropriate, 
otherwise suitable non-parametric tests were used.  
Intention to treat principle allows for modification due to missing data, 
for which there is no completely satisfactory remedy since strong 
assumptions are required regardless of the approach taken(198, 200).  
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CHAPTER 4 
Results 
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Between January 2006 and March 2012, 893 patients were recruited 
into the study having been randomised to either placebo or 
prednisolone (Figure 13). Of these, 315 patients underwent a second 
randomisation and were included in the main study. A total of 359 
lesions were treated. The remaining 578 patients were entered into the 
registry (see section 4.7). The trial was terminated early because 
changes in clinical practice, with a rapid increase in the use of DES and 
an increase in the use of follow-on angioplasty for both elective and 
acute cases (where first randomisation occurred prior to the 
angiographic findings), made continuation increasingly difficult.  
4.1 Baseline characteristics 
The mean age of participants was 60 years (range 37 to 87 years), 
85% were male, 42% were elective PCI cases and the mean number of 
lesions treated was 1.14 (range 1 to 4). As far as conventional risk 
factors for coronary artery disease were concerned, 11% were diabetic, 
56% had a positive family of ischaemic heart disease, 51% had a 
history of hypertension, 89% had hypercholesterolaemia and 65% had 
a history of smoking. 
Groups were similar at baseline, there were no significant or important 
baseline differences comparing groups apart from the maximum 
balloon inflation pressures between prednisolone and placebo (16.3 
atm vs. 17.0 atm, p=0.02) (Tables 9-11). In particular, there was no 
statistically significant difference in the proportion of diabetics, 
AHA/ACC complex lesions (type B2 or C) or lesion length and stent 
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length which are all risk factors for restenosis. Of 315 patients, 308 
(98%) received the treatment allocated to them. Failure to receive 
allocated therapy only occurred after the second randomisation where 
failed PCI with the study stent resulted in a non-study stent being used. 
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Figure 13. Consort diagram. *Physician directed, †Failure to deliver 
study stent, ‡ Saphenous vein graft treated (study exclusion criteria). 
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Table 9. Baseline demographic data and risk factors. Count data shown as: count (%); comparisons: Fisher's exact test. Numeric 
data shown as: mean (SD); comparisons: independent samples t-test. *For drug comparisons and stent comparisons only % and 
mean.  
CoCr = cobalt chromium, SS = stainless steel, Pl = placebo, Pred = prednisolone, IHD = ischaemic heart disease, MI = myocardial 
infarction, CABG = coronary artery bypass grafting, PCI = percutaneous coronary intervention, TIA = transient Ischaemic attack, 
CVA = cerebrovascular accident, PVD = peripheral vascular disease, LVSD = left ventricular systolic dysfunction  
 
Placebo 
    
Prednisolone 
    
Drug*  Stent* 
 
 
CoCr N=65 
 
SS N=80 
 
CoCr N=90 
 
SS N=80 
 
Pl Pred p CoCr SS p 
Actual treatment 64 (98.5%)  79 (98.8%)  87 (96.7%)  78 (97.5%)  100% 100% - 97% 98% 
 Male 56 (86.2%)  68 (85.0%)  74 (82.2%)  71 (88.8%)  85.5% 85.3% 1.00 83.9% 86.9% 0.52
Age, y 60.2 (9.6)  60.0 (8.5)  59.5 (10.3)  62.2 (9.7)  60.1 60.8 0.54 59.8 61.1 0.23 
Height, m 1.73 (0.08)  1.74 (0.09)  1.73 (0.09)  1.74 (0.08)  1.73 1.74 0.89 1.73 1.74 0.38 
Weight, kg 85.5 (17.6)  87.5 (15.4)  88.9 (18.8)  86.7 (14.7)  86.6 87.9 0.50 87.5 87.1 0.82 
Smoking status 
  
 
  
 
  
 
  
   0.67   0.53 
never smoked 22 (33.8%)  30 (37.5%)  33 (36.7%)  24 (30.0%)  35.9%
% 
33.5% 
 
35.4% 33.8% 
 ex-smoker 19 (29.2%)  30 (37.5%)  33 (36.7%)  33 (41.3%)  33.8  38.8% 
 
33.5% 39.4% 
 current smoker 24 (36.9%)  20 (25.0%)  24 (26.7%)  23 (28.8%)  30.3% 27.6% 
 
31.0% 26.9% 
 History of hypertension 35 (53.8%)  42 (52.5%)  50 (55.6%)  35 (43.8%)  53.1% 50.0% 0.65 54.8% 48.1% 0.26
Family history of IHD 40 (61.5%)  42 (52.5%)  50 (55.6%)  45 (56.3%)  56.6% 55.9% 0.91 58.1% 54.4% 0.57 
Previous MI 9 (13.8%)  10 (12.5%)  8 (8.9%)  12 (15.0%)  13.1% 11.8% 0.73 11.0% 13.8% 0.50 
Previous CABG 3 (4.6%)  0 (0.0%)  1 (1.1%)  1 (1.3%)  2.1% 1.2% 0.67 2.6% 0.6% 0.21 
Previous PCI 0 (0.0%)  3 (3.8%)  5 (5.6%)  7 (8.8%)  2.1% 7.1% 0.06 3.2% 6.2% 0.29 
Previous TIA/CVA 1 (1.5%)  1 (1.3%)  3 (3.3%)  4 (5.0%)  1.4% 4.1% 0.19 2.6% 3.1% 1.00 
History of PVD 1 (1.5%)  4 (5.0%)  4 (4.4%)  0 (0.0%)  3.4% 2.4% 0.74 3.2% 2.5% 0.75 
History of LVSD 2 (3.1%)  7 (8.8%)  3 (3.3%)  5 (6.3%)  6.2% 4.7% 0.62 3.2% 7.5% 0.13 
Renal disease 0 (0.0%)  0 (0.0%)  0 (0.0%)  0 (0.0%)  0.0% 0.0% - 0.0% 0.0% - 
Diabetes (I or II) 6 (9.2%)  8 (10.0%)  13 (14.4%)  7 (8.8%)  9.7% 11.8% 0.59 12.3% 9.4% 0.47 
Insulin diabetic 1 (1.5%)  2 (2.5%)  2 (2.2%)  0 (0.0%)  2.1% 1.2% 0.67 1.9% 1.2% 0.68 
Hypercholesterolaemia 61 (93.8%)  72 (90.0%)  76 (84.4%)  70 (87.5%)  91.7% 85.9% 0.11 88.4% 88.8% 1.00 
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Table 10. Baseline clinical and biochemistry characteristics. Count data shown as: count (%); comparisons: Fisher's exact test. 
Numeric data shown as: mean (SD); comparisons: independent samples t-test. *For drug comparisons and stent comparisons % 
and mean only.  
CoCr = cobalt chromium, SS = stainless steel, Pl = placebo, Pred = prednisolone, ACS = acute coronary syndrome, STEMI = ST 
elevation myocardial infarction, GP IIb/IIIa= glycoprotein IIb/IIIa inhibitor  
 
 
Placebo 
    
Prednisolone 
    
Drug  Stent 
 
 
CoCr N=65 
 
SS N=80 
 
CoCr N=90 
 
SS N=80 
 
Pl Pred p CoCr SS p 
Elective PCI 26 (40.0%) 
 
35 (43.8%) 
 
37 (41.1%) 
 
34 (42.5%)  42.1% 41.8% 1.00 40.6% 43.1% 0.73 
ACS type 
   
 
  
 
    
   0.58   0.81 
unstable angina 11 (16.9%)  6 (7.5%)  14 (15.6%)  14 (17.5%)  11.7% 16.5% 
 
16.1% 12.5% 
 non-STEMI 25 (38.5%)  32 (40.0%)  34 (37.8%)  29 (36.3%)  39.3% 37.1% 
 
38.1% 38.1% 
 STEMI 3 (4.6%)  7 (8.8%)  5 (5.6%)  3 (3.8%)  6.9% 4.7% 
 
5.2% 6.2% 
 Cholesterol, mmol/L 4.9 (1.1)  4.6 (1.3)  4.8 (1.3)  4.5 (1.0)  4.73 4.63 0.46 4.82 4.54 0.04
Creatinine value, µmol/L 91.1 (17.4)  94.0 (18.8)  90.5 (20.3)  93.4 (15.5)  92.7 91.8 0.67 90.8 93.7 0.15 
Troponin, μg/L 1.35 (4.65)  4.63 (11.54)  1.39 (2.75)  1.98 (5.52)  3.14 1.66 0.17 1.37 3.32 0.07 
GPIIb/IIIa type 
  
 
  
 
  
 
  
   0.88   0.21 
none 38 (58.5%)  47 (58.8%)  53 (58.9%)  44 (55.0%)  58.6% 57.1% 
 
58.7% 56.9% 
 Abciximab 26 (40.0%)  30 (37.5%)  37 (41.1%)  32 (40.0%)  38.6% 40.6% 
 
40.6% 38.8% 
 Tirofiban 1 (1.5%)  2 (2.5%)  0 (0.0%)  4 (5.0%)  2.1% 2.4% 
 
0.6% 3.8% 
 Number of lesions 
  
 
  
 
  
 
  
   0.46   0.72
1 59 (90.8%)  71 (88.8%)  77 (85.6%)  69 (86.3%)  89.7% 85.9% 
 
87.7% 87.5% 
 2 4 (6.2%)  9 (11.3%)  12 (13.3%)  10 (12.5%)  9.0% 12.9% 
 
10.3% 11.9% 
 3 1 (1.5%)  0 (0.0%)  1 (1.1%)  1 (1.3%)  0.7% 1.2% 
 
1.3% 0.6% 
 4 1 (1.5%)  0 (0.0%)  0 (0.0%)  0 (0.0%)  0.7% 0.0% 
 
0.6% 0.0% 
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Table 11. Baseline procedural data. Count data shown as: count (%); comparisons: Fisher's exact test. Numeric data shown as: 
mean (SD); comparisons: independent samples t-test. *For drug comparisons and stent comparisons % and mean only.  
CoCr = cobalt chromium, SS = stainless steel, Pl = placebo, Pred = prednisolone, LMS = left main stem, LAD = left anterior 
descending, Cx = circumflex, Int = intermediate, RCA = right coronary artery, SVG = saphenous vein graft, ACC/AHA = American 
College of Cardiology/ American Heart Association. 
 
 
Placebo 
    
Prednisolone 
    
Drug*   Stent* 
 
 
CoCr N=74 
 
SS N=89 
 
CoCr N=104 
 
SS N=92 
 
Pl Pred p CoCr SS p 
Vessels treated 
           
   0.77   0.18 
Protected LMS 0 (0.0%)  0 (0.0%)  1 (1.0%) 0 (0.0%)  0.0% 0.6% 
 
0.6% 0.0% 
 LAD 26  (35.1%)  39 (43.8%)  43 (41.3%)  45 (48.9%)  41.4% 43.5% 
 
39.4% 45.6% 
 Cx 14 (18.9%)  19 (21.3%)  19 (18.3%)  21 (22.8%)  20.7% 22.4% 
 
20.0% 23.1% 
 Int 1 (1.4%)  1 (1.1%)  2 (1.9%)  0 (0.0%)  1.4% 1.2% 
 
1.9% 0.6% 
 RCA 32 (43.2%)  30 (33.7%)  39 (37.5%)  26 (28.3%)  35.9% 32.4% 
 
37.4% 30.6% 
 SVG 1 (1.4%)  0 (0.0%)  0 (0.0%)  0 (0.0%)  0.7% 0.0% 
 
0.6% 0.0% 
 AHA/ACC lesion type 
  
 
  
 
  
 
  
   0.78   0.61
A 6 (8.1%)  8 (9.0%)  10 (9.6%)  7 (7.6%)  8.6% 8.7% 
 
9.0% 8.3% 
 B1 36 (48.6%)  41 (46.1%)  56 (53.8%)  45 (48.9%)  47.2% 51.5% 
 
51.7% 47.5% 
 B2 19 (25.7%)  25 (28.1%)  25 (24.0%)  19 (20.7%)  27.0% 22.4%  24.7% 24.3%  
C 13 (17.6%)  15 (16.9%)  13 (12.5%)  21 (22.8%)  17.2% 17.3% 
 
14.6% 19.9% 
 Max balloon pressure 16.9 (2.7)  17.0 (2.3)  16.3 (2.3)  16.3 (2.5)  17.0 16.3 0.02 16.5 16.7 0.62
No. of inflations 5.5 (4.3)  5.0 (3.3)  5.5 (3.6)  5.4 (2.9)  5.2 5.5 0.51 5.5 5.2 0.45 
Total inflation time (s) 84.8 (69.0)  71.5 (52.2)  77.0 (52.9)  75.4 (42.4)  77.2 76.3 0.88 80.1 73.4 0.31 
Lesion length, mm 13.8 (6.5)  13.4 (7.1)  13.9 (7.9)  14.6 (6.6)  13.6 14.2 0.41 13.9 14.0 0.86 
Stent length, mm 19.2 (7.1)  20.2 (9.3)  20.7 (9.9)  21.2 (8.4)  19.7 20.9 0.20 20.1 20.7 0.54 
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4.2 Angiographic measures 
Reference and minimal luminal diameters, with derived levels of 
stenosis are shown for all lesions in Table 12. In terms of risk factors 
for restenosis, the reference vessel diameters were not significantly 
different. There was also no evidence of difference in stenosis by any 
measure before or after PCI, or at follow up. Across all groups, average 
in-segment stenosis was: 70.3% (95%CI: 68.8% to 71.7%) at baseline 
prior to PCI; 6.6% (95%CI: 5.9% to 7.3%) immediately post-PCI; and, 
35.2% (95%CI: 33.3% to 37.0%) at final follow up. Acute gain was 
2.07mm (95%CI: 2.02 to 2.13mm), late loss was 1.04mm (95%CI: -
0.98 to 1.10mm) and net gain was 1.04 (95%CI: -0.97 to 1.12mm).  
From the angiographic data, a few observations can be made: 
 The interpolated diameter was numerically less than the 
averaged particularly in the values pre-PCI. This may be 
because this measurement takes account of the tapering of the 
vessel from proximal to distal vessel. The interpolated diameter 
has the advantage of not requiring as much user interaction.  
 At follow up, the reference vessel diameter was significantly less 
than after PCI (average reference diameter post PCI 3.24 ± 0.39 
vs. 3.06 ± 0.40, p<0.01). This is also seen in other studies using 
similar stents (171, 175, 176) and may be a marker of neointima 
within the proximal and distal reference segments or negative 
remodelling. 
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 Overall, there were no significant differences between any of the 
parameters in either the drug or stent arms of the study. This is 
consistent before and after PCI and at follow up. 
 The mean reference vessel diameters and lesion lengths were 
in line with the technology appraisal by the National Institute of 
Health and Care Excellence (NICE) recommending the use of 
drug eluting stents in arteries less than 3mm in diameter or 
lesions greater than 15mm in length (201). In other words, in line 
with the NICE recommendations, most lesions in this trial of 
bare metal stents were relatively short and in larger vessels, 
although patients with longer lesions and smaller reference 
diameters were included. 
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Table 12. Quantitative coronary angiography data and derived vessel measurements (all lesions, n=359; *for lesions with 
completed follow up n=328). CoCr = cobalt chromium, SS = stainless steel, PCI =percutaneous coronary intervention 
 
 
Placebo n=163 
 
Prednisolone n=196 
 
Drug 
 
 
 
Stent  
 
 
SS N=89 CoCr N=74 SS N=92 CoCr N=104 Placebo N=163 Pred N=196  SS  N=181 CoCr  N=178 
 
 
Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD p Mean SD Mean SD p 
Pre-PCI reference diameters, 
mm 
                 
averaged 3.17 (0.45) 3.19 (0.41) 3.18 (0.40) 3.19 (0.44) 3.17 (0.43) 3.19 (0.42) 0.83 3.18 (0.43) 3.19 (0.42) 0.79 
interpolated 3.06 (0.51) 3.02 (0.45) 3.09 (0.48) 3.08 (0.49) 3.04 (0.49) 3.08 (0.49) 0.42 3.07 (0.49) 3.06 (0.47) 0.73 
Post-PCI reference diameters, mm                  
averaged 3.17 (0.41) 3.23 (0.38) 3.24 (0.35) 3.26 (0.43) 3.20 (0.40) 3.25 (0.39) 0.22 3.21 (0.38) 3.25 (0.41) 0.30 
interpolated 3.15 (0.41) 3.16 (0.41) 3.19 (0.36) 3.20 (0.45) 3.15 (0.41) 3.20 (0.41) 0.33 3.17 (0.39) 3.18 0.43 0.77 
6-month PCI segment computer-derived*                 
averaged 3.04 (0.42) 3.04 (0.40) 3.07 (0.36) 3.06 (0.42) 3.04 (0.41) 3.07 (0.39) 0.55 3.06 (0.39) 3.05 (0.41) 0.98 
interpolated 2.96 (0.46) 2.96 (0.43) 2.99 (0.37) 3.00 (0.45) 2.96 (0.45) 2.99 (0.41) 0.49 2.97 (0.42) 2.98 (0.44) 0.90 
Minimum luminal diameters, mm                  
Pre-PCI [A] 0.96 (0.40) 1.02 (0.48) 0.96 (0.40) 0.96 (0.46) 0.99 (0.44) 0.96 (0.44) 0.55 0.96 (0.41) 0.98 (0.47) 0.55 
Post PCI, in-stent [B] 3.00 (0.39) 3.00 (0.33) 3.02 (0.35) 3.04 (0.40) 3.00 (0.37) 3.03 (0.38) 0.52 3.01 (0.37) 3.02 (0.37) 0.71 
Follow up, in-stent [C]* 1.94 (0.62) 2.05 (0.48) 2.03 (0.59) 1.97 (0.56) 1.99 (0.56) 2.00 (0.58) 0.94 1.99 (0.60) 2.01 (0.52) 0.73 
Pre-PCI stenosis, %                   
averaged 69.6% (12.3%) 68.1% (14.2%) 70.2% (11.6%) 69.9% (14.1%) 69.0% (13.2%) 70.0% (12.9%) 0.44 69.9% (11.9%) 69.2% (14.1%) 0.58 
interpolated 68.6% (12.8%) 67.0% (14.8%) 69.4% (11.8%) 68.9% (14.7%) 67.9% (13.7%) 69.1% (13.3%) 0.38 69.0% (12.2%) 68.1% (14.7%) 0.50 
Post-PCI stenosis, %                   
in-stent averaged 5.4% (5.7%) 7.1% (6.4%) 7.0% (5.8%) 6.8% (6.3%) 6.2% (6.1%) 6.9% (6.1%) 0.27 6.2% (5.8%) 7.0% (6.4%) 0.25 
in-stent interpolated 4.7% (5.3%) 5.3% (6.2%) 6.2% (6.0%) 6.0% (6.0%) 5.0% (5.7%) 6.1% (6.0%) 0.09 5.4% (5.7%) 5.7% (6.1%) 0.67 
6-month stenosis, %*                   
in-stent averaged 36.0% (18.1%) 32.7% (12.2%) 34.2% (16.3%) 35.5% (16.5%) 34.5% (15.7%) 34.9% (16.3%) 0.81 35.1% (17.1%) 34.3% (14.8%) 0.67 
in-stent interpolated 34.3% (19.0%) 30.5% (12.9%) 32.3% (17.4%) 34.1% (16.9%) 32.6% (16.5%) 33.2% (17.1%) 0.73 33.3% (18.2%) 32.6% (15.4%) 0.72 
in-segment averaged 38.7% (16.0%) 34.3% (10.7%) 36.9% (15.1%) 37.1% (15.0%) 36.7% (14.0%) 37.0% (15.0%) 0.84 37.8% (15.5%) 35.9% (13.4%) 0.25 
in-segment interpolated 37.1% (16.6%) 32.2% (11.3%) 35.0% (16.0%) 35.7% (15.4%) 34.8% (14.5%) 35.4% (15.7%) 0.75 36.0% (16.3%) 34.2% (13.8%) 0.27 
Acute Gain [B]-[A] 2.05 (0.47) 1.99 (0.51) 2.06 (0.48) 2.08 (0.54) 2.02 (0.49) 2.07 (0.51) 0.32 2.05 (0.48) 2.04 (0.53) 0.80 
Late loss [B]-[C]* 1.07 (0.54) 0.92 (0.36) 1.00 (0.52) 1.10 (0.53) 1.00 (0.59) 1.05 (0.66) 0.36 1.04 (0.53) 1.02 (0.47) 0.81 
Net gain [A]-[C]* 1.04 (0.58) 0.98 (0.60) 1.03 (0.68) 1.07 (0.63) 1.01 (0.59) 1.05 (0.66) 0.54 1.03 (0.61) 1.03 (0.64) 0.91 
Late loss index* 0.53 (0.24) 0.50 (0.23) 0.50 (0.28) 0.54 (0.29) 0.52 (0.23) 0.52 (0.28) 0.85 0.51 (0.26) 0.52 (0.26) 0.73 
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4.2 Endpoints 
The primary endpoint of binary angiographic restenosis (50% or 
greater stenosis at 6 months) is reported in Table 13.  In-segment 
average restenosis across all groups was 19.1% (95%CI: 14.7% to 
24.2%) based on the averaged reference diameter. Numerically, the 
results vary according to the whether the interpolated or averaged 
reference diameter is used but this does not affect the primary 
endpoint. For the comparison between placebo and prednisolone, by 
averaged reference diameter, restenosis rates were 19.7% vs. 20.0% 
respectively, p=1.00 and, by interpolated reference diameter, 18.9% vs. 
16.8% respectively, p=0.65. For the comparison between stainless 
steel and cobalt chromium stents, by averaged reference diameter, 
restenosis rates were 21.6% vs. 18.0% respectively, p=0.46 and, by 
interpolated reference diameter,  19.6% vs. 15.8% respectively, 
p=0.44. Overall, there was no difference in restenosis between 
treatment groups. 
There were six additional restenosis episodes when the averaged 
reference diameter was used to calculate the stenosis diameter within 
the stented segment at follow up. The difference between the diameter 
stenosis when the average reference diameter was used compared to 
the interpolated reference diameter ranged from 2-7% (Table 15).  This 
did not translate into additional clinical events; none had target lesion 
revascularisation within the follow up period.  
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The primary analysis was performed on an individual patient basis with 
one lesion chosen as the primary target lesion (first lesion treated). 
Table 14 shows the analysis for all lesions treated and in keeping with 
the primary analysis there was no statistically significant difference in 
the primary outcome. This is demonstrated graphically in the 
cumulative distribution curves for all lesions (Figures 14-17). They are 
also almost superimposed for both the drug and stent comparisons and 
the findings are similar whether diameter stenosis or minimal luminal 
diameter is used. 
There were no clinically important differences in any other study 
endpoints, adverse or serious adverse events (Table 13). Both deaths 
that occurred were cardiac deaths. In one case, a patient presented 
again with acute pulmonary oedema secondary to an ACS and in the 
other case, a patient died suddenly whilst travelling but had been to 
see the general practitioner with recurrent anginal pains in the week 
prior to this.  
There was, however, significant variation within the individual treatment 
combinations (varying from 11.7% to 26.4%) and a significant 
interaction was identified within a general-linear model.  For in-stent 
average restenosis of target lesions the log-odds findings (x) were: 
x = -2.024 + 0.804.drug + 0.999.stent - 1.555.drug∙stent 
       p<0.001           p=0.096         p=0.039         p=0.015 
where drug is an indicator variable for prednisolone, stent is an 
indicator for stainless steel stent and drug.stent is the interaction term 
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for stent and drug combined. Findings were qualitatively similar, 
regardless of the restenosis definition taken for target lesions or use of 
hierarchical models including all treated lesions.  Analysis of stenosis 
percentage (y) using a general linear model finds no suggestion of 
interaction. 
y = 33.40 + 3.11.drug + 3.20.stent – 5.82.drug∙stent 
      p<0.001         p=0.26         p=0.25          p=0.12 
Again, findings were qualitatively similar, regardless of the restenosis 
definition taken for target lesions or use of hierarchical models 
including all treated lesions.  The explanation for these findings is 
apparent in the comparison of cumulative stenosis rates comparing the 
treatment combinations (Figures 18-20).  Although there is no apparent 
difference over much of the distribution, there are apparent differences 
at the 40-50% stenosis point (leftward shift with the cobalt 
chromium/placebo and stainless steel/prednisolone group). Thus the 
finding may be an artefact of selectively dichotomising a continuous 
outcome. At this level of stenosis, this difference may not be of clinical 
importance. At the tail end with more severe stenoses, the curves 
seem to converge again except with the cobalt chromium/placebo 
group. There were fewer patients in this group and this therefore may 
just be a chance finding.  
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Table 13. Primary analysis of study events for the 315 patients. Count data shown as: count (%); comparisons: group %, Fisher's 
exact test.* Analysed as target lesion (i.e. one lesion per patient), 287 patients completed final follow-up angiography (stainless 
steel (SS)/placebo, n=72; cobalt chromium (CoCr) /placebo, n=60; SS/prednisolone (pred), n=76; CoCr/prednisolone, n=79). 
MACCE, major adverse cardiovascular cerebrovascular events. 
 Placebo, n=145     Prednisolone, n=170   Drug   Stent  
 SS, n=80  CoCr, n=65  SS, n=80  CoCr, n=90  Placebo Pred.   SS CoCr  
 Count %  Count %  Count %  Count %  % % p  % % p 
Primary endpoint*                    
Restenosis (by any measure) 19 (26.4%)  7 (11.7%)  13 (17.1%)  18 (22.8%)  19.7% 20.0% 1.00  21.6% 18.0% 0.46 
in-segment averaged 19 (26.4%)  7 (11.7%)  13 (17.1%)  18 (22.8%)  19.7% 20.0% 1.00  21.6% 18.0% 0.46 
in-segment interpolated 18 (25.0%)  7 (11.7%)  11 (14.5%)  15 (19.0%)  18.9% 16.8% 0.65  19.6% 15.8% 0.44 
Secondary endpoints                    
Target lesion revascularisation 9 (11.2%)  1 (1.5%)  6 (7.5%)  5 (5.6%)  6.9% 6.5% 1.00  9.4% 3.9% 0.07 
Target vessel revascularisation 9 (11.2%)  2 (3.1%)  6 (7.5%)  6 (6.7%)  7.6% 7.1% 1.00  9.4% 5.2% 0.19 
Any endpoint or SAE 20 (25.0%)  8 (12.3%)  13 (16.3%)  20 (22.2%)  19.3% 19.4% 1.00  20.6% 18.1% 0.67 
MACCE 
                   composite 10 (12.5%) 
 
2 (3.1%) 
 
6 (7.5%) 
 
6 (6.7%) 
 
8.3% 7.1% 0.83 
 
10.0% 5.2% 0.14 
death 1 (1.3%) 
 
0 (0.0%) 
 
0 (0.0%) 
 
1 (1.1%) 
 
0.7% 0.6% 1.00 
 
0.6% 0.6% 1.00 
MI 1 (1.3%) 
 
1 (1.5%) 
 
0 (0.0%) 
 
1 (1.1%) 
 
1.4% 0.6% 0.60 
 
0.6% 1.3% 0.62 
CVA 0 (0.0%) 
 
0 (0.0%) 
 
0 (0.0%) 
 
0 (0.0%) 
 
0.0% 0.0% - 
 
0.0% 0.0% - 
Target vessel revascularisation 9 (11.3%) 
 
2 (3.1%) 
 
6 (7.5%) 
 
6 (6.7%) 
 
7.6% 7.1% 1.00 
 
9.4% 5.2% 0.19 
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 Placebo, N=149     Prednisolone, N=179   Drug   Stent  
 SS, n=80  CoCr, n=69  SS, n=87  CoCr, n=92  Placebo Pred.   SS CoCr  
 Count %  Count %  Count %  Count %  % % p  % % p 
                    
Restenosis (by any measure)+ 19 (23.8%)  7 (10.1%)  14 (16.1%)  20 (21.7%)  17.4% 19.4% 0.78  19.8% 16.8% 0.57 
in-segment averaged 19 (23.8%)  7 (10.1%)  14 (16.1%)  20 (21.7%)  17.4% 19.4% 0.78  19.8% 16.8% 0.57 
in-segment interpolated 18 (22.5%)  7 (10.1%)  12 (13.8%)  17 (18.5%)  16.8% 16.2% 1.00  18.0% 14.9% 0.46 
in-stent averaged 19 (23.8%)  7 (10.1%)  12 (13.8%)  20 (21.7%)  17.4% 17.9% 1.00  18.6% 16.8% 0.77 
in-stent interpolated 18 (22.5%)  7 (10.1%)  10 (11.5%)  17 (18.5%)  16.8% 15.1% 0.76  16.8% 14.9% 0.65 
                    
Revascularisation*                    
Target lesion  9 (10.1%)  1 (1.4%)  7 (7.6%)  6 (5.8%)  6.1% 6.6% 1.00  8.8% 3.9% 0.08 
Target vessel  10 (11.2%)  2 (2.7%)  7 (7.6%)  7 (6.7%)  7.4% 7.1% 1.00  9.4% 5.1% 0.15 
 
Table 14. Angiographic and clinical restenosis rates for all lesions with angiographic follow up (n=328). Count data shown as: count 
(%); comparisons: group %, Fisher's exact test.* For revascularisation, clinical follow up available for all patients (359 lesions; 
stainless steel (SS)/placebo, n=89; cobalt chromium (CoCr) /placebo, n=74; SS/prednisolone (pred), n=92; CoCr/prednisolone, 
n=104). 
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Diameter stenosis (%) average reference diameter Diameter stenosis (%) interpolated reference diameter Difference (%) 
51 48 3 
50 48 2 
51 49 2 
52 47 5 
51 49 2 
51 44 7 
 
Table 15. Diameter stenosis in six patients where there was binary angiographic restenosis using the averaged reference diameter 
but not the interpolated reference diameter. 
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Figure 14. Graph showing cumulative distribution curves diameter stenosis using the interpolated reference diameter before and 
after percutaneous coronary intervention (PCI) and at follow-up for placebo and prednisolone (pred). 
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Figure 15. Graph showing cumulative distribution curves of diameter stenosis before and after percutaneous coronary intervention 
(PCI) and at follow-up for stainless steel (SS) and cobalt chromium (CoCr) stents. 
119 
 
 
Figure 16. Graph showing cumulative distribution curves of minimal luminal diameter (MLD) before and after percutaneous 
coronary intervention (PCI) and at follow-up for placebo and prednisolone (pred). 
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Figure 17. Graph showing cumulative distribution curves of minimal luminal diameter (MLD) before and after percutaneous 
coronary intervention (PCI) and at follow-up for stainless steel (SS) and cobalt chromium (CoCr) stents. 
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Figure 18. Graph showing cumulative distribution curves of diameter stenosis using the interpolated reference diameter before and 
after percutaneous coronary intervention (PCI) and at follow-up for all four possible study combinations. SS = stainless steel, CoCr 
= cobalt chromium, pred = prednisolone. 
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Figure 19. Graph showing cumulative distribution curves of diameter stenosis using the averaged reference diameter before and 
after percutaneous coronary intervention (PCI) and at follow-up for all four possible study combinations. SS = stainless steel, CoCr 
= cobalt chromium, pred = prednisolone. 
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Figure 20. Graph showing cumulative distribution curves of minimal luminal diameter (MLD) before and after percutaneous 
coronary intervention (PCI) and at follow-up for all four possible study combinations. SS = stainless steel, CoCr = cobalt chromium, 
pred = prednisolone.
124 
 
4.3 Types of restenosis 
Restenosis has been classified according to whether it is focal (type I), diffuse 
intra-stent (type II), diffuse proliferative (type III) or occlusive (type IV) (Figure 
21) (see section 1.2). Increasing TLR is seen with increasing class of 
restenosis (35) .
 
Figure 21. Schematic image of 4 patterns of introduced classification of ISR in 
relation to previous dichotomous description of focal vs. diffuse ISR. Pattern I 
contains 4 types (A-D). Patterns II through IV are defined according to 
geographic position of ISR in relation to previously implanted stent. 
Reproduced with permission from Mehran R et al. Circulation. 1999;100:1872-
1878. 
Binary angiographic restenosis occurred in 60 lesions (using averaged 
reference diameter). Of these, type I restenosis occurred in 39 (65%), type II 
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in 14 (23.3%), type III in 5 (8.3%) and type IV in 2 (3.3%). There was no 
difference in type of restenosis between placebo and prednisolone (Table 16). 
There was a difference in the type of restenosis between the stents which was 
mainly because of a difference in the focal (type I) subgroups. Within the 
stainless steel group, there were more restenostic lesions at the margins of 
the stent whilst restenosis occurred more frequently within the body of the 
stent in the cobalt chromium group. There is no clear explanation for this but 
the cobalt chromium stents were newer stents with more contemporary 
balloon technology and potentially less balloon overhang at the margins of the 
stent and therefore less injury to the vessel. 
Although not statistically significant, there were more lesions with proliferative 
or occlusive restenosis (class III/IV) within the stainless steel group (Table 
17). Of the lesions with these types of stenosis the stented segment was 
>30mm in four and they were all in the stainless steel group. 
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 Placebo (n=26) Prednisolone (n=34) p 
Class of restenosis   0.41 
I 17 (65.4%) 22 (64.7%)  
  A 0  (0.0%) 0  (0.0%)  
  B 8  (30.8%) 7  (20.6%)  
  C 8  (30.8%) 13   (38.2%)  
  D 1  (3.8%) 2   (5.9%)  
II 5 (19.2%) 9 (26.5%)  
III 4 (15.4%) 1 (2.9%)  
IV 0 (0.0%) 2 (5.9%)  
      
Diffuse (Class II,III,IV) 9 (34.6%) 12 (35.3%) 1.00 
      
Diffuse proliferative/occlusive (Class III/IV)  4 (15.4%) 3 (8.8%) 0.45 
 
Table 16. Type of restenosis, comparison between placebo and prednisolone. 
 
 Stainless steel (n=33) Chromium cobalt 
(n=27) 
p 
Class of restenosis   0.01 
I 21 (63.6%) 18 (66.7%)  
  A 0 (0.0%) 0 (0.0%)  
  B 13 (39.4%) 2 (7.4%)  
  C 7 (21.2%) 14 (51.9%)  
  D 1 (3.0%) 2 (7.4%)  
II 6 (18.2%) 8 (29.6%)  
III 4 (12.1%) 1 (3.7%)  
IV 2 (6.1%) 0 (0.0%)  
      
Diffuse (Class II,III,IV) 12 (36.4%) 9 (33.3%) 1.00 
      
Diffuse proliferative/occlusive (Class III/IV)  6 (18.2%) 1 (3.7%) 0.12 
 
Table 17. Type of restenosis, comparison between stainless steel and cobalt 
chromium stents. 
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4.4 Bleeding and hyperglycaemia 
Overall there was no difference in any bleeding episode compared to placebo 
7.6% vs. 5.5% for placebo, p=0.50. Almost all of these were minimal bleeding 
episodes, mainly related to femoral access (2.9% vs. 2.8% for placebo) at the 
time of the procedure. The minor bleeding episodes occurred in the 
prednisolone group. In one case, a patient had spontaneous frank haematuria 
after PCI. The patient was haemodynamically stable and had been on 
Abciximab which was stopped. Haemoglobin and platelet counts were within 
normal limits and the patient was discharged with outpatient investigations 
revealing the presence of renal stones. In the other case also in the 
prednisolone group, one patient was readmitted two months post procedure 
and transfused two units of packed cells for symptomatic iron deficiency 
anaemia. This was subsequently attributed to peptic ulcer disease. The only 
major bleeding episode occurred in the placebo group where one patient 
experienced bleeding per rectum with a drop in haemoglobin of >5g/dl 
requiring transfusion of three units of packed red blood cells. This occurred 
during the same hospital admission as the PCI procedure and study 
medication was stopped. The source of the bleeding was subsequently found 
to be rectal carcinoma that was successfully treated.  
With regards to hyperglycaemia, significantly more patients had home blood 
glucose monitoring levels greater than 11mmol/l in the prednisolone group, 
39(22.9%) vs. 10(6.9%) for placebo, p<0.01 during follow up. This was 
evident both in patients known to have diabetes 12(7.1%) vs. 4(2.8%) for 
placebo or not 27(15.9%) vs.  (4.1%) for placebo. In the majority of cases, 
dietary advice and reassurance was all that was necessary for these patients 
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and there was no significant difference between the groups in terms of need 
for additional oral hypoglycaemic therapy, insulin or need for study medication 
to be stopped (Figure 22). 
 
Placebo, n=145 Prednisolone, n=170 p 
Any bleeding episode 8 (5.5%) 13 (7.6%) 0.50 
Bleeding type 
    
0.40 
Insignificant 7 (4.8%) 11 (6.5%) 
 Minor 0 (0.0%) 2 (1.2%) 
 Major 1 (0.7%) 0 (0.0%)  
Bleeding site     0.69 
Access site 5 (3.5%) 6 (3.5%)  
  Femoral    4 (2.8%) 5 (2.9%)  
  Radial 1 (0.7%) 1 (0.6%)  
ENT 2 (1.4%) 3 (1.8%)  
Genitourinary 0 (0.0%) 1 (0.6%)  
Gastrointestinal 1 (0.7%) 3 (1.8%)  
 
Table 18. Bleeding events, comparison between prednisolone and placebo. 
ENT = Ear, Nose, Throat (all events were minor epistaxis episodes not 
requiring intervention (see text for detail). 
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Figure 22. Interventions for hyperglycaemia episodes during follow up. 
4.5 Biomarkers 
Hs-CRP was assayed on the Siemens Advia 2400 Chemistry analyser 
(Siemens Healthcare Diagnostics, Frimley, UK) using the Siemens wide range 
CRP latex-enhanced immunoturbidimetric assay. The analytical range for hs-
CRP was 0.03–[156-164] mg/L; the inter-assay and intra-assay variabilities 
were 4.9–7.8% from 2.25– 49.96 mg/L and 3.2–5.2% from 2.25–49.96 mg/L 
respectively. The normal range for this hs-CRP assay is 0-5mg/l.  
Table 19 shows the mean hs-CRP values at five points during the trial. There 
was some evidence of prednisolone suppressing hs-CRP response at day 7  
(-5.98 mg/L, 95%CI: -8.35 to -3.61, p<0.001) and the suggestion of a small 
rebound at day 30 (2.71mg/L, 95%CI: 0.78 to 4.65, p=0.006).  
Glycated haemoglobin (HbA1c) was also monitored at different points during 
the trial. There was a statistically significant increase in this parameter within 
the prednisolone group at 30 days but this returned back to baseline at six 
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months. This did not equate to any clinically important differences between 
treatments during the trial (Table 19). 
The majority of patients in whom hs-CRP samples were available or suitable 
for analysis had levels within the normal range prior to PCI (71%). Only a 
small proportion of these (28 patients), still had elevated levels at day 7 
(Figure 23).  
4.5.1 Raised hs-CRP before procedure and restenosis 
In those with angiographic follow up, there was no significant difference in 
restenosis between patients with raised hs-CRP before PCI (11 events out of 
71 cases) compared to those without (43 events out of 202 cases), odds ratio 
(OR) 0.68, 95%CI 0.33-1.40, p=0.29 using the averaged reference diameter. 
Using binary logistic regression and adjusting for significant co-variates 
defined as p<0.2 on univariate analysis or known risk factors for restenosis 
(Table 20), this remained non-significant, OR 0.56, 95%CI 0.26-1.22, p=0.14. 
For the patients (n=86) with raised CRP to begin with, 71 completed 
angiographic follow up (placebo, n=33 and prednisolone, n=38). Binary 
angiographic restenosis rates were 15.2% (n=5) for placebo compared to 
15.8% (n=6) for prednisolone, p=1.00 using the averaged reference diameter 
and 15.2% (n=5) for placebo compared to 13.2% (n=5) for prednisolone, 
p=1.00 using the interpolated reference diameter. 
For this cohort, binary angiographic restenosis rates were 18.6% (n=8) for 
stainless steel compared to 10.7% (n=3) for cobalt chromium, p=0.51 using 
the averaged reference diameter and 16.3% (n=7) for stainless steel 
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compared to 10.7% (n=3) for cobalt chromium, p=0.73 using the interpolated 
reference diameter. 
As there were fewer patients with high baseline hs-CRP levels, the values 
were categorised to assess for any trends using different cut-offs. Again, there 
was no significant association between hs-CRP and restenosis (Table 21).  
4.5.3 Change in hs-CRP and restenosis 
Of the 28 patients with normal CRP prior to PCI and raised post PCI, 25 
received placebo and the binary angiographic restenosis rate in this group 
was 20.0% (using averaged reference diameter) which was in keeping with 
the overall results of the trial. 
The trends in hs-CRP on an individual patient level are shown in the line 
graphs in Figure 24. For the placebo arm there is an overall upward trend in 
CRP levels (A and B) but for prednisolone treated patients (C and D), there is 
a downward trend and this is seen in both the patients who had binary 
angiographic restenosis and those who did not. Furthermore, the scatter plot 
in Figure 25 shows that there was no correlation between change in CRP and 
diameter stenosis (r=-0.09, p=0.17).  
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Figure 23. Flow chart depicting measurement of highly sensitive C-Reactive 
Protein (CRP) before and after percutaneous coronary intervention. 
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Table 19. Highly sensitive C-Reactive Protein (hs-CRP) and glycated haemoglobin (HbA1c) levels at different time points 
during the trial. 
 
 
 
 
Placebo 
 
Prednisolone 
 
Drug 
  
Stent 
 
 
CrCo 
 
SS 
 
CrCo 
 
SS 
 
Prednisolone-Placebo SS-CrCo 
 
Mean SD 
 
Mean SD 
 
Mean SD 
 
Mean SD 
 
95% CI p 
 
95% CI p 
hs-CRP, mg/L     
 
    
 
    
 
    
 
      
 
      
admission 6.31 (14.53) 
 
8.32 (13.11) 
 
5.39 (11.77) 
 
6.36 (15.07) 
 
-4.90 1.72 0.35 
 
-1.73 4.83 0.35 
pre-procedure 5.36 (12.77) 
 
6.66 (10.50) 
 
4.51 (11.32) 
 
6.69 (15.19) 
 
-3.56 2.53 0.74 
 
-1.22 4.83 0.24 
7 days 7.25 (9.38) 
 
7.57 (16.14) 
 
1.86 (6.99) 
 
0.96 (3.01) 
 
-8.35 -3.61 <0.001 
 
-2.31 2.62 0.90 
30 days 4.11 (9.85) 
 
3.33 (6.38) 
 
5.79 (6.56) 
 
7.03 (9.43) 
 
0.78 4.65 0.006 
 
-1.79 2.12 0.87 
6 months 1.48 (1.77) 
 
3.29 (4.31) 
 
2.45 (4.51) 
 
4.36 (12.82) 
 
-1.09 2.79 0.39 
 
-0.15 3.69 0.07 
HbA1c, % 
                   admission 5.75 (0.85) 
 
5.86 (0.97) 
 
5.83 (0.87) 
 
5.71 (0.50) 
 
-0.23 0.16 0.75
 
-0.21 0.18 0.88
30 days 5.72 (0.67) 
 
5.75 (0.60) 
 
6.01 (1.24) 
 
5.95 (0.55) 
 
0.05 0.44 0.016 
 
-0.23 0.16 0.73 
6 months 5.75 (0.67) 
 
5.95 (0.83) 
 
5.96 (1.14) 
 
5.82 (0.51) 
 
-0.17 0.24 0.75 
 
-0.19 0.23 0.85 
Time to 30d FU (d) 37.6 (104.5) 
 
32.6 (6.9) 
 
40.9 (79.0) 
 
28.4 (41.6) 
 
-15.1 15.2 1.00 
 
-24.0 6.1 0.24 
Time to 6m FU (d) 210 (37) 
 
204 (37) 
 
203 (34) 
 
201 (28) 
 
-12.9 3.0 0.22 
 
-11.3 4.6 0.41 
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    Univariate   Multivariate  
  Restenosis rate         
Factor Total, n n % OR 95% CI p OR 95% CI p 
Female 41 12 (29.3%) 1.85 0.88 3.90 0.11 2.08 0.88 3.90 0.08 
Diabetic 28 3 (10.7%) 0.46 0.13 1.57 0.21 0.65 0.18 2.37 0.52 
CRP raised pre-PCI 71 11 (15.5%) 0.68 0.33 1.40 0.29 0.56 0.26 1.22 0.14 
Ref. vessel  <2.5mm 27 10 (37.0%) 2.67 1.15 9.19 0.02 2.55 1.01 6.42 0.05 
Lesion length >20mm 39 15 (38.5%) 3.07 1.48 6.33 <0.01 2.09 0.90 4.84 0.09 
Complex lesion 122 35 (28.7%) 2.62 1.44 4.75 <0.01 1.97 0.99 3.94 0.06 
 
Table 20. Odds ratios (95% confidence intervals) for factors identified on univariate analysis with either p<0.2 or known risk 
factor for restenosis for all patients with angiographic follow up are shown and subsequent multivariate analysis using binary 
logistic regression. 
 All patients Restenosis rate     
Hs- CRP (mg/l) n n % OR 95% CI p 
<1.00 108 22 (20.4%) 1.06 0.58 1.95 0.84 
1.00-1.99 39 10 (25.6%) 1.49 0.68 3.28 0.32 
2.00-2.99 25 7 (28.0%) 1.66 0.66 4.21 0.28 
3.00-4.99 31 4 (12.9%) 0.57 0.19 1.70 0.57 
5.00-9.99 30 6 (20.0%) 1.02 0.39 2.62 0.97 
>10.0 40 5 (12.5%) 0.54 0.20 1.44 0.22 
 273 54      
 
Table 21. Univariate analysis for all patients with angiographic follow up and baseline (pre-procedural) hs-CRP levels 
showing restenosis rates and odds ratios (95% confidence intervals (CI) using different hs-CRP cut-off values.
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Figure 24. Relationship between CRP and binary angiographic restenosis on an individual patient basis. A and B are for 
participants in the placebo arm, and C and D in the prednisolone arm.  
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Figure 25. Relationship between change in CRP and restenosis at follow up. 
 
 
 
 
 
 
137 
 
4.6 Sirolimus eluting stents 
Of the 315 patients who underwent a second randomisation, 30 had additional 
lesions where the operator implanted a Cypher ™ sirolimus-eluting stent.  The 
mean age of participants was 60 years (range 39 to 74 years), 87% were 
male, 47% were elective PCI cases and the mean number of lesions treated 
was 1.14 (range 1 to 4).  There were 16 patients in the placebo group and 14 
patients in the prednisolone group. Groups were similar at baseline, there 
were no significant or important baseline differences comparing groups apart 
from the number of balloon inflations. (Tables 22- 23).  
Reference and minimal luminal diameters, with derived levels of stenosis are 
shown for all lesions in Table 24. There were significant differences in the 
reference vessel diameters between the two groups, with smaller vessels 
treated in the placebo group. There was no evidence of difference in stenosis 
by any measure pre or post PCI, or at follow up. For all the lesions included 
(n=33, 28 with follow up angiography), acute gain was 1.75mm ± 0.48mm , 
late loss was 0.22mm ± 0.09mm and net gain was 1.47mm ±  0.46mm. Again, 
there was no difference between patients receiving prednisolone and those on 
placebo for these parameters. None of the patients had binary angiographic 
restenosis. 
 
 
 
 
138 
 
 
Placebo, N=16 Prednisolone, N=14 p 
Male 15 (93.8%) 5 (35.7%) 0.38 
Age, y 62.3 (9.16) 58.2 (9.77) 0.25 
Height, m 1.74 (0.11) 1.71 (0.07) 0.49 
Weight, kg 82.6 (17.6) 84.6 (16.4) 0.75 
Smoking status 
    
0.59 
never smoked 6 (37.5%) 6 (42.9%) 
 ex-smoker 5 (31.2%) 6 (42.9%) 
 current smoker 5 (31.2%) 2 (14.3%) 
 History of hypertension 9 (56.2%) 7 (50.0%) 1.00
Family history of IHD 7 (43.0%) 9 (64.3%) 0.30 
Previous MI 5 (31.2%) 2 (14.3%) 0.40 
Previous CABG 1 (6.2%) 0 (0.0.%) 1.00 
Previous PCI 2 (12.5%) 0 (0.0.%) 0.49 
Previous TIA/CVA 0 (0.0.%) 0 (0.0.%) - 
History of PVD 2 (12.5%) 0 (0.0.%) 0.49 
History of LVSD 1 (6.2%) 2 (14.3%) 0.59 
Renal disease 0 (0.0.%) 0 (0.0.%) - 
Diabetes (I or II) 1 (6.2%) 1 (7.1%) 1.00 
Hypercholesterolaemia 15 (93.8% 13 (92.9%) 1.00 
Cholesterol, mmol/L 4.65 (1.13) 4.76 (1.48) 0.82 
Creatinine value, µmol/L 95.6 (16.4) 90.7 (15.8) 0.42 
Troponin, μg/L 0.40 (0.28) 0.44 (0.52) 0.88 
Elective PCI 9 (56.2%) 5 (35.7%)  
ACS type     0.15 
unstable angina 0 (0.0%) 3 (21.4%)  
non-STEMI 7 (43.8%) 5 (35.7%)  
STEMI 0 (0.0%) 1 (7.1%)  
GPIIb/IIIa type     0.72 
none 7 (43.8%) 5 (35.7%)  
Abciximab 9 (56.2%) 9 (64.3%)  
Tirofiban 0 (0.0%) 0 (0.0%)  
 
Table 22. Baseline procedural data. Count data shown as: count (%); 
comparisons: Fisher's exact test. Numeric data shown as: mean (SD); 
comparisons: independent samples t-test. 
IHD = Ischaemic heart disease, MI = Myocardial infarction, CABG = Coronary 
artery bypass grafting, PCI = Percutaneous coronary intervention, TIA = 
Transient Ischaemic attack, CVA = Cerebrovascular accident, PVD = 
Peripheral vascular disease, LVSD = Left ventricular systolic dysfunction, 
ACS = Acute coronary syndrome, GP IIb/IIIa = Glycoprotein IIb/IIIa inhibitor. 
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  Placebo, N=19 Prednisolone, N=14 p 
Vessels treated     0.10 
LAD 9 (47.4%) 9 (64.3%) 
 Cx 5 (26.3%) 0 (0.0%) 
 Int 1 (5.3%) 0 (0.0%) 
 RCA 3 (15.8%) 5 (35.7%) 
 AHA/ACC lesion type 
    
0.08
A 0 (0.0%) 0 (0.0%) 
 B1 4 (21.1%) 0 (0.0%) 
 B2 9 (47.4%) 5 (35.7%)  
C 6 (31.6%) 9 (64.3%) 
 Max balloon pressure, atm 16.0 (14.0-18.0) 16.0 (14.0-16.0) 0.87
No. of inflations 4.0 (3.0-8.0) 8.0 (4.0-10.0) 0.03 
Total inflation time, s 57.0 (35.0-104.0) 95.0 (55.0-135.0) 0.20 
Lesion length, mm 14.8 (10.8-23.7) 17.6 (12.0-33.6) 0.63 
Stent length, mm 20.5 (18.0-28.0) 23.0 (18.0-38.0) 0.51 
 
Table 23. Baseline procedural data. Count data shown as: count (%); 
comparisons: Fisher's exact test. Numeric data shown as: median (IQR); 
comparisons: independent samples Mann-Whitney U test. LMS = Left main 
stem, LAD = Left anterior descending, Cx = Circumflex, Int = Intermediate, 
RCA = Right coronary artery, SVG = Saphenous vein graft, ACC/AHA = 
American College of Cardiology/ American Heart Association. 
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Table 24. Vessel measurements for all lesions (N=33). *Follow up data, N=28 (Placebo, N=16; Prednisolone, N=14). Median 
(interquartile range) for non parametric comparisons, otherwise mean (SD).  
 
                Placebo, N=19 
 
Prednisolone,N=14 
   
            
95% CI p 
Pre-PCI reference diameters, mm              
averaged  2.50  (2.43-2.63)  2.85  (2.76-3.22)    <0.01 
interpolated  2.39  (2.31-2.61)  2.75  (2.53-3.15)    <0.01 
Post-PCI reference diameters, mm             
averaged  2.53  (2.45-2.59)  2.99  (2.92-3.32)    <0.01 
interpolated  2.54  (2.41-2.71)  3.04  (2.79-3.33)    <0.01 
6-month PCI segment computer-derived             
averaged  2.46  (2.36-2.57)  2.96  (2.73-3.27)    <0.01 
interpolated  2.46  (2.36-2.64)  2.89  (2.65-3.12)    <0.01 
Minimum luminal diameters, mm              
Pre-PCI [A]  0.81  (0.34)  1.05  (0.47)  -0.53 0.05 0.10 
Post PCI, in-stent [B]  2.50  (0.29)  2.89  (0.23)  -0.58 -0.20 <0.01 
Follow up, in-stent [C]*  2.23  (0.28)  2.63  (0.23)  -0.60 -0.20 <0.01 
Pre-PCI stenosis, %               
averaged  65.3  (58.1-68.5)  64.1  (60.6-72.4)    0.68 
interpolated  64.0  (57.5-67.0)  63.5  (59.1-71.1)    0.65 
Post-PCI stenosis, %               
in-stent averaged  2.4  (1.1-8.7)  7.2  (3.0-10.5)    0.24 
in-stent interpolated  3.6  (1.5-7.7)  5.8  (1.6-9.0)    0.65 
6-month stenosis, %               
in-stent averaged  8.0  (3.2-14.8)  12.4  (11.2-14.6)    0.17 
in-stent interpolated  10.2  (6.1-13.4)  9.6  (5.6-11.7)    0.45 
in-segment averaged  18.1  (16.0-19.8)  20.0  (16.1-24.4)    0.45 
in-segment interpolated  17.6  (15.8-22.6)  18.5  (13.7-21.9)    0.77 
Acute Gain [B]-[A]  1.69  (0.52)  1.83  (0.41)  -0.49 0.20 0.39 
Late loss [B]-[C]  0.21  (0.08)  0.24  (0.11)  -0.18 0.04 0.33 
Net gain [A]-[C]  1.38  (0.45)  1.60  (0.45)  -0.57 1.36 0.22 
Late loss index  0.14  (0.08)  0.13  (0.06)  -0.05 0.06 0.92 
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4.7 Registry 
Following first randomisation, 578 were withdrawn from the main study and 
the reasons for this are shown in Figure 26. These patients all received a 
single dose of prednisolone 40 mg prior to coronary angiography. Follow up 
data were not available for the patients recruited in Edinburgh due to funding 
and resource limitations. Of the 405 patients in the Middlesbrough cohort, the 
majority (72%) of patients did not receive a BMS because their coronary 
anatomy was such that for most of these patients either PCI with DES or 
CABG were preferable. In a minority of cases (n=20), revascularisation was 
not attractive because the lesions were in distal segments or small vessels 
and in three cases only PTCA was performed in vessels with small diameters. 
In 20 patients, follow on PCI was not performed because the lesions identified 
were not flow limiting as assessed by pressure wire studies or the vessels 
were occluded with no further symptoms and therefore revascularisation not 
indicated. A further 85 patients did not have an identifiable flow limiting or 
culprit lesion and therefore revascularisation was also not indicated. Of the 7 
patients that did receive BMSs, in 2 there was no suitably sized study stent, 2 
withdrew consent and in 3 the operator decided to use an alternative non 
study stent. 
The mean age of the participants was 59.8 years (range 30-84 years), 83% 
were male, 11% were diabetic, 56% had a positive family of ischaemic heart 
disease, 51% had a history of hypertension, 89% had hypercholesterolaemia 
and 65% had a history of smoking. This was in keeping with the patients who 
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participated in the main trial (section 4.1). There was a smaller proportion of 
patients that had elective PCI (21%) compared to the main trial (42%).  
Baseline characteristics are shown in Table 25. There were no significant 
differences between the group that received placebo and those who received 
prednisolone. In comparison to the main study, mean admission CRP was 
higher: 9.29 ± 17.0 mg/l compared to 6.65 ± 13.47 mg/l. The proportion of 
patients with a raised CRP (>5mg/l) was also higher, 40% compared to 29%. 
 
Figure 26. Consort diagram indicating the reasons bare metal stents were not 
used. PCI = percutaneous coronary intervention, CABG = coronary artery 
bypass grafting, POBA = plain old balloon angioplasty, FFR = fractional flow 
reserve, CAD = coronary artery disease. 
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Placebo, N=213 Prednisolone, N=192 p 
Male 176 (82.6%) 160 (83.3%) 0.90 
Age, y 60.6 (9.13) 58.9 (10.5) 0.08 
Height, m 1.73 (0.09) 1.73 (0.09) 0.87 
Weight, kg 87.1 (16.4) 87.6 (19.1) 0.78 
Smoking status 
    
0.54 
never smoked 77 (36.2%) 61 (31.8%) 
 ex-smoker 80 (37.6%) 72 (37.5%) 
 current smoker 56 (26.3%) 59 (30.7%) 
 History of hypertension 109 (51.2%) 95 (49.5%) 0.77
Family history of IHD 130 (61.0%) 105 (54.7%) 0.23 
Previous MI 34 (16.0%) 37 (19.3%) 0.43 
Previous CABG 6 (2.8%) 5 (2.6%) 1.00 
Previous PCI 24 (11.3%) 27 (14.1%) 0.45 
History of CVD     0.51 
TIA 6 (2.8%) 2 (1.0%)  
CVA 4 (1.9%) 3 (1.6%)  
History of PVD 2 (0.9%) 7 (3.6%) 0.09 
History of LVSD 13 (6.1%) 11 (5.7%) 1.00 
Renal disease 0 (0.0%) 1 (0.5%) 0.48 
Diabetes (I or II) 25 (11.7%) 19 (9.9%) 0.63 
Hypercholesterolaemia 185 (86.9)% 166 (86.5%) 1.00 
Cholesterol, mmol/L 4.96 (1.25) 4.91 (1.38) 0.71 
Creatinine value, µmol/L 93.0 (21.3) 92.8 (18.3) 0.90 
Troponin, μg/L 1.69 (5.51) 1.27 (3.22) 0.43 
Admission hs-CRP 9.43 (16.0) 9.14 (18.1) 0.87 
HbA1C 5.45 (1.77) 5.65 (1.42) 0.27 
Elective PCI 42 (19.7%) 43 (22.4%) 0.54 
ACS type     0.41 
Unstable angina 47 (22.1%) 33 (17.2%)  
Non-STEMI 113 (53.1%) 110 (57.3%)  
STEMI 11 (5.2%) 6 (3.1%)  
GPIIb/IIIa type     0.71 
none 174 (81.7%) 154 (80.2%)  
Abciximab 39 (18.3%) 38 (19.8%)  
Tirofiban 0 (0.0%) 0 (0.0%)  
Aspirin 211  (99.1%) 186 (96.9%) 0.71 
Clopidogrel 184 (86.4%) 168 (87.5%) 0.77 
Beta blocker 184 (86.4%) 171 (89.1%) 0.69 
ACE inhibitor 152 (71.4%) 149 (77.6%) 0.17 
Statin  198 (93.0%) 178 (92.7%) 1.00 
Table 25. Count data shown as: count (%); comparisons: Fisher's exact test. 
Numeric data shown as: mean (SD); comparisons: independent samples t-
test. 
 IHD = Ischaemic heart disease, MI = Myocardial infarction, CABG = Coronary 
artery bypass grafting, PCI = Percutaneous coronary intervention, CVD= 
cerebrovascular disease, TIA = Transient Ischaemic attack, CVA = 
Cerebrovascular accident, PVD = Peripheral vascular disease, LVSD = Left 
ventricular systolic dysfunction, ACS = Acute coronary syndrome, GP IIb/IIIa = 
Glycoprotein  IIb/IIIa inhibitor.  
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The angiographic findings, management strategies and final diagnoses are 
shown in Table 26. The two groups were well matched. In terms of 
management strategies after angiography, approximately 30% of patients 
were not revascularised. Amongst this group, 35 patients (8.6% of all 
patients), did not have a cardiac cause for their symptoms. They did not have 
any major adverse cardiovascular events within the 6 month follow up period.  
4.7.1 Outcomes 
There was no difference in any of the clinical endpoints between the two 
groups (Table 27). Of the seven patients who died: 
 Five had inpatient CABG. 
 Three of these patients died within the same hospital admission. Post 
mortems were held in two of these cases and the cause of death was 
pneumonia. In the third case, the patient fell sustaining a neck of femur 
fracture during the post-operative phase. The patient subsequently had 
a cardiac arrest during induction of anaesthesia and resuscitation was 
unsuccessful.  
 In the two other cases, one patient died two months after study entry 
and no post mortem held but cause of death was certified as Ischaemic 
Heart Disease, and the other died four months into the study and the 
cause of death after postmortem was epicardial fibrosis.  
 Of the patients who died and had not had CABG, one died of 
myocardial infarction. The patient had an elective angiogram having 
presented to the rapid access chest pain clinic with recent onset 
angina, was found to have severe three vessel disease and referred for 
145 
 
CABG. Post angiography, the patient had massive gastrointestinal 
bleeding caused by a duodenal ulcer which was controlled 
endoscopically but then had a STEMI with successful PPCI. This was 
complicated by stent thrombosis and despite prompt reperfusion, the 
patient went on to develop multi-organ failure and failed to recover. The 
other patient died of non cardiac causes, metastatic lung cancer. 
Nine patients had myocardial infarction after entry into the study: 
 One with STEMI as described above and the others had non ST 
elevation MI.  
 Only two of these had repeat revascularisation, one in which a patient 
had thrombus aspiration following the index event and as the artery 
was ectatic with no flow limiting lesion, no stents were implanted. 
Repeat angiography during the same admission after a period of 
intravenous GpIIb/IIIa inhibitor therapy was unchanged. The patient 
was then readmitted one week later with further MI and had PPCI with 
stent implantation. In the other case, a patient with three vessel 
coronary artery disease was referred for CABG after presenting with 
an ACS but became unstable whilst waiting for this, had new ECG 
changes and further troponin rise and went on to have PCI with DES 
instead. This patient represented with unstable angina and 
angiography revealed significant ISR and therefore had repeat 
revascularisation.  
 One had an early saphenous vein graft occlusion managed medically. 
 One was felt to have coronary spasm. 
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 Another patient also had a STEMI whilst waiting for CABG and 
therefore had PCI with DES instead. 
 One was admitted 2 days post PCI with further chest pain and an 
increase in troponin and repeat angiography revealed a small 
occluded side branch that was managed medically. 
 Two presented to their local hospitals with ACS and were not referred 
for angiography. 
Of the other 2 patients who had repeat revascularisation: 
 One had ongoing angina with known residual coronary artery disease 
and therefore had further PCI to the non-target lesion. 
 The other patient had recurrent angina with target lesion 
revascularisation for ISR within a DES.  
The stroke occurred in a patient post CABG.  
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Placebo, N=213 Prednisolone, N=192 p 
Angiographic findings     0.13 
1 VD 48 (22.5%) 58 (30.2%) 
 2 VD with proximal LAD 21 (9.9%) 17 (8.9%) 
 2 VD other 24 (11.3%) 27 (14.1%) 
 3 VD 61 (28.6%) 41 (21.4%) 
 LMS 13 (6.1%) 10  (5.2%) 
 Management after angiography 
    
0.94
PCI 88 (41.3%) 82 (42.7%) 
 CABG 60 (28.2%) 51 (26.6%) 
 No revascularisation 65 (30.5%) 59 (30.7%)  
Reason BMS not used     0.94 
Unsuitable anatomy 155 (72.8%) 138 (71.9%)  
No culprit lesion 44 (20.7%) 41 (21.4%)  
No indication for revascularisation 10 (4.7%) 10 (5.2%)   
BMS used 4 (1.9%) 3 (1.6%)  
Diagnosis      0.96 
Stable angina 34 (16.0%) 33 (17.2%)  
Unstable angina 33 (15.5%) 27 (14.1%)  
Non-STEMI 110 (51.6%) 102 (53.1%)   
STEMI 11 (5.2%) 6 (3.1%)  
Arrhythmia 4 (1.9%) 3 (1.6%)  
Other cardiac cause 3 (1.4%) 4 (2.1%)  
Non cardiac cause 18  (8.5%) 17 (8.9%)  
 
Table 26. Angiographic findings, management and final diagnosis. VD = 
vessel disease. 
 
Placebo, N=213 Prednisolone, N=192 p 
MACCE 11 (5.2%) 7 (3.6%) 0.48 
Death 3 (1.4%) 4 (2.1%) 0.71 
Repeat MI 7 (3.3%) 2 (1.0%) 0.18 
CVA 1 (0.5%) 0 (0.0%) 1.00 
Repeat revascularisation 3 (1.4%) 1  (0.5%) 0.63 
Repeat hospitalisation 17 (8.0%) 20 (10.4%) 0.94 
Recurrent angina 12 (5.6%) 7 (3.6%)  
 
Table 27. Clinical endpoints. Count data shown as: count (%); comparisons: 
group %, Fisher's exact test. MACCE, major adverse cardiovascular and 
cerebrovascular events. 
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4.8 Longer term follow up 
Patient recruitment took longer than anticipated and hence provided an 
opportunity for longer term follow up for clinical endpoints including death, 
target vessel revascularisation and repeat revascularisation. These data were 
collected  by linking the hospital identification numbers with other databases 
that tracked mortality and in the case of repeat revascularisation, the British 
Cardiovascular Intervention Society dataset. This follow up could only be 
extended to the patients recruited at the James Cook University Hospital 
(n=242) due to resource limitations. Mean follow up was 1772 days (range 
115-3226 days). 
4.7.1 Placebo versus Prednisolone 
With regards to death, there was no difference between placebo and 
prednisolone, four deaths compared to seven, log rank p=0.50 (Figure 27). 
There was no difference in TVR, 19 events vs. 15 for prednisolone, log rank 
p=0.24 (Figure 28). There was additionally no difference in any repeat 
revascularisation between the groups, 22 events vs. 24 for prednisolone, log 
rank p = 0.82 (Figure 29). 
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Placebo         
n 145 109 109 109 99 85 60 41 20 
events 1 0 0 1 0 1 0 1 0 
Prednisolone         
n 170 131 130 129 118 95 73 47 19 
events 2 1 1 2 1 0 0 0 0 
 
Figure 277. Kaplan-Meier event free cumulative survival comparing mortality 
between patients treated with prednisolone and placebo. 
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Placebo         
n 145 101 99 99 89 74 53 36 18 
events 13 2 0 2 1 0 1 0 0 
Prednisolone         
n 170 122 120 118 107 86 67 41 17 
events 12 1 1 0 0 0 0 0 1 
 
Figure 288. Kaplan-Meier event free cumulative survival comparing target 
lesion revascularisation between patients treated with prednisolone and 
placebo. 
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Placebo         
n 145 99 96 96 87 73 52 35 18 
events 15 3 0 2 1 0 1 0 0 
Prednisolone         
n 170 118 115 112 102 81 61 38 17 
events 16 2 2 1 0 1 1 0 1 
 
Figure 29. Kaplan-Meier event free cumulative survival comparing any repeat 
revascularisation between patients treated with prednisolone and placebo. 
 
 
 
 
 
152 
 
4.7.2 Cobalt Chromium versus Stainless steel 
There was no difference between the stents in death, eight vs. three for 
stainless steel, log rank p=0.11 (Figure 30). 
 
There was also no difference in target vessel revascularisation, 13 vs. 21 
events for stainless steel, log rank p=0.19 (Figure 31). 
There was also no difference in any repeat revascularisation, 21 vs. 25 events 
for stainless steel, log rank p=0.66 (Figure 32). 
 
 
 
 
153 
 
 
 
Cobalt Chromium 
Cobalt 
       
n 155 118 117 117 110 87 66 40 16 
events 2 1 0 2 1 1 0 1 0 
Stainless Steel        
n 160 122 122 121 107 93 67 48 23 
events 1 0 1 1 0 0 0 0 0 
 
Figure 29. Kaplan-Meier event free cumulative survival comparing mortality 
between patients treated with cobalt chromium and stainless steel stents. 
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Cobalt  Chromium 
Cobalt 
       
n 155 110 108 107 99 77 58 34 15 
events 9 1 1 1 1 0 0 0 0 
Stainless Steel        
n 160 113 111 110 97 83 62 43 20 
events 16 2 0 1 0 0 1 0 1 
 
Figure 30. Kaplan-Meier event free cumulative survival comparing target 
lesion revascularisation between patients treated with cobalt chromium and 
stainless steel stents. 
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Cobalt  Chromium         
N 155 106 102 101 94 73 53 31 15 
events 13 3 1 1 1 1 1 0 0 
Stainless Steel        
N 160 111 109 107 95 81 60 42 20 
events 18 2 1 2 0 0 1 0 1 
 
 
Figure 31. Kaplan-Meier event free cumulative survival comparing any repeat 
revascularisation between patients treated with cobalt chromium and stainless 
steel stents.  
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CHAPTER 5 
Discussion  
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This trial was designed to address two separate questions. The first was 
whether there was any benefit of systemic corticosteroid therapy in preventing 
binary angiographic restenosis and the second was whether there was any 
impact upon on this outcome of introducing cobalt alloys in BMS. At the time it 
was conceived, both of these were seen as promising avenues to reduce 
restenosis rates particularly as there was concern about long term safety 
regarding DES with regards to stent thrombosis, particularly with first 
generation DES (73). The findings provide no support for improved outcomes 
from the use of 28-day prednisolone started at least six hours pre-
procedurally or from the use of cobalt chromium stents.  This was apparent in 
the primary outcome of binary angiographic restenosis and consistent in 
secondary outcomes.  
5.1 The impact of glucocorticoids 
The key studies investigating the role of glucocorticoids and their main 
findings prior to this study were reviewed in section 1.7.4. They included two 
randomised studies of balloon angioplasty alone by Stone et al. (n=105, 53% 
had repeat coronary angiography) and the M-HEART group of investigators 
(n=915, 74% had repeat angiography) respectively (122, 123). As discussed 
previously, there was no benefit of glucocorticoids in preventing restenosis in 
these groups. The lack of efficacy could be explained by the additional 
mechanism of elastic recoil and arterial remodelling following angioplasty 
alone which steroids might have no effect on.  
Additionally, there were two randomised studies involving BMS implantation 
These included a study by Lee et al. (124) and the IMPRESS study (125). In 
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comparison to SSTARS, for the Lee et al. study (n=140, 91% had repeat 
angiography), only a single pulsed dose of intravenous methylprednisolone 
was used prior to the procedure and complex lesions were excluded but the 
results were similar.  
With regards to IMPRESS, only a highly select group of patients were 
included (n=83, 98% had repeat angiography). These were patients with 
evidence of a persistent inflammatory response defined as those patients with 
normal CRP levels prior to their procedure with subsequently elevated levels 
(>0.5mg/dl) at 72 hours. Prednisone (reducing regimen of 1mg/kg for the first 
10 days, 0.5 mg/kg from day 11 to day 30 and 0.25mg/kg from day 31 to 45) 
was administered 72 hours post procedure for 45 days and was associated 
with a quite marked reduction in restenosis; three patients (7%) in the 
prednisone arm had binary angiographic restenosis compared to 14 (33%) in 
the placebo group, p<0.01.  
There were only a small proportion of patients in this study who would have 
met the IMPRESS inclusion criteria (n=28) albeit CRP was measured at day 
seven as opposed to day three. This was a key difference and notably there 
was no association between reducing CRP and lowering restenosis. This was 
demonstrated in the prednisolone treated group where although CRP was 
lowered significantly when compared to placebo, the rates of restenosis were 
similar.  
Overall, from this cohort of non-selected patients, only a minority of patients 
fulfil the requirements of the IMPRESS protocol. Moreover, in routine clinical 
practice, the choice of stent at the time of the procedure i.e. BMS or DES 
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cannot be determined by what the hs-CRP might be a few days later. The 
logistics of arranging for a routine hs-CRP measurement at 72 hours and then 
determining the use of steroids is difficult for centres offering a regional 
service with early discharge as the standard protocol. 
The results of the SSTARS study also differs from the Cortisone plus BMS or 
DES alone to Eliminate Restenosis (CEREA-DES) trial (n=375) (202). In this 
Italian multicenter trial, from the same group of investigators as IMPRESS, the 
study endpoint was not angiographic restenosis but rather a combined clinical 
endpoint of major adverse cardiovascular events (MACE) which was defined 
as cardiac death, myocardial infarction or repeat revascularisation (target 
vessel only). Participants were randomised into any of three arms, treatment 
with BMS alone, prednisone and BMS, and DES alone.  The BMS plus 
prednisone group and DES groups were compared with the designated 
control arm (BMS alone). The IMPRESS steroid regimen was used but 
prednisone was commenced within the 48 hours after PCI rather than 72 
hours post procedure as in IMPRESS.  
Based on Kaplan-Meier survival analysis, there was a significant reduction of 
the primary endpoint in the prednisone plus BMS arm compared to BMS 
alone, event free survival 88.0% vs. 80.8% (hazard ratio [HR] = 0.51; 95% CI, 
0.20 to 0.76; p = 0.006). The comparison between DES alone and BMS alone 
yielded similar results, event free survival 88.8% vs. 80.8% (HR = 0.46; 95% 
CI, 0.23 to 0.84; p = 0.004).  
It is worth noting that there were no statistically significant differences in the 
individual components of MACE. In particular, clinical restenosis (TLR) 
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occurred in 15 out of 125 patients for BMS alone (12%) vs. 10 out of 125 (8%) 
for BMS plus oral prednisone, p=0.23. As with IMPRESS, diabetic patients 
were not included in this study but this was a more inclusive study with no 
prerequisite for elevated CRP levels. There was, however, a separate 
analysis performed in 61 patients in whom CRP was raised post PCI and 
there was a significant reduction in MACE (23% for BMS alone vs. 8% for 
prednisone plus BMS, p=0.03) but it is not clear whether this was driven by a 
need for less TLR. Another limitation of this trial was that there was no 
blinding of treatment in this study and in conjunction with mandated exercise 
stress testing at 6 months, this could have had a potential confounding 
influence on repeat revascularisation. In the DES group, for example, TLR 
was only 3.2% at one year but TVR was higher than would be expected at 
11.2%.  
The five randomised studies mentioned above were all included in the only 
meta-analysis investigating the role of corticosteroids in reducing restenosis 
rates  in BMS (203). Separate analyses were performed for the two trials 
involving balloon angioplasty alone (122, 123) and three involving BMS 
implantation (124, 125, 202). In keeping with the individual trial data, there 
was no benefit of corticosteroids in preventing restenosis in the angioplasty 
alone group (RR 1.02, 95% CI 0.84-1.23, p=0.85). But corticosteroids did 
reduce restenosis following BMS implantation (RR 0.60, 95% CI 0.37-0.97, 
p=0.04) driven mainly by the results of the IMPRESS and CEREA-DES trials. 
The results of CEREA-DES were included but there was no repeat 
angiography in this trial and the authors have used the hierarchal TLR in 
place of binary angiographic restenosis in their analysis. Overall, the number 
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of patients was small despite the inclusion of the CEREA-DES cohort (n=460) 
and there was substantial heterogeneity both methodologically (timing of 
steroid, dose of steroid, elevated CRP only in IMPRESS) and statistically (I² = 
54%). These factors limit the applicability of this analysis to the wider 
population. 
There is only one other randomised trial that has investigated the use of 
glucocorticoids in preventing restenosis in BMS from an Iranian group of 
investigators (204). This study was not included in the meta-analysis 
described above. In this double blind randomised study that also excluded 
diabetic patients,100 patients in each arm received either intramuscular 
placebo or 40mg methylprednisolone 48 hours prior to PCI and then again 
two weeks later. There was no significant difference in restenosis at 6 months 
21% for methylprednisolone vs. 24% for placebo, p=NS.  
Apart from IMPRESS and CEREA-DES, all the randomised steroid trials, 
including SSTARS, have not shown a benefit for glucocorticoids in BMS. One 
of the possible reasons for this has already been highlighted, the selective 
inclusion of patients with persistent inflammatory response after 72 hours 
(only 15% of consecutive patients) in the case of IMPRESS. Another 
difference is that both IMPRESS and CEREA-DES utilised a high dose steroid 
regimen (reducing regimen of 1mg/kg for the first 10 days, 0.5 mg/kg from day 
11 to day 30 and 0.25mg/kg from day 31 to 45) whilst not including diabetic 
patients. This dose was substantially higher than that used in all of the other 
trials including SSTARS.  
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The inclusion of diabetics in SSTARS influenced the steroid regimen chosen. 
It was selected after discussion with the local endocrine team to represent an 
“anti-inflammatory” dose used in other areas of medicine. The regimen utilised 
a lower total dose of steroid including a lower maximum dose in the early 
phase of treatment but would be sufficiently high to achieve the beneficial 
anti-inflammatory action sought whilst minimising the risk of side effects.  
However, it is noteworthy that the results of the case-control IMPRESS-LD 
study suggested that a higher dose intensity for a longer period of time was 
needed to impact on restenosis. The “low-dose” regimen in this small study 
itself included a high dose of 1mg/kg for the first 5 days of treatment started 
after PCI (205). This may partly explain the difference in findings between 
IMPRESS and CEREA-DES compared to SSTARS and all the other trials. In 
the Italian studies, prednisone was well tolerated but in SSTARS, with more 
patients, there was an increase in transient hyperglycaemia in patients on 
prednisolone, even amongst non-diabetics. Bearing in mind the proportion of 
diabetics in the study was small (11%), the potentially greater anti-
inflammatory activity with higher doses of prednisolone may therefore come at 
the cost of increased adverse effects. 
The safety and tolerability of a course of glucocorticoids were a concern given 
the additional requirement for DAPT. The issue of hyperglycaemia has 
already been mentioned but in this group of patients did not result in any 
clinically important changes in outcomes or management. The other major 
concern was bleeding and it is reassuring that there was no significant 
difference between the groups with regards to this and in particular, major 
bleeding did not occur in any of the patients on prednisolone.  
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The steroid regimen in SSTARS was also chosen to address the issues of 
both timing and duration of therapy. In the previous studies various regimens 
were used including parenteral pulsed therapy pre-procedure only, parenteral 
pulsed therapy pre-procedure ± short course of oral therapy/further pulses 
and longer courses of oral therapy commenced post procedure (122-125, 
202, 204). In SSTARS, by administering the prednisolone prior to PCI, this 
would ensure that there were already therapeutic levels of anti-inflammatory 
activity from the steroid to cover the initial injury from stenting as well as the 
resultant inflammation. The subsequent course over 28 days would cover any 
persistent inflammation to cover the duration of neo-intimal formation in BMS. 
Despite this potentially all-encompassing regimen, there was no significant 
reduction in restenosis. 
5.2 The impact of CRP 
As discussed above, the success of glucocorticoids in preventing restenosis 
has largely been seen only in the IMPRESS study which highlighted the 
potential role of CRP in identifying those patients most at risk or most likely to 
benefit from glucocorticoid therapy. Other observational studies also 
addressed the role of CRP mainly in the context of raised pre-procedural  
levels with varying results although a meta-analysis seemed to suggest a role 
for identifying patients at risk of restenosis if CRP was raised (see section 
1.8). Based on these observations, separate analyses based on CRP 
measurements were performed in the SSTARS study. 
In SSTARS, elevated pre-procedural hs-CRP was not associated with higher 
rates of restenosis OR 0.68, 95%CI 0.33-1.40, p=0.29. Even after adjusting 
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for significant factors and known risk factors for restenosis, this remained non-
significant, OR 0.56, 95%CI 0.26-1.22, p=0.14 (section 4.5.1). Different cut-
offs have been used in preceding studies to define elevated CRP and despite 
applying this to the SSTARS dataset, no significant association between CRP 
levels pre-procedure and restenosis was seen. Further analysis of these 
subsets may help to explain the reasons for this. Hs-CRP levels between 1.0-
2.99 mg/l, although not statistically significant, appear to have higher 
restenosis rates than the other groups. Whilst this is within the normal 
laboratory reference range, these values may represent a group of patients 
with a baseline inflammatory tendency not likely to be associated with any 
other process. Approximately 60% of the patients in SSTARS were acute 
admissions and therefore hospitalised patients who are exposed to greater 
inflammatory stimuli e.g. hospital acquired infections. CRP is very much an 
acute phase reactant and so will rise in response to other inflammatory stimuli 
and so much higher levels of baseline CRP values might have occurred in 
some patients in response to these unknown stimuli, which may have no 
bearing on whether they are more likely to have restenosis (206). It is of note 
that in the SSTARS study the patients with the highest levels of CRP at 
baseline had the least restenosis. This, of course, has to be interpreted 
cautiously in the context of the small numbers of patients when categorising 
the data this way. Another important factor may be the relatively high use of 
statin therapy which also has been shown to have some anti-inflammatory 
effect and this may in effect have "watered down" any reaction that might 
have occurred in association with an elevated CRP.  
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There was also no correlation between lowering CRP and reducing 
restenosis. Prednisolone reduced hs-CRP levels significantly but this had no 
impact on restenosis. The reasoning above may also apply to this observation 
because systemic therapy with prednisolone may also have been effective 
against non-PCI related inflammation. The timing of CRP measurement is 
also relevant here because post procedure levels were measured at 7 day 
follow up. As discussed in section 1.8, increases in CRP levels can be 
detected at 12- 48 hours and the plasma half life is 19 hours (207). In 
SSTARS, CRP was not checked within this time period. Also, asking patients 
to return so early after discharge was not practical given that for some, it 
would mean travelling significant distances. As a result, patients with raised 
CRP post PCI which could be attributed to the procedure, based on the 
temporal relationship to the procedure and kinetic profile of CRP, might have 
been missed. In the IMPRESS study, the investigators managed to recruit 
these patients but there were only 83 patients in the study and this 
represented 15% of consecutive patients at their institution. In SSTARS, with 
day seven CRP rather than day three measurements, only 28 patients out of 
275 patients with available samples (10.2%) fulfilled the IMPRESS criteria. 
5.3 The impact of stent alloy 
Another important factor that this trial investigated was the comparison 
between stainless steel and cobalt alloy stents. The background to this is 
related to randomised studies assessing the thickness of stent struts (section 
1.9.2.4). In the ISAR-STEREO  trial, thinner strut stainless steel stents 
compared to thicker strut stent  with a similar design had significantly less late 
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lumen loss and binary angiographic restenosis (15% vs. 26%, p=0.003) (173). 
Similarly the ISAR-STEREO 2 trial showed that thicker strut stainless steel 
stents with a different design resulted in more restenosis compared to thin 
strut stents (18% vs. 31%, p<0.001) (19). As discussed in section 1.9, strut 
thickness is one of many stent design issues that have been investigated with 
regards to restenosis. The influence of these other design factors were 
minimised by using stents of similar design (Multilink) but composed of the 
two different alloys.   
In SSTARS, there was no significant reduction in restenosis rates in the 
thinner strut cobalt alloy stent. An obvious difference was that the difference in 
strut thickness between the stents was more marked in the earlier trials. In the 
ISAR-STEREO trials, the comparison was between 50µm and 140µm stents 
whereas in SSTARS, the cobalt chromium stents were 81µm thick compared 
to 90-125µm for the stainless steel stents (variable strut thickness system 
which is thicker in straight areas and less in areas where the stent needs to 
bend).  It also may be that the expected reduction of restenosis due to 
reduced strut thickness with cobalt chromium might have been countered by 
some other unknown factor.   
Only one other single centre randomised study from Brazil (n=187) has 
compared the influence of metal alloy (stainless steel vs. cobalt chromium) on 
restenosis and in keeping with SSTARS there was no difference in this 
outcome (208). The study design was, however, different from SSTARS in 
that both types of stents were implanted in the same patient. In the majority of 
patients, the stents were implanted into different vessels but in 30% of cases, 
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both stents were implanted into the same vessels where lesions were more 
than 10mm apart. Randomisation was to determine which stent was 
implanted first. There were also differences in baseline characteristics 
particularly a larger proportion of diabetics (36%) with resultant higher rates of 
restenosis (34% vs. 32%, SS vs. CoCr, p=0.80).  
A number of different stainless steel stents were used in the trial and a 
separate three way analysis comparing the cobalt chromium stent used 
(60µm, Prokinetic™, Biotronik, Germany), thin strut stainless steel stents 
(<100µm) and thick strut stainless steel stents was also performed. The 
restenosis rates were 32.3%,33.2% and 35.1% respectively, p=0.89.  
There is also scant experimental data on the subject. A small non-randomised 
animal study compared stainless steel stents (120µm strut thickness) and 
cobalt chromium stents (90µm strut thickness) implanted into normal porcine 
coronary arteries (n=9, 18 stents implanted, 7 CoCr, 11 SS). QCA and 
histopathological analysis was performed and there was no advantage of 
cobalt chromium compared to stainless steel  with regards to late lumen loss 
and neointimal area from histopathological samples (209). 
In SSTARS, there was a trend towards more target lesion revascularisation 
with the stainless steel stents compared to cobalt chromium (9.4% vs. 3.9% , 
p=0.07). The results on types of restenosis (section 4.3) may provide an 
explanation for this. Class III or IV restenosis (proliferative or occlusive 
respectively) occurred more often in the stainless steel group and higher TLR 
is known to occur with higher restenosis class (35). Of the six patients (7 
lesions), the stented segment was >30mm in five lesions and they were all 
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treated with stainless steel stents. The reasons for this difference may 
therefore be to do with the types of lesion treated as opposed to the stent 
material. Other factors such as differences in the delivery system may also be 
a factor and the possibility of this being a chance finding cannot be excluded. 
Being a 2x2 factorial design, the trial was not powered to detect a stent-drug 
interaction but nonetheless provided an interaction observation which was 
evident in the way binary angiographic restenosis was distributed.  Within the 
stainless steel group, there is a numerical reduction in restenosis by 
prednisolone whereas the opposite occurs in the cobalt chromium group. The 
weight percentage of nickel and molybdenum is higher in 316L stainless steel 
than cobalt chromium (156) and the release of these metal ions may trigger 
local immune and inflammatory responses in susceptible individuals (177). 
Whilst this may provide a plausible basis for a stent-drug interaction, it is more 
likely that this observation is a chance finding and an artefact of dichotomising 
continuous data as it is only apparent in the restenosis data (section 4.2) for 
dichotomised thresholds around 40-50% and not apparent for higher or lower 
threshold values. 
Whilst there was no advantage seen with the use of cobalt chromium stents 
over stainless steel stents there was also no disadvantage. Most of the 
discussion has focussed on strut thickness and because of the ISAR-
STEREO trials this led to the assumption that thinner struts induce less injury 
and therefore there is less restenosis as a consequence. However, their own 
analysis showed that the advantage of thin strut stents was predominantly in 
the more complex lesions (B2 or C). In SSTARS, the majority of lesions were 
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not complex lesions because the availability of DES precluded their use in the 
most complex lesions whereas ISAR-STEREO was undertaken prior to the 
DES era with resultant higher rates of complex lesions treated. This may, in 
part, have contributed to the lack of success of the cobalt stents in SSTARS. 
Separate analysis of restenosis (using the averaged reference diameter) for 
complex lesions only did not reveal any significant difference between the 
stents either (25.5% for CoCr vs. 31.1% for SS, p=0.55) but this is limited by 
the small numbers of patients (n=122). The properties of cobalt chromium 
stents including better radiopacity and higher radial strength allows them to be 
more deliverable and better suited to treating more complex lesions in 
smaller, more tortuous arteries and with ostial lesions with elastic fibres. In 
current practice, DES are more likely to be employed in these types of lesions 
and it is therefore not surprising that these newer alloys have replaced 
stainless steel as the platform for DES. One of the key reasons for exploring 
other avenues to reduce restenosis in the DES era was the safety concerns 
especially with regards to DAPT duration but there have been further 
developments including the evolution of newer generation DES and optimal 
duration of DAPT (see section 6.0). 
In conclusion, the SSTARS study showed that treating patients upstream with 
a moderately high dose of prednisolone to cover most of the period of 
inflammation associated with restenosis in BMS did not reduce the incidence 
of binary angiographic restenosis. In addition, there was no significant 
reduction in restenosis rates with stents composed of cobalt chromium alloy 
compared to stainless steel. There was also no difference in longer term 
clinical outcomes between the different arms of the study.  
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CHAPTER 6 
Study Limitations 
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This study was designed as a superiority study to compare the effects of two 
interventions, oral prednisolone and cobalt chromium stents, in reducing the 
restenosis seen with stainless steel stents.  This required two randomisations. 
Changing circumstances during the course of the study presented recruitment 
challenges, ultimately resulting in the recruitment target not being met. There 
was a change in the pattern of PCI delivery, with a shift towards more acute 
cases and an increasing use of  ad hoc PCI (and so the angiographic features 
were not known when many patients were first approached and recruited). 
This, coupled with the progressive increase in DES use, resulted in failure of 
patients initially recruited to progress to the second randomisation. The 
increase in DES use was largely the result of the evidence base behind a 
National Institute of Health and Care Excellence (NICE) recommendation that 
DES should be used in arteries less than 3mm in diameter or lesions greater 
than 15mm in length (210). Patient concerns about prednisolone and side 
effects and the need for repeat coronary angiography were also factors. As a 
result we approached many patients with a smaller proportion being recruited 
than was anticipated.  As time progressed, the number of patients who were 
eligible for the study (i.e. who were deemed to be preferentially treated with 
BMS) fell dramatically. We approached approximately four patients for every 
patient who consented to the first randomisation. Of those who consented, 
only about 1 in 3 were suitable for randomisation after angiography. The 
Steering Committee of the trial recommended its early termination when it 
became clear that the resources of the study were insufficient to extend the 
time needed or to set up new centres. However, given the small differences in 
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results observed, it is unlikely that a statistically significant difference in 
restenosis would have been achieved if the recruitment target had been met.   
Another potential limitation is lack of operator blinding to stent type. This 
would not have been easy to achieve considering the different appearances of 
the stents used. However, the primary endpoint of binary angiographic 
restenosis was assessed  without knowledge of stent type deployed. Hence 
we do not believe this is a major failing. There was no core laboratory analysis 
of the angiograms but analyses were performed by a single research fellow 
separate from the clinical team. Statistical analysis was performed 
independently from the clinical team. 
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CHAPTER 7 
Safety concerns and the evolution of DES 
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In section 1.6 the initial evolution and concerns about DES were reviewed. 
The encouraging early results of first generation DES compared to BMS in 
terms of reduced restenosis and repeat revascularisation were dampened by 
the ESC firestorm controversy particularly with regards to the risk of stent 
thrombosis and perceived increased mortality. Some of these concerns were 
allayed at the time and multiple subsequent patient based meta-analyses 
found that first generation DES were safe when compared to BMS (71, 211-
213). The controversy surrounding this issue led to renewed interest in the 
field and a knock-on effect of this was the development of second generation 
DES. 
As has been alluded to already, stent thrombosis was the major safety 
concern with regards to DES but there were limitations in its definition which 
revolved around a 30 day limit. Within 30 days, acute or sub-acute stent 
thrombosis had occurred if there was angiographic vessel occlusion, any new 
Q-wave MI in an area supplied by the stented vessel, and/or unexplained 
death from a cardiac cause. Beyond 30 days, late stent thrombosis occurred 
only if there was angiographically confirmed new MI with occlusion of the 
stented artery, and, importantly, excluded patients who had previously 
undergone repeat TLR (214). Based on this definition, an increased incidence 
of late stent thrombosis was observed following first generation DES 
compared to BMS (211, 212, 215).  
There were two main problems with this definition. Firstly, it underestimated 
the incidence of stent thrombosis since unexplained MI in the territory of the 
stented vessels and late deaths, which may have been due to stent 
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thrombosis, were usually not included. Secondly, there was potential for bias 
in favour of BMS because repeat TLR was more likely to occur in a patient 
with a BMS due to the more frequent need for repeat revascularisation. 
New definitions were subsequently introduced by the Academic Research 
Consortium, a collaboration between academic research organisations in 
Europe and the United States (33). This definition includes three temporal 
categories with acute (<30 days), late (30 days to 1 year), and very late (>1 
year) stent thrombosis. There are also three levels of evidence: 
 Definite - which includes angiographic confirmation of a thrombus that 
originates in the stent or in the segment 5 mm proximal or distal to the 
stent, with or without vessel occlusion, which is associated with acute 
onset of ischaemic symptoms at rest or electrocardiogram (ECG) signs 
of acute ischemia or typical rise and fall of in cardiac biomarkers within 
48 hours of angiography OR pathologic confirmation of stent 
thrombosis determined at autopsy or from tissue obtained following 
thrombectomy. 
 Probable - which includes unexplained death occurring within 30 days 
after the index procedure, or an MI occurring at any time after the 
index procedure that was documented by ECG or imaging to occur in 
an area supplied by the stented vessel in the absence of angiographic 
confirmation of stent thrombosis or other culprit lesion. 
 Possible - which includes unexplained death occurring more than 30 
days after the index procedure. 
176 
 
Furthermore, the inclusion of all target lesion–related re-interventions was 
proposed. The combination of “definite” and “probable” has been 
recommended as the best way to characterize DES safety. Revisiting a 
pooled analysis using the ARC definitions resulted in an overall increase in 
rates of stent thrombosis (214) , with a nearly identical combined incidence in 
DES and BMS, and a trend toward more very late stent thrombosis with DES 
(213).  
To recap, DES are usually composed of a metal stent platform and a polymer 
loaded onto this from which there is local delivery of the drug. Whilst stent 
thrombosis is a multifactorial entity where patient, lesion and procedural 
aspects can all be implicated, specific DES related issues such as delayed or 
incomplete endothelialisation and potential for hypersensitivity were targeted. 
This was particularly the case for first generation DES because of the non-bio-
compatible polymers used where histopathological studies showed that they 
induced hypereosonophilia, localised vascular inflammation and apoptosis of 
smooth muscle cells all with potential for activating thrombosis (77, 216-219).  
Both types of first generation DES, the Cypher sirolimus eluting stent (C-SES) 
and Taxus paclitaxel eluting stent (T-PES), had thick strut stainless steel 
platforms with non-bio-compatible polymers polyethylene co-vinyl 
acetate/poly-n-butyl methacrylate and polystyrene-b-isobutylene-b-styrene 
respectively. For C-SES, 80% of drug was released by 28 days and less than 
10% for T-PES in the same time period. For the second generation DES, the 
aim was to improve all elements of the stent to minimise both the injury and 
healing phases of the artery. The second generation Endeavor ™ (Medtronic, 
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Minneapolis, Minnesota) zotarolimus eluting stent (E-ZES) and Xience V™ 
(Abbott Vascular, Santa Clara, California) everolimus eluting stent (X-EES) 
both employed thinner strut cobalt chromium stent platforms (Vision and 
Driver respectively). They also utilised thinner, more biocompatible polymers,  
phosphorylcholine for E-ZES and polyvinylidene fluoride co-
hexafluoropropylene and poly-n-butyl methacrylate for X-EES. Both drugs 
were derivatives of sirolimus with similar mechanism of action (see section 
1.6). The drug elution kinetics were also altered for E-ZES, 95% of the drug 
being released within 14 days in order to reduce delayed endothelialisation. 
For X-EES, as with C-SES, 80% of drug was released by 28 days (220).  
The impact of these changes when compared to first generation DES was 
assessed in randomised trials. The Endeavour (Endeavor ABT-578-eluting 
phosphorylcholine-encapsulated stent system in de novo native coronary 
artery lesions) III trial compared E-ZES (n=436) with C-SES (n=113). In this 
relatively small single blinded trial in low risk patients with single vessel 
disease, somewhat predictably, E-ZES, with shorter release time of the drug, 
had higher late loss compared to C-SES (0.34±0.44 mm vs. 0.13±0.32 mm 
respectively; p < 0.001). In-segment binary angiographic restenosis was also 
higher in the E-ZES cohort (11.7% vs. 4.3%, p = 0.04) (221). Clinically-driven 
target lesion revascularization was also numerically higher for E-ZES at nine 
months (6.3 versus 3.5 percent, p=NS). Although not powered to assess this, 
the protocol specified five year follow up (95% complete) reported lower 
clinical endpoints for E-ZES including all-cause mortality (5.2% vs. 13.0%, p = 
0.02), MI (1.0% vs. 4.6%, p = 0.03), and the composite event rates of cardiac 
death/MI (1.3% vs. 6.5%, p = 0.009) and major adverse cardiac events 
178 
 
(14.0% vs. 22.2%, p = 0.05) but no statistically significant difference in TLR 
(222). E-ZES (n=773) were also compared to T-PES (n=775) in the 
Endeavour IV trial. Once again, late loss was higher 0.67±0.49 mm compared 
to 0.42±0.50, p<0.001. In segment binary restenosis rates were 15.3% vs. 
10.4%, p=0.28 in patients with angiographic follow up (n=144 for E-ZES and 
n=135 for T-PES). There was no statistically significant difference in the 
primary clinical end point of target vessel failure (TVF), defined as the 
composite of cardiac death, MI, or clinically driven target vessel 
revascularization (TVR) at 9 months after the procedure: 6.6% for E-ZES 
versus 7.1% for T-PES (223).  At five years, the difference in TVF was not 
statistically significant (17.2 vs. 21.1 percent, respectively, p=0.06), but the 
rate of death or MI was lower with E-ZES (6.4 versus 9.1; p = 0.048) (224).  In 
summary, E-ZES are inferior to SES and PES with respect to the 
angiographic finding of late loss. With respect to clinical outcomes, E-ZES has 
similar or better outcomes than PES but this is less clear when comparing 
ZES to SES. There appears to be similar or improved safety but with higher 
early rates of revascularisation with E-ZES. 
X-EES were also subjected to randomised comparisons initially against T-
PES.  The SPIRIT (Clinical Evaluation of the Xience V Everolimus Eluting 
Coronary Stent System in the treatment of patients with de novo native 
coronary artery lesions) II (X-EES, n=223; T-PES, n=77) and III (X-EES, 
n=669; T-PES, n=333) studies both showed superiority of X-EES in terms of 
late loss (0.11±0.27 mm vs. 0.36±0.39 mm, p<0.001 and 0.14±0.41mm vs. 
0.28±0.48 mm, p <0.05 respectively) (225, 226). For the SPIRIT III cohort 
(92% follow up), at five years, X-EES had lower 5-year Kaplan-Meier rates of 
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TVF (death, MI, or ischemia-driven TVR), 19.3% vs. 24.5%, p = 0.05; TLF 
(cardiac death, target-vessel MI, or ischemia-driven TLR) 12.7% vs. 19.0%, 
p = 0.008; and MACE (cardiac death, MI, or ischemia-driven TLR) 13.2% vs. 
20.7%, p = 0.007. X-EES also resulted in reduced rates of all-cause death 
(5.9% vs. 10.1%, p=0.02) (227). Additionally the SPIRIT IV (n=3687, 2:1 
randomisation) and the COMPARE (Second-Generation Everolimus-Eluting 
and Paclitaxel-Eluting Stents in Real-Life Practice; n=1800, 1:1 
randomisation) studies were the first to demonstrate a significant reduction in 
stent thrombosis between two DES. At 12-month follow-up, rates of 
definite/probable stent thrombosis for X-EES and T-PES were 0.17% vs. 
0.85% (p = 0.004), and 0.7% versus 2.6% (p = 0.002) in the SPIRIT IV and 
COMPARE studies, respectively (228, 229). A meta-analysis including these 
trials (n=6792) also supported clinical superiority of X-EES compared to T-
PES in terms of MI (OR 0.56, 95% CI 0.43-0.72), definite and probable stent 
thrombosis (OR 0.32, 95% CI 0.20-0.51) and ischaemia-driven TLR (OR 0.57, 
95% CI 0.46-0.71). Importantly, for stent thrombosis, the reductions applied to 
early stent thrombosis (within 30 days) (0.2% versus 0.9%; OR: 0.24; 
p=0.0005), late (day 31-365 days) (0.2% versus 0.6%; OR: 0.32; p=0.01), and 
very late stent thrombosis (>365 days) (0.2% versus 0.8%; OR: 0.34; 
p=0.009). For death, the results were not statistically significant (OR 0.8, 95% 
CI 0.59-1.07) (230). In summary, these studies have shown superiority both in 
terms of efficacy and efficacy in favour of X-EES compared to T-PES. 
When compared to C-SES, the results have been more comparable. The 
SORT OUT IV trial (Scandinavian Organization for Randomized Trials with 
Clinical Outcome) randomised patients between X-EES (n=1390) and C-SES 
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(n=1384). At nine month follow-up, the  primary composite end point of 
cardiac death, MI, definite stent thrombosis and TVR occurred in 68 patients 
(4.9%) treated with the X-EES compared with 72 patients (5.2%) treated with 
C-SES (HR 0.94; 95% CI, 0.67-1.31). There was also no significant difference 
at 18 month follow-up (HR 0.94; 95% CI, 0.71-1.23). With regards to definite 
stent thrombosis, the results favoured X-EES. At nine months, this  occurred 
in two patients (0.1%) treated with X-EES versus nine (0.7%) in the C-SES 
group patients (hazard ratio, 0.22; 95% confidence interval, 0.05-1.02) and at 
18 months this difference was sustained (3 patients [0.2%] vs. 12 patients 
[0.9%]; HR 0.25; 95% CI, 0.07-0.88) (231). At three year follow up, there was 
also no significant difference in a composite outcome of all death, all MI, or 
any revascularisation or a stent-related composite outcome of cardiac death, 
target vessel MI, or symptom-driven TLR. The rate of definite stent thrombosis 
was however lower for X-EES (0.2 versus 1.4 percent; hazard ratio 0.15, 95% 
CI 0.04-0.50) (232).  A meta-analysis of five randomized trials (n= 7370 
patients with no significant heterogeneity), including SORT OUT IV, found no 
significant difference in the rate of the major composite end point (HR 0.91, 
95% CI, 0.77-1.08,p=0.28) or in any of the components (cardiac death, MI, 
repeat revascularisation, and the composite of definite and probable stent 
thrombosis) at a median follow-up of 13.3 months (233).  
Key findings from the studies above are that the second generation DES 
have, at the very least, showed similar efficacy compared to first generation 
C-SES but also, particularly with X-EES, a more impressive safety profile 
particularly against T-PES. There was also a relatively high late lumen loss 
observed in the above studies of E-ZES. Given that the newer DES all 
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benefitted from improved stent platforms and polymers, it would therefore 
appear that drug choice and release kinetics are also important components 
of DES technology, especially as they relate to the vascular responses elicited 
by these devices.  
Whilst both sirolimus (and its analogues everolimus and zotarolimus) and 
paclitaxel reduce restenosis by disrupting smooth muscle cell cycle 
progression, their mode of action differs, sirolimus being predominantly 
cystotatic compared to the more cytotoxic paclitaxel (see section 1.6). There 
are also data from animal studies on how sirolimus and paclitaxel are different 
in terms of their effects on the arterial wall. In a rabbit study of iliac artery stent 
implantation, oral everolimus has been shown to dose-dependently suppress 
neointimal formation. With high dose everolimus treatment, there was 
markedly reduced neointimal formation at the expense of delayed arterial 
healing, characterised by prolonged fibrin deposition and poor re-
endothelialisation. Lower doses resulted in a similar benefit in terms of 
neointimal inhibition but signs of delayed arterial healing were absent, 
suggesting a wide therapeutic index of everolimus (234). The cytotoxic 
properties of paclitaxel on porcine arteries, on the other hand, have been 
reported with increased medial wall necrosis, smooth muscle cell loss, and 
arterial dilation with increasing doses in paclitaxel-coated Palmaz-Schatz 
stents  (235). This coupled with the slower release profile of paclitaxel from T-
PES already mentioned may explain the main differences between X-EES 
and T-PES.   
One study that deserves separate mention is the PROTECT trial (Patient 
Related OuTcomes with Endeavour vs. Cypher Stenting Trial). This was the 
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largest head to head DES study and only study powered to detect a difference 
in rates of definite or probable stent thrombosis. Participants were randomised 
to E-ZES (n=4357) or C-SES (n=4352) based on the premise that they have 
different anti-proliferative properties and thus different vascular healing 
responses. After three years (98% follow up), there was a non-significant 
difference in the primary endpoint of definite or probable stent thrombosis 
(1.4% for E-ZES vs. 1.8% for C-SES, p=0.17) with higher rates of TVR with E-
ZES (236). At pre-specified longer term follow up of 4 years (98% follow up) 
and 5 years (96% follow up) this difference was now significant (1.6% for E-
ZES vs. 2.5% for C-SES, p=0.003 and 1.7% for E-ZES vs. 2.8% for C-SES, 
p<0.001 respectively) (237, 238). There was also a reduction in the composite 
secondary endpoint of death/MI (8.2% for E-ZES vs. 9.6% for C-SES, 
p=0.02). Dual antiplatelet therapy was used in 96% of patients at discharge, 
88% at 1 year, 37% at 2 years, 30% at 3 years, 27% at 4 years and 26% at 5 
years. This highlighted the importance of longer term follow up in these types 
of studies particularly as the higher incidence of these events occurred very 
late when DAPT use decreased.  
The mechanisms of very late thrombosis with regards to DES warrant further 
mention. These include stent malapposition, particularly late acquired stent 
malapposition. This is thought to be caused by positive vascular remodelling 
which occurs when the vessel pulls away from the stent. More commonly 
seen in first generation DES and rarely with BMS, it therefore probably 
represents a local effect of the drug or the polymer. Inflammatory changes 
and hypersensitivity reactions in the intima and media with vasculitis, 
apoptosis, eosinophil and lymphocyte infiltration, and necrosis have been 
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seen in autopsy studies of stent thrombosis. Chronic inflammation of this type 
is associated with local release of collagenases that weaken the vessel wall 
and lead to its expansion (239). Another prevailing mechanism that has been 
put forward is in-stent neo-atherosclerosis already discussed in section 1.6 
and as mentioned there, it occurs earlier in first generation DES when 
compared to BMS. In essence, these mechanisms for very late stent 
thrombosis are a consequence of a local vascular response following stent 
deployment, particularly first generation DES. The results of the trials 
discussed above, seem to indicate that both X-EES and E-ZES with their 
changes in drug and delivery have had a beneficial impact. Stent thrombosis 
has remained an issue in the second generation DES era but like with BMS, it 
has been accepted that this complication of PCI will occur, but fortunately, 
relatively infrequently.  
In the BMS era, the advent of DAPT, particularly the addition of P2Y12 
inhibitors such as clopidogrel, heralded improvements in outcomes after PCI 
but it was standard practice to only use combination therapy for one month. 
Because of the stent thrombosis concerns with first generation DES, most 
authorities recommended 12 month duration of DAPT and this was a reason 
for exploring other avenues to reduce restenosis (as with SSTARS). With the 
new found confidence in second generation DES with less inflammatory 
polymers amongst other changes, the case could now be made for a shorter 
duration of DAPT but at the same time, the mechanisms of very late stent 
thrombosis were becoming apparent and given that these issues may still 
apply in second and third generation DES, there has been continuing 
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uncertainty about the optimal duration of DAPT. A number of trials have 
investigated this further. 
7.1 Duration of anti-platelet therapy after stenting 
The safety of using shorter duration of DAPT with second generation DES has 
been investigated using both E-ZES and X-EES in a series of relatively small 
randomised non-inferiority trials with short to medium term follow up: 
 In the EXCELLENT (Efficacy of Xience/Promus Versus Cypher to 
Reduce Late Loss After Stenting) trial, patients were randomised to six 
(n=722) versus 12 (n=721) months of DAPT after implantation of first 
(C-SES, n=364) and second generation (X-EES, n=1079) DES. The 
primary outcome of target-vessel failure (cardiac death, MI, or 
ischaemia-driven TVR) was similar (4.8% vs. 4.3% for 12 month 
DAPT, p=NS) and in addition, landmark analysis at 6 months showed 
comparable event rates with six versus 12 months of DAPT (hazard 
ratio, 1.06; 95% CI, 0.56–2.03; P=0.85) (240). Approximately 50% of 
patients had presented with an ACS. 
 In the PRODIGY (Prolonging Dual Antiplatelet Treatment After 
Grading Stent-Induced Intima Hyperplasia Study), patients were first 
randomized to receive BMS (n=492) versus E-ZES (n=493) versus T-
PES (n= 490) versus X-EES (n=495) and 30 days after the procedure 
underwent a second randomization for allocation to six versus 24 
months of DAPT. The majority of patients included had presented with 
an ACS (75%). At 24 months, the primary outcome (death from any 
cause, MI, or stroke) was similar, 10.1% in the 24-month DAPT group 
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compared with 10.0% in the six month DAPT group (HR, 0.98; 95% CI, 
0.74–1.29) (241). There was also no difference in the cumulative rates 
of definite or probable late or very late stent thrombosis (1.3% vs. 
1.5%, p=0.70). With regards to bleeding, in patients assigned to 
receive 24 month DAPT, there was a roughly 2-fold greater risk of 
clinically important bleeding (HR 2.17; 95% CI, from 1.44–
3.22; P=0.00018) (241) according to the Bleeding Academic Research 
Consortium classification (types 2-5) (242).  A subsequent pre-
specified post hoc analysis from PRODIGY with landmark analysis at 6 
months showed lack of benefit for prolonged DAPT with BMS and 
second generation DES (E-ZES and X-EES). Patients treated solely 
with paclitaxel-eluting stents did, however, benefit from prolonged dual 
antiplatelet therapy (243).  
 In the RESET (Real Safety and Efficacy of 3-Month Dual Antiplatelet 
Therapy Following Endeavor Zotarolimus-Eluting Stent Implantation) 
trial, 2117 patients were randomized to treatment with E-ZES plus 
three months of dual antiplatelet therapy compared to first or second 
generation DES plus 12 months of DAPT. For the 12 month group, 
multiple stents were used depending on lesion length. Approximately 
half of the patients were recruited following an ACS.  Patients with 
short lesions (≤ 24mm) received E-ZES or C-SES and those with long 
lesions received E-ZES or X-EES. At 12 months’ follow-up, the primary 
outcome (cardiac death, MI, stent thrombosis, or ischemia-driven 
target-vessel revascularization) was equal in both groups, 4.0% for 
three months therapy compared to 4.7% for 12 months therapy (95% 
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CI -2.5 to 2.5%). The rates of stent thrombosis were also similar (0.2% 
for three months therapy versus 0.3% for 12 months therapy, 95% CI: 
−0.5 to 0.3) (244).  
 In the OPTIMIZE ( Optimized duration of clopidogrel therapy following 
treatment with the Endeavor zotarolimus-eluting stent in real-world 
clinical practice) trial 1563 patients were randomised to three month 
DAPT versus 1556 patients randomised to 12 month DAPT (245). 
There was excellent compliance with DAPT and approximately 30% of 
patients were enrolled following recent ACS (NSTEMI 5%).There was 
no difference in the primary endpoint at one year of net adverse 
clinical and cerebral events (NACCE) which was a composite of death 
from any cause, MI, stroke, or major bleeding (6.0% vs. 5.8% for 12 
month DAPT, 95% CI, −1.52 to 1.86). Definite or probable stent 
thrombosis rates were low and not different (0.6% vs.0.7% for 12 
month DAPT (HR, 0.81 [95% CI, 0.34 to 1.96]) up to 90 days. Beyond 
90 days, there was also no significant difference in these events (0.3% 
vs. 0.1% for 12 month DAPT groups, HR, 3.97 [95% CI, 0.44-35.49]) 
bearing in mind that the study was not powered to assess these. 
These results suggested safety and efficacy of short-term DAPT in patients 
treated with second-generation drug-eluting stents but they are limited by 
their small sample sizes and low event rates. An attempt to address this with 
a recent meta-analysis with a median follow-up of 17 months has been 
performed (n=8595) but there was significant heterogeneity between the 
trials, highlighted in the discussion above, with differences in study population 
and treatments mentioned. There was no significant difference in the rate of 
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the composite outcome of cardiac death or myocardial infarction between the 
short (3-6 months) and prolonged (12-24 months DAPT groups (OR 1.11, 
95% confidence interval 0.87 to 1.43, p=0.41). A landmark analysis 
performed at the time of discontinuation of DAPT demonstrated a non-
significant higher rate of stent thrombosis in patients treated with a short 
course of DAPT (0.35% vs. 0.20%, p=0.22). The risk of major bleeding was 
higher with longer therapy (OR 1.97, 95% CI 2.97-28.62) (246).  
More recent studies have looked at the implications of longer term DAPT, i.e. 
beyond the conventional 12 month period. Amongst these, the Dual 
AntiPlatelet Therapy (DAPT) study compared  patients who had been 
successfully treated with 12 months of aspirin and a thienopyridine (either 
clopidogrel or prasugrel) to continue receiving the thienopyridine (n=5020) or 
placebo (n=4941) for another 18 months in addition to aspirin (247). 
Successful treatment was defined as freedom from all major adverse 
cardiovascular and cerebrovascular events (MACCE) or major bleeding 
events, repeat revascularisation and compliance with thienopyridine 
treatment. Enrolled patients had either stable (38 percent) or unstable 
disease. The rates for each of the co-primary end points of stent thrombosis 
and MACCE (a composite of death from any cause, MI, or stroke) were lower 
with continued thienopyridine therapy (0.4% vs. 1.4%; HR 0.29, 95% CI 0.17-
0.48 and 4.3% vs. 5.9%; HR 0.71, 95% CI 0.59-0.85, respectively). The 
reduction in events with continued DAPT was mostly attributable to a lower 
rate of MI (2.1% vs. 4.1%; HR 0.47, p<0.001). With regards to the primary 
safety end point of moderate or severe bleeding applying the GUSTO criteria 
(248), this was increased with continued DAPT (2.5% vs. 1.6%, p = 0.001). 
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One of the headlines from the trial was that the rate of death from any cause 
was higher in the DAPT group (2.0% vs. 1.5%%; HR 1.36, 95% CI 1.00-1.85) 
which was due to an increase in non-cardiac deaths (1.0% vs. 0.5%, 
p=0.002). Another finding provided in the supplementary appendix of the trial 
was that there was an increased risk of MI during the three months following 
cessation of the thienopyridine therapy in both randomised groups. 
The results of the DAPT study contrast with earlier smaller studies comparing 
DAPT beyond 12 months with aspirin alone. One study from South Korea 
combined the results of two trials, Correlation of Clopidogrel Therapy 
Discontinuation in Real-World Patients Treated with Drug-Eluting Stent 
Implantation and Late Coronary Arterial Thrombotic. Events (REAL-LATE) 
and Evaluation of the Long-Term Safety after Zotarolimus-Eluting Stent, 
Sirolimus-Eluting Stent, or Paclitaxel-Eluting Stent Implantation for Coronary 
Lesions - Late Coronary Arterial Thrombotic Events (ZEST-LATE). They had 
similar designs and due to slow recruitment, the data and safety committee 
agreed to merge the trials (249). Of 2701 patients recruited, the cumulative 
risk of the primary outcome (death or MI) at 2 years was 1.8% with dual 
antiplatelet therapy, as compared with 1.2% with aspirin monotherapy (HR, 
1.65; 95% confidence interval [CI], 0.80 to 3.36; P=0.17). There was no 
significant difference in TIMI major bleeding (HR 2.96, 95% CI 0.31-28.6, 
p=0.35. In the Dual-antiplatelet treatment beyond 1 year after drug-eluting 
stent implantation (ARCTIC-Interruption) study, 1259 patients from multiple 
centres in France were randomly allocated to continued treatment with DAPT 
for 6-18 months or aspirin alone(250). Once again there was no significant 
difference in the primary endpoint of primary endpoint of death, MI, stent 
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thrombosis, stroke, or urgent revascularisation (4% for aspirin group vs. 4% 
for DAPT continuation group; HR 1·17,95% CI 0·68–2·03; p=0·58) after a 
median follow-up of 17 months. Major bleeding events occurred more often in 
the DAPT continuation group (seven [1%] patients) compared with the 
interruption group (one [<0·5%] patient; HR 0·15 [0·02–1·20]; p=0·073). A 
2014 meta-analysis of these trials and four others (n = 12,536) found no 
difference in the rate of death (OR 1.18, 95% CI 0.61-2.29), but the risk of 
major bleeding was higher with longer therapy (OR 4.69, 95% CI 1.01-21.87) 
at a median follow-up of 17 months.  
It is difficult to draw firm conclusions from these studies about the optimal 
duration of DAPT following DES implantation, particularly second generation 
DES. Although occurring at a lower frequency than with first generation DES, 
stent thrombosis remains a real concern. The trials discussed provide some 
reassurance concerning shorter courses of DAPT, but the larger DAPT trial 
suggests that there may be continuing cardiovascular benefits but achieved 
(as with most of these studies) at a higher risk of bleeding. The latest 
European revascularisation guidelines recommend DAPT for six months 
following elective DES implantation (251). Given these improvements, the 
focus on finding alternative strategies to DES has dissipated and research 
over the last few years has concentrated more on developing further 
improvements in DES platforms. 
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CHAPTER 8 
Current and future directions 
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Although the scare around early and late stent thrombosis reinforced the need 
to examine other options to reduce the restenosis rates seen with stainless 
steel stents, the clinical research over the last 5-10 years, much of which is 
described in Section 7, led to developments in DES resulting in better and 
safer clinical results with DES. Given the fall in cost of DES, there are now 
fewer cases where there is a clinical impetus to use a bare metal stent. 
However, research to develop new technology to mitigate the pathogenic 
mechanisms behind the adverse events described continues. During the 
course of the SSTARS study, there have already been developments to try 
and build upon the success of second generation DES both in terms of 
reducing restenosis and improved safety. Broadly, these can be divided 
according to the components of a DES.  
8.1 New polymer technology 
The realisation that appropriate drug choice, along with optimised release 
kinetics were fundamental determinants affecting the long-term success of 
DES drove the development of the Resolute™ (Medtronic, Santa Rosa, 
California) -ZES (R-ZES), which has longer drug elution than the original 
Endeavor stent. Using the same cobalt chromium platform as E-ZES, R-ZES 
incorporated a new Biolinx polymer comprised of a hydrophobic C10 polymer 
to control drug release, a biocompatible and hydrophilic C19 polymer and 
polyvinyl pyrrolidone to allow an early burst of drug release. The polymer 
combinations also allowed delayed drug release, such that at least 85% of the 
zotarolimus was released within 60 days, with the remainder being released 
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within 180 days (252). E-ZES and R-ZES have not been directly compared 
but results from a study (n=139) that examined late lumen loss with single de 
novo coronary lesions suggested benefit from this polymer (253). At nine 
month follow-up, late loss was 0.22 +/- 0.27 mm with the R-ZES, which was 
lower than previously observed in E-ZES.   
R-ZES has been compared to another durable biocompatible polymer stent, 
X-EES, in the TWENTE trial (254). This was a single bind (patient only), 
randomised non-inferiority trial involving 1391 patients. The primary 
composite endpoint of target vessel failure (cardiac death, target vessel 
related MI or clinically driven TVR)  occurred in 8.2% for R-ZES and 8.1% for 
X-EES during 12 months follow up meeting the non inferiority margin 
(absolute risk difference of ≤4.48%). The definite-or-probable stent thrombosis 
rates were similar for R-ZES and X-EES (0.9% and 1.2%, respectively, p = 
0.59). 
8.2 New metal stent platforms 
In the SSTARS study, the impact of cobalt chromium stents with regards to 
restenosis was investigated and no advantage was seen compared to 
stainless steel. However, there was no disadvantage and one of the 
advantages that this alloy offers in comparison to stainless steel was greater 
radial strength allowing production of thinner struts, which also has the 
potential to enhance trackability and deliverability. This premise has 
subsequently led to the development of platinum chromium alloy stents which 
have even greater radial strength. Platinum is also more dense than cobalt or 
stainless steel and therefore more radio-opaque. The Promus Element ™ 
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(Boston Scientific, Natick, Massachusetts) used the same polymer eluting 
everolimus as X-EES with a platinum chromium platform. In the Prospective, 
Randomized, Multicenter Trial to Assess an Everolimus-Eluting Coronary 
Stent System [PROMUS Element] for the Treatment of up to Two De Novo 
Coronary Artery Lesions (PLATINUM) trial, the platinum chromium alloy was 
found to have similar efficacy and safety compared to its cobalt chromium 
counterpart (n=1530) (255). The 12-month rates of target lesion failure (a 
composite of target vessel-related cardiac death, target vessel-related 
myocardial infarction, or ischemia-driven target lesion revascularization) were 
2.9 and 3.4 percent, respectively. By intention-to-treat, there were no 
significant differences between CoCr-EES and PtCr-EES in the 12-month 
rates of TLF (3.2% vs. 3.5%, p = 0.72), cardiac death or MI (2.5% vs. 2.0%, p 
= 0.56), TLR (1.9% vs. 1.9%, p = 0.96), or Academic Research Consortium 
definite or probable stent thrombosis (0.4% vs. 0.4%, p = 1.00). 
8.3 Biodegradeable polymers 
One of the proposed mechanisms for stent thrombosis in DES is chronic 
inflammation related to the polymer that houses the antiproliferative drug. 
Conventional DES have what is described as durable or permanent polymers 
and the impact of using more biocompatible durable polymers has already 
been highlighted (section 5.4). Another potential method to decrease the rate 
of very late stent thrombosis with DES is to remove the polymer altogether as 
a potential chronic inflammatory stimulus leaving the patient with the potential 
long term safety advantage of a BMS. This approach has been employed in a 
number of stents using different polymers and drugs.  
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Amongst these types of stents, one of the most widely used and tested is the 
BioMatrix® stent (Biosensors Inc., Newport Beach, CA, USA). This utilises a 
stainless steel platform, the sirolimus analogue biolimus, and a biodegradable 
poly-L-lactide (PLA) polymer that is applied only to the abluminal (outer) 
surface of the stent. The Limus Eluted From A Durable Versus ERodable 
Stent Coating (LEADERS) trial was a randomised non-inferiority trial of 1707 
patients with both stable and unstable coronary artery disease. Patients were 
randomly assigned to either the Biomatrix biolimus eluting stent (BES) or to 
the first generation C-SES. At nine months, the Biomatrix BES was non-
inferior to the C-SES for the primary composite end point of cardiac death, MI, 
or clinically indicated TVR (9.0% vs. 11.0% respectively; RR 0.88, 95% CI 
0.64–1.19) (256). This was maintained at five years follow up (22.3% vs. 
26.1%, respectively; RR 0.83, 95% CI 0.68-1.02) but, interestingly, a pre-
specified secondary analysis of very late stent thrombosis at this juncture was 
in favour of the BES (0.7% vs. 2.5%; RR0.26, 95% CI 0.10-0.68) (257). This 
may reflect the late safety advantage of the biodegradeable polymer. 
Another BES, the Nobori® stent (Terumo Corporation, Tokyo, Japan) also 
uses the same stainless steel platform and the abluminal PLA polymer as the 
Biomatrix stent above but differs in the delivery system, balloon and stent 
coating process. The fifth Scandinavian Organisation for Randomised Trials 
with clinical OUTcome (SORT OUT V) compared Nobori BES (n=1229) with 
C-SES (n=1239) with both stable and unstable coronary artery disease. 
Surprisingly, the BES was not non-inferior to C-SES at one year for the 
composite endpoint of cardiac death, MI and definite stent thrombosis (4.1% 
BES vs. 3.1% SES, p=0.06) (258). All of the components were numerically 
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higher with the Nobori BES but particularly so for definite stent thrombosis (9 
0·7% vs. 0·2%,95% CI 0·0-1·1; p=0·034). In the Comparison of the 
Everolimus eluting with Biolimus A9 eluting stent (COMPARE II) eluting stent) 
study (n=2707), Nobori BES was found to be non-inferior to X-EES at 12 
months for the composite endpoint of cardiac death, MI, and TVR (5.2% vs. 
4.8% respectively; RR 1·07, 95% CI 0·75-1·52 ; p(non-inferiority)<0·0001) 
(259). The study designs and endpoints use in these BES studies were 
different and this makes direct comparisons difficult. Further studies and more 
long term safety data are needed before firm conclusions can be drawn. 
Another stent with a  biodegradable polymer that has been trialled is the 
Synergy™ stent (Boston Scientific) which utilizes a platinum chromium stent 
with an abluminal biodegradeable polymer (polylactic acid/polyglycolic acid) 
and elutes everolimus. The Evolution Everolimus-Eluting Monorail Coronary 
Stent System for the Treatment of a De Novo Atherosclerotic Lesion 
(EVOLVE) trial compared two dose formulations of the SYNERGY stent with 
the durable polymer platinum chromium EES (n=291). Patients were 
randomized 1:1:1 and at 30 days, there was a non-significant difference in the 
primary clinical endpoint of target lesion failure (death, target vessel MI, target 
lesion revascularization) which occurred in 0 percent, 1.1 percent, and 3.1 
percent of patients in the durable polymer EES, SYNERGY, and SYNERGY 
half-dose groups, respectively. Angiographic follow up was also performed at 
six months and there was no difference between the three groups in the 
primary angiographic endpoint of in-stent late loss (0.15 ± 0.34 mm for 
durable polymer EES, 0.10 ± 0.25 mm for SYNERGY, and 0.13 ± 0.26 mm for 
SYNERGY half dose, p for noninferiority <0.001). No stent thromboses 
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occurred through six-month follow-up within this small group of patients (260). 
Similarly, the two year follow up results were comparable between the three 
groups, target lesion failure rates of 6.1% for the durable polymer EES, 5.5% 
for Synergy, and 5.2%  for Synergy half dose (p=0.87) (261). At two years, 
target lesion failure (TLF) was 6.1% for PE vs. 5.5% for SYNERGY (p=0.87) 
and 5.2% for SYNERGY ½ dose (p=0.81). There were no significant 
differences between groups for cardiac death, repeat revascularisation, MI or 
stent thrombosis through two years.  
8.4 Bioresorbable stents 
Coronary stents were developed to reduce the risk of restenosis after balloon 
angioplasty. Their evolution through to the development of DES has been 
reviewed in chapter 1. They are essentially "scaffolds" and are required 
acutely to seal intimal tears and prevent recoil following arterial barotrauma. 
They subsequently prevent constrictive remodelling which occurs within 6 
months of the procedure (262). An ideal situation would be one where a 
"scaffold" is only present during this period. This has led to the development 
of bioresorbable vascular stents. Amongst these, the Absorb bioresorbable 
vascular scaffold (Abbott Vascular) consists of a 150μm thick bioresorbable 
poly(l-lactide) scaffold (PLLA) with a 7μm thick bioresorbable poly(d,l-lactide) 
coating, which elutes everolimus (263). PLLA has other medical applications 
and has been used in absorbable sutures and orthopaedic plates and screws. 
In the coronary setting, it is absorbed after approximately two years (262). 
The main attraction of developing these stents is that the development of late 
adverse events after placement of permanent metallic stents can be avoided. 
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These include persistent inflammation, impaired vasomotion and neo-
atherosclerosis. 
The everolimus-eluting bioresorbable Absorb scaffold has been compared 
with an everolimus-eluting metallic counterpart in six randomized trials (264-
269). Data from these trials including 2337 patients that were treated with 
everolimus-eluting bioresorbable non-metallic vascular scaffolds and 1401 
with everolimus-eluting metallic stents have been included in a meta-analysis 
(270). AT 12 months, the risk of target lesion revascularization (primary 
efficacy outcome) was similar in the two groups (odds ratio [OR] 0.97, 95% CI 
0.66-1.43) as was the risk of target lesion failure (OR 1.20, 95% CI 0.90-1.60), 
myocardial infarction (OR 1.36, 95% CI 0.98-1.89), and death (OR 0. 97, 95% 
CI 0.45-2.00). The risk of definite or probable stent thrombosis was higher in 
those treated with a bioresorbable vascular scaffold (OR 1.99, 95% CI 1.00-
3.98). 
The ABSORB III trial was the largest in the meta-analysis. It included 2008 
patients with stable or unstable angina who were randomly assigned in a 2:1 
ratio to receive an everolimus-eluting bioresorbable vascular scaffold or an 
everolimus-eluting cobalt chromium stent (267). Patients with acute 
myocardial infarction and specific complex lesions were excluded. There was 
no significant difference between the two groups in the rate of the primary 
outcome of target lesion failure (cardiac death, target vessel myocardial 
infarction, or ischaemia driven target lesion revascularization) at one year (7.8 
versus 6.1 percent, respectively). Results for the individual components of the 
primary end point did not differ. Device thrombosis at one year occurred in 1.5 
and 0.7 percent (p = 0.13 for superiority) of the two groups, respectively.   
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At present, the results of these studies suggest no advantage for efficacy with 
the emerging polymer, metal stent or bioresorbable stents compared with 
second generation DES. Bioresorbable stents had a higher rate of stent 
thrombosis at one year. These technologies have potential benefits but 
longer-term outcomes are needed. It is possible that an advantage will appear 
in due course.  
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Conclusion 
As discussed, inflammation is a key process in restenosis and so systemic 
anti-inflammatory therapy is a potentially attractive approach of limiting this. 
Additionally, thinner stent struts have been associated with less restenosis 
and there has been a corresponding drive towards the production of thinner 
strut stents and the use of different alloys to facilitate this. There was a need 
for more randomised trial data in this area and this formed the basis for this 
study.   
SSTARS showed that treating patients upstream with a moderately high dose 
of prednisolone to cover most of the period of inflammation associated with 
restenosis in BMS did not reduce the incidence of binary angiographic 
restenosis. In addition, there was no significant reduction in restenosis rates 
with stents composed of cobalt chromium alloy compared to stainless steel. 
There was also no relationship between higher levels of hs-CRP and 
restenosis. Whilst systemic therapy with Prednisolone did reduce hs-CRP 
levels, this was not associated with a reduction in restenosis.  
The study adds important information in this subject area, albeit with a 
negative finding. The results help bring perspective to other trial results 
including meta-analyses which seemed to indicate a role for systemic anti-
inflammatory therapy. The impact of stent alloy has not previously been 
investigated in this context and this is the largest study involving the use of 
systemic prednisolone to prevent restenosis. Drug-eluting stents now 
dominate the clinical landscape and this study supports the concept of local 
as opposed to systemic delivery of drugs to reduce restenosis and further 
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research should continue to focus on improvements in the stent platforms as 
well as drug delivery systems (see sections 8.1 - 8.4). 
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